ID ACACB_HUMAN Reviewed; 2458 AA. AC O00763; A6NK36; Q16852; Q1HEC1; Q6KE87; Q6KE89; Q6TY48; DT 01-NOV-1997, integrated into UniProtKB/Swiss-Prot. DT 05-OCT-2010, sequence version 3. DT 28-JAN-2026, entry version 224. DE RecName: Full=Acetyl-CoA carboxylase 2 {ECO:0000305}; DE EC=6.4.1.2 {ECO:0000269|PubMed:16854592, ECO:0000269|PubMed:19236960, ECO:0000269|PubMed:19900410, ECO:0000269|PubMed:20457939, ECO:0000269|PubMed:20952656, ECO:0000269|PubMed:26976583}; DE AltName: Full=ACC-beta; DE Flags: Precursor; GN Name=ACACB {ECO:0000312|HGNC:HGNC:85}; Synonyms=ACC2, ACCB; OS Homo sapiens (Human). OC Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia; OC Eutheria; Euarchontoglires; Primates; Haplorrhini; Catarrhini; Hominidae; OC Homo. OX NCBI_TaxID=9606; RN [1] RP NUCLEOTIDE SEQUENCE [MRNA] (ISOFORMS 1 AND 2), AND TISSUE SPECIFICITY. RC TISSUE=Liver; RX PubMed=9099716; DOI=10.1074/jbc.272.16.10669; RA Abu-Elheiga L., Almarza-Ortega D.B., Baldini A., Wakil S.J.; RT "Human acetyl-CoA carboxylase 2. Molecular cloning, characterization, RT chromosomal mapping, and evidence for two isoforms."; RL J. Biol. Chem. 272:10669-10677(1997). RN [2] RP NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 1), FUNCTION, COFACTOR, RP BIOPHYSICOCHEMICAL PROPERTIES, CATALYTIC ACTIVITY, ACTIVITY REGULATION, AND RP VARIANT ILE-2141. RX PubMed=16854592; DOI=10.1016/j.pep.2006.06.005; RA Cheng D., Chu C.-H., Chen L., Feder J.N., Mintier G.A., Wu Y., Cook J.W., RA Harpel M.R., Locke G.A., An Y., Tamura J.K.; RT "Expression, purification, and characterization of human and rat acetyl RT coenzyme A carboxylase (ACC) isozymes."; RL Protein Expr. Purif. 51:11-21(2007). RN [3] RP NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 1), AND VARIANT ILE-2141. RC TISSUE=Heart; RA Peng X.R., Lindgren K., Corneliussen B.; RT "Corrected sequence for human acetyl-CoA carboxylase 2 obtained by RT alignment to human genomic DNA and PCR cloning from human skeletal muscle RT and heart cDNA."; RL Submitted (JUL-2003) to the EMBL/GenBank/DDBJ databases. RN [4] RP NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 1). RC TISSUE=Heart; RA Mao J., Wakil S.J.; RT "Alternative splicing in the human acetyl-CoA carboxylase 2 (ACC2) gene."; RL Submitted (SEP-2003) to the EMBL/GenBank/DDBJ databases. RN [5] RP NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA]. RX PubMed=16541075; DOI=10.1038/nature04569; RA Scherer S.E., Muzny D.M., Buhay C.J., Chen R., Cree A., Ding Y., RA Dugan-Rocha S., Gill R., Gunaratne P., Harris R.A., Hawes A.C., RA Hernandez J., Hodgson A.V., Hume J., Jackson A., Khan Z.M., Kovar-Smith C., RA Lewis L.R., Lozado R.J., Metzker M.L., Milosavljevic A., Miner G.R., RA Montgomery K.T., Morgan M.B., Nazareth L.V., Scott G., Sodergren E., RA Song X.-Z., Steffen D., Lovering R.C., Wheeler D.A., Worley K.C., Yuan Y., RA Zhang Z., Adams C.Q., Ansari-Lari M.A., Ayele M., Brown M.J., Chen G., RA Chen Z., Clerc-Blankenburg K.P., Davis C., Delgado O., Dinh H.H., RA Draper H., Gonzalez-Garay M.L., Havlak P., Jackson L.R., Jacob L.S., RA Kelly S.H., Li L., Li Z., Liu J., Liu W., Lu J., Maheshwari M., RA Nguyen B.-V., Okwuonu G.O., Pasternak S., Perez L.M., Plopper F.J.H., RA Santibanez J., Shen H., Tabor P.E., Verduzco D., Waldron L., Wang Q., RA Williams G.A., Zhang J., Zhou J., Allen C.C., Amin A.G., Anyalebechi V., RA Bailey M., Barbaria J.A., Bimage K.E., Bryant N.P., Burch P.E., RA Burkett C.E., Burrell K.L., Calderon E., Cardenas V., Carter K., Casias K., RA Cavazos I., Cavazos S.R., Ceasar H., Chacko J., Chan S.N., Chavez D., RA Christopoulos C., Chu J., Cockrell R., Cox C.D., Dang M., Dathorne S.R., RA David R., Davis C.M., Davy-Carroll L., Deshazo D.R., Donlin J.E., RA D'Souza L., Eaves K.A., Egan A., Emery-Cohen A.J., Escotto M., Flagg N., RA Forbes L.D., Gabisi A.M., Garza M., Hamilton C., Henderson N., RA Hernandez O., Hines S., Hogues M.E., Huang M., Idlebird D.G., Johnson R., RA Jolivet A., Jones S., Kagan R., King L.M., Leal B., Lebow H., Lee S., RA LeVan J.M., Lewis L.C., London P., Lorensuhewa L.M., Loulseged H., RA Lovett D.A., Lucier A., Lucier R.L., Ma J., Madu R.C., Mapua P., RA Martindale A.D., Martinez E., Massey E., Mawhiney S., Meador M.G., RA Mendez S., Mercado C., Mercado I.C., Merritt C.E., Miner Z.L., Minja E., RA Mitchell T., Mohabbat F., Mohabbat K., Montgomery B., Moore N., Morris S., RA Munidasa M., Ngo R.N., Nguyen N.B., Nickerson E., Nwaokelemeh O.O., RA Nwokenkwo S., Obregon M., Oguh M., Oragunye N., Oviedo R.J., Parish B.J., RA Parker D.N., Parrish J., Parks K.L., Paul H.A., Payton B.A., Perez A., RA Perrin W., Pickens A., Primus E.L., Pu L.-L., Puazo M., Quiles M.M., RA Quiroz J.B., Rabata D., Reeves K., Ruiz S.J., Shao H., Sisson I., RA Sonaike T., Sorelle R.P., Sutton A.E., Svatek A.F., Svetz L.A., RA Tamerisa K.S., Taylor T.R., Teague B., Thomas N., Thorn R.D., Trejos Z.Y., RA Trevino B.K., Ukegbu O.N., Urban J.B., Vasquez L.I., Vera V.A., RA Villasana D.M., Wang L., Ward-Moore S., Warren J.T., Wei X., White F., RA Williamson A.L., Wleczyk R., Wooden H.S., Wooden S.H., Yen J., Yoon L., RA Yoon V., Zorrilla S.E., Nelson D., Kucherlapati R., Weinstock G., RA Gibbs R.A.; RT "The finished DNA sequence of human chromosome 12."; RL Nature 440:346-351(2006). RN [6] RP NUCLEOTIDE SEQUENCE [MRNA] OF 1324-2109. RC TISSUE=Adipose tissue; RX PubMed=8670171; DOI=10.1042/bj3160915; RA Widmer J., Fassihi K.S., Schlichter S.C., Wheeler K.S., Crute B.E., RA King N., Nutile-Mcmenemy N., Noll W.W., Daniel S., Ha J., Kim K.-H., RA Witters L.A.; RT "Identification of a second human acetyl-CoA carboxylase gene."; RL Biochem. J. 316:915-922(1996). RN [7] RP SUBCELLULAR LOCATION. RX PubMed=10677481; DOI=10.1073/pnas.97.4.1444; RA Abu-Elheiga L., Brinkley W.R., Zhong L., Chirala S.S., Woldegiorgis G., RA Wakil S.J.; RT "The subcellular localization of acetyl-CoA carboxylase 2."; RL Proc. Natl. Acad. Sci. U.S.A. 97:1444-1449(2000). RN [8] RP PHOSPHORYLATION AT SER-222 BY AMPK, AND ACTIVITY REGULATION. RX PubMed=12488245; DOI=10.1152/ajpendo.00436.2002; RA Wojtaszewski J.F., MacDonald C., Nielsen J.N., Hellsten Y., Hardie D.G., RA Kemp B.E., Kiens B., Richter E.A.; RT "Regulation of 5'AMP-activated protein kinase activity and substrate RT utilization in exercising human skeletal muscle."; RL Am. J. Physiol. 284:E813-E822(2003). RN [9] RP IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS]. RC TISSUE=Cervix carcinoma; RX PubMed=18669648; DOI=10.1073/pnas.0805139105; RA Dephoure N., Zhou C., Villen J., Beausoleil S.A., Bakalarski C.E., RA Elledge S.J., Gygi S.P.; RT "A quantitative atlas of mitotic phosphorylation."; RL Proc. Natl. Acad. Sci. U.S.A. 105:10762-10767(2008). RN [10] RP BIOPHYSICOCHEMICAL PROPERTIES, CATALYTIC ACTIVITY, AND FUNCTION. RX PubMed=19236960; DOI=10.1016/j.bbapap.2009.02.004; RA Kaushik V.K., Kavana M., Volz J.M., Weldon S.C., Hanrahan S., Xu J., RA Caplan S.L., Hubbard B.K.; RT "Characterization of recombinant human acetyl-CoA carboxylase-2 steady- RT state kinetics."; RL Biochim. Biophys. Acta 1794:961-967(2009). RN [11] RP BIOPHYSICOCHEMICAL PROPERTIES, ALTERNATIVE SPLICING (ISOFORM 3), AND TISSUE RP SPECIFICITY. RX PubMed=19190759; DOI=10.1371/journal.pone.0004369; RA Castle J.C., Hara Y., Raymond C.K., Garrett-Engele P., Ohwaki K., Kan Z., RA Kusunoki J., Johnson J.M.; RT "ACC2 is expressed at high levels in human white adipose and has an isoform RT with a novel N-terminus."; RL PLoS ONE 4:E4369-E4369(2009). RN [12] RP FUNCTION, CATALYTIC ACTIVITY, ACTIVITY REGULATION, SUBUNIT, AND INTERACTION RP WITH MID1IP1. RX PubMed=20457939; DOI=10.1073/pnas.1001292107; RA Kim C.W., Moon Y.A., Park S.W., Cheng D., Kwon H.J., Horton J.D.; RT "Induced polymerization of mammalian acetyl-CoA carboxylase by MIG12 RT provides a tertiary level of regulation of fatty acid synthesis."; RL Proc. Natl. Acad. Sci. U.S.A. 107:9626-9631(2010). RN [13] RP CATALYTIC ACTIVITY, SUBUNIT, ACTIVITY REGULATION, AND INTERACTION WITH RP MID1IP1. RX PubMed=20952656; DOI=10.1073/pnas.1012736107; RA Colbert C.L., Kim C.W., Moon Y.A., Henry L., Palnitkar M., McKean W.B., RA Fitzgerald K., Deisenhofer J., Horton J.D., Kwon H.J.; RT "Crystal structure of Spot 14, a modulator of fatty acid synthesis."; RL Proc. Natl. Acad. Sci. U.S.A. 107:18820-18825(2010). RN [14] RP PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-35; THR-70; SER-91; SER-95; RP SER-200; SER-469 AND THR-1342, AND IDENTIFICATION BY MASS SPECTROMETRY RP [LARGE SCALE ANALYSIS]. RC TISSUE=Liver; RX PubMed=24275569; DOI=10.1016/j.jprot.2013.11.014; RA Bian Y., Song C., Cheng K., Dong M., Wang F., Huang J., Sun D., Wang L., RA Ye M., Zou H.; RT "An enzyme assisted RP-RPLC approach for in-depth analysis of human liver RT phosphoproteome."; RL J. Proteomics 96:253-262(2014). RN [15] RP X-RAY CRYSTALLOGRAPHY (2.5 ANGSTROMS) OF 217-775. RX PubMed=17876819; DOI=10.1002/prot.21611; RA Cho Y.S., Lee J.I., Shin D., Kim H.T., Cheon Y.H., Seo C.I., Kim Y.E., RA Hyun Y.L., Lee Y.S., Sugiyama K., Park S.Y., Ro S., Cho J.M., Lee T.G., RA Heo Y.S.; RT "Crystal structure of the biotin carboxylase domain of human acetyl-CoA RT carboxylase 2."; RL Proteins 70:268-272(2008). RN [16] RP STRUCTURE BY NMR OF 885-971. RG RIKEN structural genomics initiative (RSGI); RT "Solution structure of RSGI RUH-053, an apo-biotin carboxy carrier protein RT from human transcarboxylase."; RL Submitted (OCT-2006) to the PDB data bank. RN [17] RP STRUCTURE BY NMR OF 891-965, BIOTINYLATION AT LYS-929, COFACTOR, AND RP DOMAIN. RX PubMed=18247344; DOI=10.1002/prot.21952; RA Lee C.K., Cheong H.K., Ryu K.S., Lee J.I., Lee W., Jeon Y.H., Cheong C.; RT "Biotinoyl domain of human acetyl-CoA carboxylase: Structural insights into RT the carboxyl transfer mechanism."; RL Proteins 72:613-624(2008). RN [18] RP X-RAY CRYSTALLOGRAPHY (3.19 ANGSTROMS) OF 1693-2450 IN COMPLEX WITH RP INHIBITOR, AND DOMAIN. RX PubMed=19390150; DOI=10.1107/s0907444909008014; RA Madauss K.P., Burkhart W.A., Consler T.G., Cowan D.J., Gottschalk W.K., RA Miller A.B., Short S.A., Tran T.B., Williams S.P.; RT "The human ACC2 CT-domain C-terminus is required for full functionality and RT has a novel twist."; RL Acta Crystallogr. D 65:449-461(2009). RN [19] RP X-RAY CRYSTALLOGRAPHY (2.50 ANGSTROMS) OF 217-775 IN COMPLEX WITH SORAPHEN RP A, FUNCTION, CATALYTIC ACTIVITY, ACTIVITY REGULATION, PATHWAY, SUBUNIT, RP PHOSPHORYLATION AT SER-222, AND MUTAGENESIS OF ARG-277 AND GLU-671. RX PubMed=19900410; DOI=10.1016/j.bbrc.2009.11.029; RA Cho Y.S., Lee J.I., Shin D., Kim H.T., Jung H.Y., Lee T.G., Kang L.W., RA Ahn Y.J., Cho H.S., Heo Y.S.; RT "Molecular mechanism for the regulation of human ACC2 through RT phosphorylation by AMPK."; RL Biochem. Biophys. Res. Commun. 391:187-192(2010). RN [20] RP X-RAY CRYSTALLOGRAPHY (2.60 ANGSTROMS) OF 238-760 IN COMPLEX WITH RP INHIBITOR, FUNCTION, CATALYTIC ACTIVITY, AND PATHWAY. RX PubMed=26976583; DOI=10.1073/pnas.1520686113; RA Harriman G., Greenwood J., Bhat S., Huang X., Wang R., Paul D., Tong L., RA Saha A.K., Westlin W.F., Kapeller R., Harwood H.J. Jr.; RT "Acetyl-CoA carboxylase inhibition by ND-630 reduces hepatic steatosis, RT improves insulin sensitivity, and modulates dyslipidemia in rats."; RL Proc. Natl. Acad. Sci. U.S.A. 113:E1796-E1805(2016). RN [21] RP VARIANT [LARGE SCALE ANALYSIS] LEU-193. RX PubMed=18772397; DOI=10.1126/science.1164368; RA Jones S., Zhang X., Parsons D.W., Lin J.C., Leary R.J., Angenendt P., RA Mankoo P., Carter H., Kamiyama H., Jimeno A., Hong S.M., Fu B., Lin M.T., RA Calhoun E.S., Kamiyama M., Walter K., Nikolskaya T., Nikolsky Y., RA Hartigan J., Smith D.R., Hidalgo M., Leach S.D., Klein A.P., Jaffee E.M., RA Goggins M., Maitra A., Iacobuzio-Donahue C., Eshleman J.R., Kern S.E., RA Hruban R.H., Karchin R., Papadopoulos N., Parmigiani G., Vogelstein B., RA Velculescu V.E., Kinzler K.W.; RT "Core signaling pathways in human pancreatic cancers revealed by global RT genomic analyses."; RL Science 321:1801-1806(2008). CC -!- FUNCTION: Mitochondrial enzyme that catalyzes the carboxylation of CC acetyl-CoA to malonyl-CoA and plays a central role in fatty acid CC metabolism (PubMed:16854592, PubMed:19236960, PubMed:19900410, CC PubMed:20457939, PubMed:20952656, PubMed:26976583). Catalyzes a 2 steps CC reaction starting with the ATP-dependent carboxylation of the biotin CC carried by the biotin carboxyl carrier (BCC) domain followed by the CC transfer of the carboxyl group from carboxylated biotin to acetyl-CoA CC (PubMed:19236960, PubMed:20457939, PubMed:20952656, PubMed:26976583). CC Through the production of malonyl-CoA that allosterically inhibits CC carnitine palmitoyltransferase 1 at the mitochondria, negatively CC regulates fatty acid oxidation (By similarity). Together with its CC cytosolic isozyme ACACA, which is involved in de novo fatty acid CC biosynthesis, promotes lipid storage (By similarity). CC {ECO:0000250|UniProtKB:E9Q4Z2, ECO:0000269|PubMed:16854592, CC ECO:0000269|PubMed:19236960, ECO:0000269|PubMed:19900410, CC ECO:0000269|PubMed:20457939, ECO:0000269|PubMed:20952656, CC ECO:0000269|PubMed:26976583}. CC -!- CATALYTIC ACTIVITY: CC Reaction=hydrogencarbonate + acetyl-CoA + ATP = malonyl-CoA + ADP + CC phosphate + H(+); Xref=Rhea:RHEA:11308, ChEBI:CHEBI:15378, CC ChEBI:CHEBI:17544, ChEBI:CHEBI:30616, ChEBI:CHEBI:43474, CC ChEBI:CHEBI:57288, ChEBI:CHEBI:57384, ChEBI:CHEBI:456216; EC=6.4.1.2; CC Evidence={ECO:0000269|PubMed:16854592, ECO:0000269|PubMed:19236960, CC ECO:0000269|PubMed:19900410, ECO:0000269|PubMed:20457939, CC ECO:0000269|PubMed:20952656, ECO:0000269|PubMed:26976583}; CC PhysiologicalDirection=left-to-right; Xref=Rhea:RHEA:11309; CC Evidence={ECO:0000269|PubMed:19900410, ECO:0000269|PubMed:26976583}; CC -!- COFACTOR: CC Name=biotin; Xref=ChEBI:CHEBI:57586; CC Evidence={ECO:0000269|PubMed:16854592, ECO:0000269|PubMed:18247344}; CC -!- COFACTOR: CC Name=Mg(2+); Xref=ChEBI:CHEBI:18420; CC Evidence={ECO:0000255|PROSITE-ProRule:PRU00409, CC ECO:0000255|PROSITE-ProRule:PRU00969}; CC Name=Mn(2+); Xref=ChEBI:CHEBI:29035; CC Evidence={ECO:0000255|PROSITE-ProRule:PRU00409, CC ECO:0000255|PROSITE-ProRule:PRU00969}; CC Note=Binds 2 magnesium or manganese ions per subunit. CC {ECO:0000255|PROSITE-ProRule:PRU00409, ECO:0000255|PROSITE- CC ProRule:PRU00969}; CC -!- ACTIVITY REGULATION: Activity is increased by oligomerization of the CC protein into filaments (PubMed:19900410). The oligomerization and the CC activity of the enzyme are inhibited by phosphorylation at Ser-222 CC (PubMed:12488245). Inhibited by its product, malonyl-CoA CC (PubMed:16854592). Activated by citrate (PubMed:16854592). Activation CC by MID1IP1 is citrate-dependent (PubMed:20457939). Soraphen A, inhibits CC the enzyme by preventing the formation of active filamentous oligomers CC (Probable). {ECO:0000269|PubMed:12488245, ECO:0000269|PubMed:16854592, CC ECO:0000269|PubMed:19900410, ECO:0000269|PubMed:20457939, CC ECO:0000305|PubMed:19236960}. CC -!- BIOPHYSICOCHEMICAL PROPERTIES: CC Kinetic parameters: CC KM=120 uM for ATP {ECO:0000269|PubMed:16854592}; CC KM=110 uM for ATP (isoform 2) {ECO:0000269|PubMed:19190759}; CC KM=58 uM for acetyl-CoA {ECO:0000269|PubMed:16854592}; CC KM=94 uM for acetyl-CoA (isoform 3) {ECO:0000269|PubMed:19190759}; CC KM=6.5 mM for NaHCO3 (isoform 3) {ECO:0000269|PubMed:19190759}; CC KM=3.0 mM for NaHCO(3) {ECO:0000269|PubMed:16854592}; CC pH dependence: CC Optimum pH is 7.5. {ECO:0000305|PubMed:19236960}; CC -!- PATHWAY: Lipid metabolism; malonyl-CoA biosynthesis; malonyl-CoA from CC acetyl-CoA: step 1/1. {ECO:0000269|PubMed:19900410, CC ECO:0000269|PubMed:26976583}. CC -!- SUBUNIT: Monomer, homodimer, and homotetramer (PubMed:18772397, CC PubMed:20952656). Forms filamentous polymers (PubMed:19900410, CC PubMed:20457939, PubMed:20952656). Interacts with MID1IP1; interaction CC with MID1IP1 promotes oligomerization and increases its activity in a CC citrate-dependent manner (PubMed:20457939, PubMed:20952656). CC {ECO:0000269|PubMed:18772397, ECO:0000269|PubMed:19900410, CC ECO:0000269|PubMed:20457939, ECO:0000269|PubMed:20952656}. CC -!- INTERACTION: CC O00763; O00763: ACACB; NbExp=2; IntAct=EBI-2211739, EBI-2211739; CC O00763; P50747: HLCS; NbExp=4; IntAct=EBI-2211739, EBI-3915568; CC O00763; Q9CQ20: Mid1ip1; Xeno; NbExp=4; IntAct=EBI-2211739, EBI-473024; CC -!- SUBCELLULAR LOCATION: Mitochondrion {ECO:0000269|PubMed:10677481}. CC -!- ALTERNATIVE PRODUCTS: CC Event=Alternative splicing; Named isoforms=3; CC Name=1; Synonyms=Long; CC IsoId=O00763-1; Sequence=Displayed; CC Name=2; Synonyms=Short; CC IsoId=O00763-2; Sequence=VSP_000547; CC Name=3 {ECO:0000305}; Synonyms=ACC2.v2 {ECO:0000303|PubMed:19190759}; CC IsoId=O00763-3; Sequence=VSP_057081, VSP_057082; CC -!- TISSUE SPECIFICITY: Widely expressed with highest levels in heart, CC skeletal muscle, liver, adipose tissue, mammary gland, adrenal gland CC and colon (PubMed:9099716). Isoform 3 is expressed in skeletal muscle, CC adipose tissue and liver (at protein level) (PubMed:19190759). Isoform CC 3 is detected at high levels in adipose tissue with lower levels in CC heart, liver, skeletal muscle and testis (PubMed:19190759). CC {ECO:0000269|PubMed:19190759, ECO:0000269|PubMed:9099716}. CC -!- DOMAIN: Consists of an N-terminal biotin carboxylation/carboxylase (BC) CC domain that catalyzes the ATP-dependent transient carboxylation of the CC biotin covalently attached to the central biotinyl-binding/biotin CC carboxyl carrier (BCC) domain (Probable). The C-terminal carboxyl CC transferase (CT) domain catalyzes the transfer of the carboxyl group CC from carboxylated biotin to acetyl-CoA to produce malonyl-CoA CC (Probable). {ECO:0000305|PubMed:18247344, ECO:0000305|PubMed:19390150}. CC -!- PTM: The biotin cofactor is covalently attached to the central CC biotinyl-binding domain and is required for the catalytic activity. CC {ECO:0000305|PubMed:18247344}. CC -!- PTM: Phosphorylation at Ser-222 by AMPK inactivates the enzyme CC (PubMed:12488245). Required for the maintenance of skeletal muscle CC lipid and glucose homeostasis (By similarity). CC {ECO:0000250|UniProtKB:E9Q4Z2, ECO:0000269|PubMed:12488245}. CC -!- BIOTECHNOLOGY: Inhibition of ACACB may prevent lipid-induced insulin CC resistance and type 2 diabetes, making the enzyme a potential CC pharmaceutical target for treatment of obesity and type 2 diabetes. CC {ECO:0000305}. CC -!- SEQUENCE CAUTION: CC Sequence=AAB58382.1; Type=Miscellaneous discrepancy; Note=Many Frameshifts and conflicts.; Evidence={ECO:0000305}; CC Sequence=CAE01470.2; Type=Erroneous translation; Note=Wrong choice of CDS.; Evidence={ECO:0000305}; CC --------------------------------------------------------------------------- CC Copyrighted by the UniProt Consortium, see https://www.uniprot.org/terms CC Distributed under the Creative Commons Attribution (CC BY 4.0) License CC --------------------------------------------------------------------------- DR EMBL; U89344; AAB58382.1; ALT_SEQ; mRNA. DR EMBL; DQ493870; ABF48723.1; -; mRNA. DR EMBL; AJ575431; CAE01470.2; ALT_SEQ; mRNA. DR EMBL; AJ575592; CAE01471.3; -; mRNA. DR EMBL; AY382667; AAR37018.1; -; mRNA. DR EMBL; AC007637; -; NOT_ANNOTATED_CDS; Genomic_DNA. DR EMBL; U34591; AAC50571.1; -; mRNA. DR CCDS; CCDS31898.1; -. [O00763-1] DR PIR; S71091; S71091. DR RefSeq; NP_001084.3; NM_001093.4. [O00763-1] DR RefSeq; NP_001399663.1; NM_001412734.1. [O00763-1] DR RefSeq; NP_001399664.1; NM_001412735.1. [O00763-1] DR RefSeq; NP_001399665.1; NM_001412736.1. [O00763-3] DR PDB; 2DN8; NMR; -; A=885-971. DR PDB; 2HJW; X-ray; 2.50 A; A=217-775. DR PDB; 2KCC; NMR; -; A=891-965. DR PDB; 3FF6; X-ray; 3.19 A; A/B/C/D=1693-2450. DR PDB; 3GID; X-ray; 2.30 A; A/B=238-760. DR PDB; 3GLK; X-ray; 2.10 A; A=238-760. DR PDB; 3JRW; X-ray; 2.60 A; A=217-775. DR PDB; 3JRX; X-ray; 2.50 A; A=217-775. DR PDB; 3TDC; X-ray; 2.41 A; A=1690-2445. DR PDB; 4HQ6; X-ray; 2.70 A; A=217-776. DR PDB; 5KKN; X-ray; 2.60 A; B/C=238-760. DR PDBsum; 2DN8; -. DR PDBsum; 2HJW; -. DR PDBsum; 2KCC; -. DR PDBsum; 3FF6; -. DR PDBsum; 3GID; -. DR PDBsum; 3GLK; -. DR PDBsum; 3JRW; -. DR PDBsum; 3JRX; -. DR PDBsum; 3TDC; -. DR PDBsum; 4HQ6; -. DR PDBsum; 5KKN; -. DR AlphaFoldDB; O00763; -. DR SMR; O00763; -. DR BioGRID; 106550; 180. DR DIP; DIP-51617N; -. DR FunCoup; O00763; 2599. DR IntAct; O00763; 69. DR MINT; O00763; -. DR STRING; 9606.ENSP00000341044; -. DR BindingDB; O00763; -. DR ChEMBL; CHEMBL4829; -. DR DrugBank; DB03781; 2-[4-(2,4-Dichlorophenoxy)Phenoxy]Propanoic Acid. DR DrugBank; DB00173; Adenine. DR DrugBank; DB00121; Biotin. DR DrugBank; DB07870; Haloxyfop-P. DR DrugBank; DB00331; Metformin. DR DrugBank; DB12096; PF-05175157. DR DrugBank; DB02859; Soraphen A. DR GuidetoPHARMACOLOGY; 1264; -. DR SwissLipids; SLP:000000730; -. DR GlyGen; O00763; 1 site, 1 O-linked glycan (1 site). DR iPTMnet; O00763; -. DR PhosphoSitePlus; O00763; -. DR BioMuta; ACACB; -. DR jPOST; O00763; -. DR MassIVE; O00763; -. DR PaxDb; 9606-ENSP00000341044; -. DR PeptideAtlas; O00763; -. DR ProteomicsDB; 48022; -. [O00763-1] DR ProteomicsDB; 48023; -. [O00763-2] DR Antibodypedia; 1321; 163 antibodies from 30 providers. DR DNASU; 32; -. DR Ensembl; ENST00000338432.12; ENSP00000341044.7; ENSG00000076555.16. [O00763-1] DR Ensembl; ENST00000377848.7; ENSP00000367079.3; ENSG00000076555.16. [O00763-1] DR GeneID; 32; -. DR KEGG; hsa:32; -. DR MANE-Select; ENST00000338432.12; ENSP00000341044.7; NM_001093.4; NP_001084.3. DR UCSC; uc001tob.4; human. [O00763-1] DR AGR; HGNC:85; -. DR ClinPGx; PA24422; -. DR CTD; 32; -. DR DisGeNET; 32; -. DR GeneCards; ACACB; -. DR HGNC; HGNC:85; ACACB. DR HPA; ENSG00000076555; Tissue enhanced (adipose tissue, skeletal muscle). DR MalaCards; ACACB; -. DR MIM; 601557; gene. DR OpenTargets; ENSG00000076555; -. DR VEuPathDB; HostDB:ENSG00000076555; -. DR eggNOG; KOG0368; Eukaryota. DR GeneTree; ENSGT00940000155049; -. DR HOGENOM; CLU_000395_5_0_1; -. DR InParanoid; O00763; -. DR OMA; TEHCKVA; -. DR OrthoDB; 14612at2759; -. DR PAN-GO; O00763; 3 GO annotations based on evolutionary models. DR PhylomeDB; O00763; -. DR BioCyc; MetaCyc:HS01211-MONOMER; -. DR BRENDA; 6.3.4.14; 2681. DR BRENDA; 6.4.1.2; 2681. DR PathwayCommons; O00763; -. DR Reactome; R-HSA-163765; ChREBP activates metabolic gene expression. DR Reactome; R-HSA-196780; Biotin transport and metabolism. DR Reactome; R-HSA-200425; Carnitine shuttle. DR Reactome; R-HSA-2426168; Activation of gene expression by SREBF (SREBP). DR SABIO-RK; O00763; -. DR SignaLink; O00763; -. DR SIGNOR; O00763; -. DR UniPathway; UPA00655; UER00711. DR Agora; ENSG00000076555; -. DR BioGRID-ORCS; 32; 8 hits in 1154 CRISPR screens. DR ChiTaRS; ACACB; human. DR EvolutionaryTrace; O00763; -. DR GeneWiki; ACACB; -. DR GenomeRNAi; 32; -. DR Pharos; O00763; Tchem. DR PRO; PR:O00763; -. DR Proteomes; UP000005640; Chromosome 12. DR RNAct; O00763; protein. DR Bgee; ENSG00000076555; Expressed in tendon of biceps brachii and 208 other cell types or tissues. DR ExpressionAtlas; O00763; baseline and differential. DR GO; GO:0005829; C:cytosol; TAS:Reactome. DR GO; GO:0016507; C:mitochondrial fatty acid beta-oxidation multienzyme complex; IEA:Ensembl. DR GO; GO:0005741; C:mitochondrial outer membrane; TAS:Reactome. DR GO; GO:0005739; C:mitochondrion; IDA:UniProtKB. DR GO; GO:0005634; C:nucleus; IDA:UniProtKB. DR GO; GO:0003989; F:acetyl-CoA carboxylase activity; IDA:UniProtKB. DR GO; GO:0005524; F:ATP binding; IEA:UniProtKB-KW. DR GO; GO:0009374; F:biotin binding; IEA:Ensembl. DR GO; GO:0042802; F:identical protein binding; IPI:IntAct. DR GO; GO:0046872; F:metal ion binding; IEA:UniProtKB-KW. DR GO; GO:0006084; P:acetyl-CoA metabolic process; IDA:UniProtKB. DR GO; GO:0046323; P:D-glucose import; IEA:Ensembl. DR GO; GO:0097009; P:energy homeostasis; IEA:Ensembl. DR GO; GO:0006633; P:fatty acid biosynthetic process; IBA:GO_Central. DR GO; GO:0055089; P:fatty acid homeostasis; TAS:Reactome. DR GO; GO:0019395; P:fatty acid oxidation; IEA:Ensembl. DR GO; GO:0090459; P:intracellular aspartate homeostasis; IEA:Ensembl. DR GO; GO:0090461; P:intracellular glutamate homeostasis; IEA:Ensembl. DR GO; GO:0046722; P:lactic acid secretion; IEA:Ensembl. DR GO; GO:2001295; P:malonyl-CoA biosynthetic process; IEA:UniProtKB-UniPathway. DR GO; GO:0031999; P:negative regulation of fatty acid beta-oxidation; IEA:Ensembl. DR GO; GO:0006098; P:pentose-phosphate shunt; IEA:Ensembl. DR GO; GO:0060421; P:positive regulation of heart growth; IEA:Ensembl. DR GO; GO:0010884; P:positive regulation of lipid storage; IEA:Ensembl. DR GO; GO:0051289; P:protein homotetramerization; IDA:UniProtKB. DR GO; GO:1903242; P:regulation of cardiac muscle hypertrophy in response to stress; IEA:Ensembl. DR GO; GO:0010906; P:regulation of glucose metabolic process; IEA:Ensembl. DR GO; GO:0061771; P:response to caloric restriction; IEA:Ensembl. DR GO; GO:0007584; P:response to nutrient; IEA:Ensembl. DR GO; GO:0009410; P:response to xenobiotic stimulus; IEA:Ensembl. DR GO; GO:0072350; P:tricarboxylic acid metabolic process; IEA:Ensembl. DR CDD; cd06850; biotinyl_domain; 1. DR FunFam; 2.40.460.10:FF:000001; Acetyl-CoA carboxylase 1; 1. DR FunFam; 2.40.50.100:FF:000005; Acetyl-CoA carboxylase 1; 1. DR FunFam; 3.30.470.20:FF:000005; Acetyl-CoA carboxylase 1; 1. DR FunFam; 3.90.1770.10:FF:000001; acetyl-CoA carboxylase 1; 1. DR FunFam; 3.30.1490.20:FF:000003; acetyl-CoA carboxylase isoform X1; 1. DR FunFam; 3.40.50.20:FF:000005; acetyl-CoA carboxylase isoform X2; 1. DR FunFam; 3.90.226.10:FF:000010; acetyl-CoA carboxylase isoform X2; 1. DR Gene3D; 2.40.50.100; -; 1. DR Gene3D; 3.40.50.20; -; 1. DR Gene3D; 3.90.226.10; 2-enoyl-CoA Hydratase, Chain A, domain 1; 2. DR Gene3D; 3.30.1490.20; ATP-grasp fold, A domain; 1. DR Gene3D; 3.30.470.20; ATP-grasp fold, B domain; 1. DR Gene3D; 2.40.460.10; Biotin dependent carboxylase carboxyltransferase; 1. DR Gene3D; 3.90.1770.10; PreATP-grasp domain; 1. DR InterPro; IPR049076; ACCA. DR InterPro; IPR049074; ACCA_BT. DR InterPro; IPR034733; AcCoA_carboxyl_beta. DR InterPro; IPR013537; AcCoA_COase_cen. DR InterPro; IPR011761; ATP-grasp. DR InterPro; IPR013815; ATP_grasp_subdomain_1. DR InterPro; IPR005481; BC-like_N. DR InterPro; IPR011764; Biotin_carboxylation_dom. DR InterPro; IPR005482; Biotin_COase_C. DR InterPro; IPR000089; Biotin_lipoyl. DR InterPro; IPR029045; ClpP/crotonase-like_dom_sf. DR InterPro; IPR011763; COA_CT_C. DR InterPro; IPR011762; COA_CT_N. DR InterPro; IPR005479; CPAse_ATP-bd. DR InterPro; IPR016185; PreATP-grasp_dom_sf. DR InterPro; IPR011054; Rudment_hybrid_motif. DR InterPro; IPR011053; Single_hybrid_motif. DR PANTHER; PTHR45728:SF1; ACETYL-COA CARBOXYLASE 2; 1. DR PANTHER; PTHR45728; ACETYL-COA CARBOXYLASE, ISOFORM A; 1. DR Pfam; PF08326; ACC_central; 1. DR Pfam; PF21385; ACCA_BT; 1. DR Pfam; PF02785; Biotin_carb_C; 1. DR Pfam; PF00289; Biotin_carb_N; 1. DR Pfam; PF00364; Biotin_lipoyl; 1. DR Pfam; PF01039; Carboxyl_trans; 1. DR Pfam; PF02786; CPSase_L_D2; 1. DR SMART; SM00878; Biotin_carb_C; 1. DR SUPFAM; SSF52096; ClpP/crotonase; 2. DR SUPFAM; SSF56059; Glutathione synthetase ATP-binding domain-like; 1. DR SUPFAM; SSF52440; PreATP-grasp domain; 1. DR SUPFAM; SSF51246; Rudiment single hybrid motif; 1. DR SUPFAM; SSF51230; Single hybrid motif; 1. DR PROSITE; PS50975; ATP_GRASP; 1. DR PROSITE; PS50979; BC; 1. DR PROSITE; PS50968; BIOTINYL_LIPOYL; 1. DR PROSITE; PS50989; COA_CT_CTER; 1. DR PROSITE; PS50980; COA_CT_NTER; 1. DR PROSITE; PS00866; CPSASE_1; 1. DR PROSITE; PS00867; CPSASE_2; 1. PE 1: Evidence at protein level; KW 3D-structure; Allosteric enzyme; Alternative splicing; ATP-binding; Biotin; KW Fatty acid biosynthesis; Fatty acid metabolism; Ligase; Lipid biosynthesis; KW Lipid metabolism; Magnesium; Manganese; Metal-binding; Mitochondrion; KW Multifunctional enzyme; Nucleotide-binding; Phosphoprotein; KW Proteomics identification; Reference proteome; Transit peptide. FT TRANSIT 1..? FT /note="Mitochondrion" FT /evidence="ECO:0000250|UniProtKB:E9Q4Z2" FT CHAIN ?..2458 FT /note="Acetyl-CoA carboxylase 2" FT /evidence="ECO:0000305" FT /id="PRO_0000146767" FT DOMAIN 259..761 FT /note="Biotin carboxylation" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00969" FT DOMAIN 414..609 FT /note="ATP-grasp" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00409" FT DOMAIN 888..962 FT /note="Biotinyl-binding" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU01066" FT DOMAIN 1695..2025 FT /note="CoA carboxyltransferase N-terminal" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU01136" FT DOMAIN 2029..2345 FT /note="CoA carboxyltransferase C-terminal" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU01137" FT REGION 35..155 FT /note="Disordered" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT REGION 174..193 FT /note="Disordered" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT REGION 1695..2345 FT /note="Carboxyltransferase" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU01138" FT COMPBIAS 51..60 FT /note="Polar residues" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT COMPBIAS 77..87 FT /note="Basic and acidic residues" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT COMPBIAS 103..146 FT /note="Polar residues" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT ACT_SITE 584 FT /evidence="ECO:0000250" FT BINDING 458..463 FT /ligand="ATP" FT /ligand_id="ChEBI:CHEBI:30616" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00409" FT BINDING 567 FT /ligand="Mg(2+)" FT /ligand_id="ChEBI:CHEBI:18420" FT /ligand_label="1" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00409, FT ECO:0000255|PROSITE-ProRule:PRU00969" FT BINDING 567 FT /ligand="Mn(2+)" FT /ligand_id="ChEBI:CHEBI:29035" FT /ligand_label="1" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00409, FT ECO:0000255|PROSITE-ProRule:PRU00969" FT BINDING 580 FT /ligand="Mg(2+)" FT /ligand_id="ChEBI:CHEBI:18420" FT /ligand_label="1" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00409, FT ECO:0000255|PROSITE-ProRule:PRU00969" FT BINDING 580 FT /ligand="Mg(2+)" FT /ligand_id="ChEBI:CHEBI:18420" FT /ligand_label="2" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00409, FT ECO:0000255|PROSITE-ProRule:PRU00969" FT BINDING 580 FT /ligand="Mn(2+)" FT /ligand_id="ChEBI:CHEBI:29035" FT /ligand_label="1" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00409, FT ECO:0000255|PROSITE-ProRule:PRU00969" FT BINDING 580 FT /ligand="Mn(2+)" FT /ligand_id="ChEBI:CHEBI:29035" FT /ligand_label="2" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00409, FT ECO:0000255|PROSITE-ProRule:PRU00969" FT BINDING 582 FT /ligand="Mg(2+)" FT /ligand_id="ChEBI:CHEBI:18420" FT /ligand_label="2" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00409, FT ECO:0000255|PROSITE-ProRule:PRU00969" FT BINDING 582 FT /ligand="Mn(2+)" FT /ligand_id="ChEBI:CHEBI:29035" FT /ligand_label="2" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00409, FT ECO:0000255|PROSITE-ProRule:PRU00969" FT BINDING 1934 FT /ligand="CoA" FT /ligand_id="ChEBI:CHEBI:57287" FT /evidence="ECO:0000250" FT BINDING 2238 FT /ligand="CoA" FT /ligand_id="ChEBI:CHEBI:57287" FT /evidence="ECO:0000250" FT BINDING 2240 FT /ligand="CoA" FT /ligand_id="ChEBI:CHEBI:57287" FT /evidence="ECO:0000250" FT MOD_RES 35 FT /note="Phosphoserine" FT /evidence="ECO:0007744|PubMed:24275569" FT MOD_RES 70 FT /note="Phosphothreonine" FT /evidence="ECO:0007744|PubMed:24275569" FT MOD_RES 91 FT /note="Phosphoserine" FT /evidence="ECO:0007744|PubMed:24275569" FT MOD_RES 95 FT /note="Phosphoserine" FT /evidence="ECO:0007744|PubMed:24275569" FT MOD_RES 169 FT /note="Phosphoserine" FT /evidence="ECO:0000250|UniProtKB:Q13085" FT MOD_RES 175 FT /note="Phosphoserine" FT /evidence="ECO:0000250|UniProtKB:Q13085" FT MOD_RES 192 FT /note="Phosphoserine" FT /evidence="ECO:0000250|UniProtKB:Q13085" FT MOD_RES 195 FT /note="Phosphoserine" FT /evidence="ECO:0000250|UniProtKB:Q13085" FT MOD_RES 200 FT /note="Phosphoserine" FT /evidence="ECO:0007744|PubMed:24275569" FT MOD_RES 207 FT /note="Phosphothreonine" FT /evidence="ECO:0000250|UniProtKB:E9Q4Z2" FT MOD_RES 220 FT /note="Phosphoserine" FT /evidence="ECO:0000250|UniProtKB:P11497" FT MOD_RES 222 FT /note="Phosphoserine; by AMPK" FT /evidence="ECO:0000269|PubMed:12488245, FT ECO:0000269|PubMed:19900410" FT MOD_RES 469 FT /note="Phosphoserine" FT /evidence="ECO:0007744|PubMed:24275569" FT MOD_RES 753 FT /note="Phosphothreonine" FT /evidence="ECO:0000250|UniProtKB:Q13085" FT MOD_RES 929 FT /note="N6-biotinyllysine" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU01066, FT ECO:0000269|PubMed:18247344" FT MOD_RES 1340 FT /note="Phosphoserine" FT /evidence="ECO:0000250|UniProtKB:E9Q4Z2" FT MOD_RES 1342 FT /note="Phosphothreonine" FT /evidence="ECO:0007744|PubMed:24275569" FT MOD_RES 1360 FT /note="Phosphoserine" FT /evidence="ECO:0000250|UniProtKB:E9Q4Z2" FT MOD_RES 1405 FT /note="Phosphoserine" FT /evidence="ECO:0000250|UniProtKB:Q13085" FT VAR_SEQ 1..202 FT /note="Missing (in isoform 3)" FT /evidence="ECO:0000269|PubMed:19190759" FT /id="VSP_057081" FT VAR_SEQ 203..218 FT /note="AYLTTGEAETRVPTMR -> MSPAKCKICFPDREVK (in isoform 3)" FT /evidence="ECO:0000269|PubMed:19190759" FT /id="VSP_057082" FT VAR_SEQ 1118..1187 FT /note="Missing (in isoform 2)" FT /evidence="ECO:0000303|PubMed:9099716" FT /id="VSP_000547" FT VARIANT 193 FT /note="R -> L (in a pancreatic ductal adenocarcinoma FT sample; somatic mutation)" FT /evidence="ECO:0000269|PubMed:18772397" FT /id="VAR_062667" FT VARIANT 552 FT /note="I -> V (in dbSNP:rs16940029)" FT /id="VAR_031255" FT VARIANT 651 FT /note="A -> T (in dbSNP:rs2300455)" FT /id="VAR_031256" FT VARIANT 2141 FT /note="V -> I (in dbSNP:rs2075260)" FT /evidence="ECO:0000269|PubMed:16854592, ECO:0000269|Ref.3" FT /id="VAR_031257" FT MUTAGEN 277 FT /note="R->A: Loss of regulation of oligomerization by FT phosphorylation at S-222." FT /evidence="ECO:0000269|PubMed:19900410" FT MUTAGEN 671 FT /note="E->A: Altered regulation of oligomerization by FT phosphorylation at S-222." FT /evidence="ECO:0000269|PubMed:19900410" FT CONFLICT 9 FT /note="C -> R (in Ref. 2; ABF48723)" FT /evidence="ECO:0000305" FT CONFLICT 120 FT /note="T -> I (in Ref. 4; AAR37018)" FT /evidence="ECO:0000305" FT CONFLICT 422 FT /note="I -> T (in Ref. 4; AAR37018)" FT /evidence="ECO:0000305" FT CONFLICT 1340 FT /note="S -> N (in Ref. 6; AAC50571)" FT /evidence="ECO:0000305" FT CONFLICT 1383 FT /note="D -> G (in Ref. 6; AAC50571)" FT /evidence="ECO:0000305" FT CONFLICT 1425 FT /note="V -> M (in Ref. 6; AAC50571)" FT /evidence="ECO:0000305" FT CONFLICT 1819..1821 FT /note="AEG -> PEA (in Ref. 6; AAC50571)" FT /evidence="ECO:0000305" FT CONFLICT 1892..1893 FT /note="MI -> IM (in Ref. 6; AAC50571)" FT /evidence="ECO:0000305" FT HELIX 247..253 FT /evidence="ECO:0007829|PDB:3GLK" FT STRAND 262..265 FT /evidence="ECO:0007829|PDB:3GLK" FT HELIX 269..287 FT /evidence="ECO:0007829|PDB:3GLK" FT STRAND 292..299 FT /evidence="ECO:0007829|PDB:3GLK" FT HELIX 301..305 FT /evidence="ECO:0007829|PDB:3GLK" FT HELIX 309..313 FT /evidence="ECO:0007829|PDB:3GLK" FT STRAND 314..319 FT /evidence="ECO:0007829|PDB:3GLK" FT HELIX 325..327 FT /evidence="ECO:0007829|PDB:3GLK" FT TURN 328..330 FT /evidence="ECO:0007829|PDB:3GLK" FT HELIX 332..341 FT /evidence="ECO:0007829|PDB:3GLK" FT STRAND 345..348 FT /evidence="ECO:0007829|PDB:3GLK" FT HELIX 353..356 FT /evidence="ECO:0007829|PDB:3GLK" FT HELIX 359..366 FT /evidence="ECO:0007829|PDB:3GLK" FT STRAND 370..373 FT /evidence="ECO:0007829|PDB:3GLK" FT HELIX 376..379 FT /evidence="ECO:0007829|PDB:3GLK" FT HELIX 385..394 FT /evidence="ECO:0007829|PDB:3GLK" FT TURN 403..406 FT /evidence="ECO:0007829|PDB:3GLK" FT HELIX 426..431 FT /evidence="ECO:0007829|PDB:3GLK" FT HELIX 437..447 FT /evidence="ECO:0007829|PDB:3GLK" FT STRAND 449..455 FT /evidence="ECO:0007829|PDB:3GLK" FT STRAND 464..467 FT /evidence="ECO:0007829|PDB:3GLK" FT TURN 470..472 FT /evidence="ECO:0007829|PDB:3GLK" FT HELIX 473..483 FT /evidence="ECO:0007829|PDB:3GLK" FT STRAND 489..493 FT /evidence="ECO:0007829|PDB:3GLK" FT STRAND 496..507 FT /evidence="ECO:0007829|PDB:3GLK" FT STRAND 509..511 FT /evidence="ECO:0007829|PDB:3JRX" FT STRAND 513..523 FT /evidence="ECO:0007829|PDB:3GLK" FT STRAND 524..527 FT /evidence="ECO:0007829|PDB:4HQ6" FT STRAND 530..535 FT /evidence="ECO:0007829|PDB:3GLK" FT HELIX 541..558 FT /evidence="ECO:0007829|PDB:3GLK" FT STRAND 562..571 FT /evidence="ECO:0007829|PDB:3GLK" FT STRAND 572..574 FT /evidence="ECO:0007829|PDB:2HJW" FT STRAND 576..582 FT /evidence="ECO:0007829|PDB:3GLK" FT HELIX 589..596 FT /evidence="ECO:0007829|PDB:3GLK" FT HELIX 600..608 FT /evidence="ECO:0007829|PDB:3GLK" FT HELIX 613..615 FT /evidence="ECO:0007829|PDB:3GLK" FT HELIX 617..622 FT /evidence="ECO:0007829|PDB:3GLK" FT STRAND 635..637 FT /evidence="ECO:0007829|PDB:2HJW" FT STRAND 646..653 FT /evidence="ECO:0007829|PDB:3GLK" FT STRAND 669..671 FT /evidence="ECO:0007829|PDB:3GLK" FT STRAND 679..685 FT /evidence="ECO:0007829|PDB:3GLK" FT STRAND 700..709 FT /evidence="ECO:0007829|PDB:3GLK" FT HELIX 710..724 FT /evidence="ECO:0007829|PDB:3GLK" FT HELIX 728..730 FT /evidence="ECO:0007829|PDB:2HJW" FT HELIX 732..742 FT /evidence="ECO:0007829|PDB:3GLK" FT HELIX 744..748 FT /evidence="ECO:0007829|PDB:3GLK" FT HELIX 754..756 FT /evidence="ECO:0007829|PDB:2HJW" FT STRAND 896..898 FT /evidence="ECO:0007829|PDB:2DN8" FT STRAND 900..902 FT /evidence="ECO:0007829|PDB:2KCC" FT STRAND 903..910 FT /evidence="ECO:0007829|PDB:2DN8" FT STRAND 914..916 FT /evidence="ECO:0007829|PDB:2DN8" FT STRAND 921..927 FT /evidence="ECO:0007829|PDB:2DN8" FT STRAND 930..935 FT /evidence="ECO:0007829|PDB:2DN8" FT STRAND 937..944 FT /evidence="ECO:0007829|PDB:2DN8" FT STRAND 957..961 FT /evidence="ECO:0007829|PDB:2DN8" FT TURN 1698..1700 FT /evidence="ECO:0007829|PDB:3FF6" FT HELIX 1703..1711 FT /evidence="ECO:0007829|PDB:3TDC" FT HELIX 1717..1719 FT /evidence="ECO:0007829|PDB:3TDC" FT HELIX 1720..1732 FT /evidence="ECO:0007829|PDB:3TDC" FT STRAND 1742..1750 FT /evidence="ECO:0007829|PDB:3TDC" FT STRAND 1756..1759 FT /evidence="ECO:0007829|PDB:3TDC" FT STRAND 1767..1777 FT /evidence="ECO:0007829|PDB:3TDC" FT STRAND 1786..1793 FT /evidence="ECO:0007829|PDB:3TDC" FT HELIX 1798..1800 FT /evidence="ECO:0007829|PDB:3TDC" FT HELIX 1804..1820 FT /evidence="ECO:0007829|PDB:3TDC" FT STRAND 1824..1828 FT /evidence="ECO:0007829|PDB:3TDC" FT HELIX 1839..1842 FT /evidence="ECO:0007829|PDB:3TDC" FT STRAND 1846..1850 FT /evidence="ECO:0007829|PDB:3TDC" FT HELIX 1855..1857 FT /evidence="ECO:0007829|PDB:3TDC" FT STRAND 1859..1864 FT /evidence="ECO:0007829|PDB:3TDC" FT HELIX 1866..1872 FT /evidence="ECO:0007829|PDB:3TDC" FT TURN 1873..1876 FT /evidence="ECO:0007829|PDB:3TDC" FT STRAND 1878..1885 FT /evidence="ECO:0007829|PDB:3TDC" FT STRAND 1888..1896 FT /evidence="ECO:0007829|PDB:3TDC" FT STRAND 1899..1901 FT /evidence="ECO:0007829|PDB:3TDC" FT HELIX 1905..1924 FT /evidence="ECO:0007829|PDB:3TDC" FT STRAND 1927..1931 FT /evidence="ECO:0007829|PDB:3TDC" FT STRAND 1933..1936 FT /evidence="ECO:0007829|PDB:3TDC" FT HELIX 1938..1946 FT /evidence="ECO:0007829|PDB:3TDC" FT STRAND 1948..1952 FT /evidence="ECO:0007829|PDB:3TDC" FT STRAND 1956..1960 FT /evidence="ECO:0007829|PDB:3TDC" FT HELIX 1962..1969 FT /evidence="ECO:0007829|PDB:3TDC" FT HELIX 1977..1981 FT /evidence="ECO:0007829|PDB:3TDC" FT HELIX 1983..1986 FT /evidence="ECO:0007829|PDB:3TDC" FT TURN 1987..1990 FT /evidence="ECO:0007829|PDB:3TDC" FT STRAND 1993..1998 FT /evidence="ECO:0007829|PDB:3TDC" FT HELIX 1999..2010 FT /evidence="ECO:0007829|PDB:3TDC" FT HELIX 2045..2050 FT /evidence="ECO:0007829|PDB:3TDC" FT STRAND 2055..2057 FT /evidence="ECO:0007829|PDB:3TDC" FT STRAND 2072..2075 FT /evidence="ECO:0007829|PDB:3TDC" FT STRAND 2082..2089 FT /evidence="ECO:0007829|PDB:3TDC" FT STRAND 2092..2099 FT /evidence="ECO:0007829|PDB:3TDC" FT STRAND 2104..2108 FT /evidence="ECO:0007829|PDB:3TDC" FT STRAND 2120..2124 FT /evidence="ECO:0007829|PDB:3TDC" FT HELIX 2131..2147 FT /evidence="ECO:0007829|PDB:3TDC" FT STRAND 2151..2154 FT /evidence="ECO:0007829|PDB:3TDC" FT HELIX 2164..2168 FT /evidence="ECO:0007829|PDB:3TDC" FT HELIX 2171..2183 FT /evidence="ECO:0007829|PDB:3TDC" FT STRAND 2189..2193 FT /evidence="ECO:0007829|PDB:3TDC" FT STRAND 2198..2200 FT /evidence="ECO:0007829|PDB:3TDC" FT HELIX 2201..2205 FT /evidence="ECO:0007829|PDB:3TDC" FT HELIX 2209..2211 FT /evidence="ECO:0007829|PDB:3TDC" FT TURN 2213..2215 FT /evidence="ECO:0007829|PDB:3TDC" FT STRAND 2216..2221 FT /evidence="ECO:0007829|PDB:3TDC" FT STRAND 2225..2229 FT /evidence="ECO:0007829|PDB:3TDC" FT HELIX 2231..2238 FT /evidence="ECO:0007829|PDB:3TDC" FT HELIX 2241..2251 FT /evidence="ECO:0007829|PDB:3TDC" FT HELIX 2253..2261 FT /evidence="ECO:0007829|PDB:3TDC" FT HELIX 2269..2299 FT /evidence="ECO:0007829|PDB:3TDC" FT HELIX 2300..2302 FT /evidence="ECO:0007829|PDB:3TDC" FT HELIX 2304..2309 FT /evidence="ECO:0007829|PDB:3TDC" FT STRAND 2312..2317 FT /evidence="ECO:0007829|PDB:3TDC" FT HELIX 2319..2321 FT /evidence="ECO:0007829|PDB:3TDC" FT HELIX 2322..2344 FT /evidence="ECO:0007829|PDB:3TDC" FT HELIX 2345..2348 FT /evidence="ECO:0007829|PDB:3FF6" FT HELIX 2352..2365 FT /evidence="ECO:0007829|PDB:3TDC" FT HELIX 2369..2376 FT /evidence="ECO:0007829|PDB:3TDC" FT HELIX 2378..2388 FT /evidence="ECO:0007829|PDB:3TDC" FT HELIX 2404..2420 FT /evidence="ECO:0007829|PDB:3TDC" FT TURN 2423..2425 FT /evidence="ECO:0007829|PDB:3FF6" FT HELIX 2426..2435 FT /evidence="ECO:0007829|PDB:3FF6" FT HELIX 2439..2448 FT /evidence="ECO:0007829|PDB:3FF6" SQ SEQUENCE 2458 AA; 276541 MW; ED12674A1A8A0706 CRC64; MVLLLCLSCL IFSCLTFSWL KIWGKMTDSK PITKSKSEAN LIPSQEPFPA SDNSGETPQR NGEGHTLPKT PSQAEPASHK GPKDAGRRRN SLPPSHQKPP RNPLSSSDAA PSPELQANGT GTQGLEATDT NGLSSSARPQ GQQAGSPSKE DKKQANIKRQ LMTNFILGSF DDYSSDEDSV AGSSRESTRK GSRASLGALS LEAYLTTGEA ETRVPTMRPS MSGLHLVKRG REHKKLDLHR DFTVASPAEF VTRFGGDRVI EKVLIANNGI AAVKCMRSIR RWAYEMFRNE RAIRFVVMVT PEDLKANAEY IKMADHYVPV PGGPNNNNYA NVELIVDIAK RIPVQAVWAG WGHASENPKL PELLCKNGVA FLGPPSEAMW ALGDKIASTV VAQTLQVPTL PWSGSGLTVE WTEDDLQQGK RISVPEDVYD KGCVKDVDEG LEAAERIGFP LMIKASEGGG GKGIRKAESA EDFPILFRQV QSEIPGSPIF LMKLAQHARH LEVQILADQY GNAVSLFGRD CSIQRRHQKI VEEAPATIAP LAIFEFMEQC AIRLAKTVGY VSAGTVEYLY SQDGSFHFLE LNPRLQVEHP CTEMIADVNL PAAQLQIAMG VPLHRLKDIR LLYGESPWGV TPISFETPSN PPLARGHVIA ARITSENPDE GFKPSSGTVQ ELNFRSSKNV WGYFSVAATG GLHEFADSQF GHCFSWGENR EEAISNMVVA LKELSIRGDF RTTVEYLINL LETESFQNND IDTGWLDYLI AEKVQAEKPD IMLGVVCGAL NVADAMFRTC MTDFLHSLER GQVLPADSLL NLVDVELIYG GVKYILKVAR QSLTMFVLIM NGCHIEIDAH RLNDGGLLLS YNGNSYTTYM KEEVDSYRIT IGNKTCVFEK ENDPTVLRSP SAGKLTQYTV EDGGHVEAGS SYAEMEVMKM IMTLNVQERG RVKYIKRPGA VLEAGCVVAR LELDDPSKVH PAEPFTGELP AQQTLPILGE KLHQVFHSVL ENLTNVMSGF CLPEPVFSIK LKEWVQKLMM TLRHPSLPLL ELQEIMTSVA GRIPAPVEKS VRRVMAQYAS NITSVLCQFP SQQIATILDC HAATLQRKAD REVFFINTQS IVQLVQRYRS GIRGYMKTVV LDLLRRYLRV EHHFQQAHYD KCVINLREQF KPDMSQVLDC IFSHAQVAKK NQLVIMLIDE LCGPDPSLSD ELISILNELT QLSKSEHCKV ALRARQILIA SHLPSYELRH NQVESIFLSA IDMYGHQFCP ENLKKLILSE TTIFDVLPTF FYHANKVVCM ASLEVYVRRG YIAYELNSLQ HRQLPDGTCV VEFQFMLPSS HPNRMTVPIS ITNPDLLRHS TELFMDSGFS PLCQRMGAMV AFRRFEDFTR NFDEVISCFA NVPKDTPLFS EARTSLYSED DCKSLREEPI HILNVSIQCA DHLEDEALVP ILRTFVQSKK NILVDYGLRR ITFLIAQEKE FPKFFTFRAR DEFAEDRIYR HLEPALAFQL ELNRMRNFDL TAVPCANHKM HLYLGAAKVK EGVEVTDHRF FIRAIIRHSD LITKEASFEY LQNEGERLLL EAMDELEVAF NNTSVRTDCN HIFLNFVPTV IMDPFKIEES VRYMVMRYGS RLWKLRVLQA EVKINIRQTT TGSAVPIRLF ITNESGYYLD ISLYKEVTDS RSGNIMFHSF GNKQGPQHGM LINTPYVTKD LLQAKRFQAQ TLGTTYIYDF PEMFRQALFK LWGSPDKYPK DILTYTELVL DSQGQLVEMN RLPGGNEVGM VAFKMRFKTQ EYPEGRDVIV IGNDITFRIG SFGPGEDLLY LRASEMARAE GIPKIYVAAN SGARIGMAEE IKHMFHVAWV DPEDPHKGFK YLYLTPQDYT RISSLNSVHC KHIEEGGESR YMITDIIGKD DGLGVENLRG SGMIAGESSL AYEEIVTISL VTCRAIGIGA YLVRLGQRVI QVENSHIILT GASALNKVLG REVYTSNNQL GGVQIMHYNG VSHITVPDDF EGVYTILEWL SYMPKDNHSP VPIITPTDPI DREIEFLPSR APYDPRWMLA GRPHPTLKGT WQSGFFDHGS FKEIMAPWAQ TVVTGRARLG GIPVGVIAVE TRTVEVAVPA DPANLDSEAK IIQQAGQVWF PDSAYKTAQA VKDFNREKLP LMIFANWRGF SGGMKDMYDQ VLKFGAYIVD GLRQYKQPIL IYIPPYAELR GGSWVVIDAT INPLCIEMYA DKESRGGVLE PEGTVEIKFR KKDLIKSMRR IDPAYKKLME QLGEPDLSDK DRKDLEGRLK AREDLLLPIY HQVAVQFADF HDTPGRMLEK GVISDILEWK TARTFLYWRL RRLLLEDQVK QEILQASGEL SHVHIQSMLR RWFVETEGAV KAYLWDNNQV VVQWLEQHWQ AGDGPRSTIR ENITYLKHDS VLKTIRGLVE ENPEVAVDCV IYLSQHISPA ERAQVVHLLS TMDSPAST // ID E2AK2_HUMAN Reviewed; 551 AA. AC P19525; A8K3P0; D6W584; E9PC80; Q52M43; Q7Z6F6; Q9UIR4; DT 01-FEB-1991, integrated into UniProtKB/Swiss-Prot. DT 01-MAY-1991, sequence version 2. DT 28-JAN-2026, entry version 260. DE RecName: Full=Interferon-induced, double-stranded RNA-activated protein kinase; DE EC=2.7.11.1; DE AltName: Full=Eukaryotic translation initiation factor 2-alpha kinase 2; DE Short=eIF-2A protein kinase 2; DE AltName: Full=Interferon-inducible RNA-dependent protein kinase; DE AltName: Full=P1/eIF-2A protein kinase; DE AltName: Full=Protein kinase RNA-activated; DE Short=PKR; DE Short=Protein kinase R {ECO:0000303|PubMed:11438532}; DE AltName: Full=Tyrosine-protein kinase EIF2AK2; DE EC=2.7.10.2; DE AltName: Full=p68 kinase; GN Name=EIF2AK2; Synonyms=PKR, PRKR; OS Homo sapiens (Human). OC Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia; OC Eutheria; Euarchontoglires; Primates; Haplorrhini; Catarrhini; Hominidae; OC Homo. OX NCBI_TaxID=9606; RN [1] RP NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 1), PROTEIN SEQUENCE OF 101-118 AND RP 309-325, AND INDUCTION. RX PubMed=1695551; DOI=10.1016/0092-8674(90)90374-n; RA Meurs E., Chong K., Galabru J., Thomas N.S.B., Kerr I.M., Williams B.R.G., RA Hovanessian A.G.; RT "Molecular cloning and characterization of the human double-stranded RNA- RT activated protein kinase induced by interferon."; RL Cell 62:379-390(1990). RN [2] RP SEQUENCE REVISION. RA Meurs E.; RL Submitted (AUG-1990) to the EMBL/GenBank/DDBJ databases. RN [3] RP NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 1). RX PubMed=1373553; DOI=10.1016/0042-6822(92)90732-5; RA Thomis D.C., Doohan J.P., Samuel C.E.; RT "Mechanism of interferon action: cDNA structure, expression, and regulation RT of the interferon-induced, RNA-dependent P1/eIF-2 alpha protein kinase from RT human cells."; RL Virology 188:33-46(1992). RN [4] RP NUCLEOTIDE SEQUENCE [GENOMIC DNA / MRNA] (ISOFORM 1). RX PubMed=8921913; DOI=10.1016/0378-1119(96)00314-9; RA Kuhen K.L., Shen X., Samuel C.E.; RT "Mechanism of interferon action sequence of the human interferon-inducible RT RNA-dependent protein kinase (PKR) deduced from genomic clones."; RL Gene 178:191-193(1996). RN [5] RP NUCLEOTIDE SEQUENCE [GENOMIC DNA]. RC TISSUE=Placenta; RX PubMed=8812437; DOI=10.1006/geno.1996.0446; RA Kuhen K.L., Shen X., Carlisle E.R., Richardson A.L., Weier H.-U.G., RA Tanaka H., Samuel C.E.; RT "Structural organization of the human gene (PKR) encoding an interferon- RT inducible RNA-dependent protein kinase (PKR) and differences from its mouse RT homolog."; RL Genomics 36:197-201(1996). RN [6] RP NUCLEOTIDE SEQUENCE [GENOMIC DNA]. RX PubMed=9726442; DOI=10.1089/jir.1998.18.609; RA Xu Z., Williams B.R.; RT "Genomic features of human PKR: alternative splicing and a polymorphic CGG RT repeat in the 5'-untranslated region."; RL J. Interferon Cytokine Res. 18:609-616(1998). RN [7] RP NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 2). RA Li H., Huang F., Shen C., Zhou G., Zheng G., Ke R., Lin L., Yang S.; RL Submitted (MAY-2003) to the EMBL/GenBank/DDBJ databases. RN [8] RP NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM 1). RC TISSUE=Brain, and Embryo; RX PubMed=14702039; DOI=10.1038/ng1285; RA Ota T., Suzuki Y., Nishikawa T., Otsuki T., Sugiyama T., Irie R., RA Wakamatsu A., Hayashi K., Sato H., Nagai K., Kimura K., Makita H., RA Sekine M., Obayashi M., Nishi T., Shibahara T., Tanaka T., Ishii S., RA Yamamoto J., Saito K., Kawai Y., Isono Y., Nakamura Y., Nagahari K., RA Murakami K., Yasuda T., Iwayanagi T., Wagatsuma M., Shiratori A., Sudo H., RA Hosoiri T., Kaku Y., Kodaira H., Kondo H., Sugawara M., Takahashi M., RA Kanda K., Yokoi T., Furuya T., Kikkawa E., Omura Y., Abe K., Kamihara K., RA Katsuta N., Sato K., Tanikawa M., Yamazaki M., Ninomiya K., Ishibashi T., RA Yamashita H., Murakawa K., Fujimori K., Tanai H., Kimata M., Watanabe M., RA Hiraoka S., Chiba Y., Ishida S., Ono Y., Takiguchi S., Watanabe S., RA Yosida M., Hotuta T., Kusano J., Kanehori K., Takahashi-Fujii A., Hara H., RA Tanase T.-O., Nomura Y., Togiya S., Komai F., Hara R., Takeuchi K., RA Arita M., Imose N., Musashino K., Yuuki H., Oshima A., Sasaki N., RA Aotsuka S., Yoshikawa Y., Matsunawa H., Ichihara T., Shiohata N., Sano S., RA Moriya S., Momiyama H., Satoh N., Takami S., Terashima Y., Suzuki O., RA Nakagawa S., Senoh A., Mizoguchi H., Goto Y., Shimizu F., Wakebe H., RA Hishigaki H., Watanabe T., Sugiyama A., Takemoto M., Kawakami B., RA Yamazaki M., Watanabe K., Kumagai A., Itakura S., Fukuzumi Y., Fujimori Y., RA Komiyama M., Tashiro H., Tanigami A., Fujiwara T., Ono T., Yamada K., RA Fujii Y., Ozaki K., Hirao M., Ohmori Y., Kawabata A., Hikiji T., RA Kobatake N., Inagaki H., Ikema Y., Okamoto S., Okitani R., Kawakami T., RA Noguchi S., Itoh T., Shigeta K., Senba T., Matsumura K., Nakajima Y., RA Mizuno T., Morinaga M., Sasaki M., Togashi T., Oyama M., Hata H., RA Watanabe M., Komatsu T., Mizushima-Sugano J., Satoh T., Shirai Y., RA Takahashi Y., Nakagawa K., Okumura K., Nagase T., Nomura N., Kikuchi H., RA Masuho Y., Yamashita R., Nakai K., Yada T., Nakamura Y., Ohara O., RA Isogai T., Sugano S.; RT "Complete sequencing and characterization of 21,243 full-length human RT cDNAs."; RL Nat. Genet. 36:40-45(2004). RN [9] RP NUCLEOTIDE SEQUENCE [GENOMIC DNA]. RG NIEHS SNPs program; RL Submitted (JAN-2003) to the EMBL/GenBank/DDBJ databases. RN [10] RP NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA]. RX PubMed=15815621; DOI=10.1038/nature03466; RA Hillier L.W., Graves T.A., Fulton R.S., Fulton L.A., Pepin K.H., Minx P., RA Wagner-McPherson C., Layman D., Wylie K., Sekhon M., Becker M.C., RA Fewell G.A., Delehaunty K.D., Miner T.L., Nash W.E., Kremitzki C., Oddy L., RA Du H., Sun H., Bradshaw-Cordum H., Ali J., Carter J., Cordes M., Harris A., RA Isak A., van Brunt A., Nguyen C., Du F., Courtney L., Kalicki J., RA Ozersky P., Abbott S., Armstrong J., Belter E.A., Caruso L., Cedroni M., RA Cotton M., Davidson T., Desai A., Elliott G., Erb T., Fronick C., Gaige T., RA Haakenson W., Haglund K., Holmes A., Harkins R., Kim K., Kruchowski S.S., RA Strong C.M., Grewal N., Goyea E., Hou S., Levy A., Martinka S., Mead K., RA McLellan M.D., Meyer R., Randall-Maher J., Tomlinson C., RA Dauphin-Kohlberg S., Kozlowicz-Reilly A., Shah N., Swearengen-Shahid S., RA Snider J., Strong J.T., Thompson J., Yoakum M., Leonard S., Pearman C., RA Trani L., Radionenko M., Waligorski J.E., Wang C., Rock S.M., RA Tin-Wollam A.-M., Maupin R., Latreille P., Wendl M.C., Yang S.-P., Pohl C., RA Wallis J.W., Spieth J., Bieri T.A., Berkowicz N., Nelson J.O., Osborne J., RA Ding L., Meyer R., Sabo A., Shotland Y., Sinha P., Wohldmann P.E., RA Cook L.L., Hickenbotham M.T., Eldred J., Williams D., Jones T.A., She X., RA Ciccarelli F.D., Izaurralde E., Taylor J., Schmutz J., Myers R.M., RA Cox D.R., Huang X., McPherson J.D., Mardis E.R., Clifton S.W., Warren W.C., RA Chinwalla A.T., Eddy S.R., Marra M.A., Ovcharenko I., Furey T.S., RA Miller W., Eichler E.E., Bork P., Suyama M., Torrents D., Waterston R.H., RA Wilson R.K.; RT "Generation and annotation of the DNA sequences of human chromosomes 2 and RT 4."; RL Nature 434:724-731(2005). RN [11] RP NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA]. RA Mural R.J., Istrail S., Sutton G.G., Florea L., Halpern A.L., Mobarry C.M., RA Lippert R., Walenz B., Shatkay H., Dew I., Miller J.R., Flanigan M.J., RA Edwards N.J., Bolanos R., Fasulo D., Halldorsson B.V., Hannenhalli S., RA Turner R., Yooseph S., Lu F., Nusskern D.R., Shue B.C., Zheng X.H., RA Zhong F., Delcher A.L., Huson D.H., Kravitz S.A., Mouchard L., Reinert K., RA Remington K.A., Clark A.G., Waterman M.S., Eichler E.E., Adams M.D., RA Hunkapiller M.W., Myers E.W., Venter J.C.; RL Submitted (SEP-2005) to the EMBL/GenBank/DDBJ databases. RN [12] RP NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM 1). RC TISSUE=Brain; RX PubMed=15489334; DOI=10.1101/gr.2596504; RG The MGC Project Team; RT "The status, quality, and expansion of the NIH full-length cDNA project: RT the Mammalian Gene Collection (MGC)."; RL Genome Res. 14:2121-2127(2004). RN [13] RP PROTEIN SEQUENCE OF 2-18; 27-40; 70-77; 414-426 AND 430-440, CLEAVAGE OF RP INITIATOR METHIONINE, ACETYLATION AT ALA-2, AND IDENTIFICATION BY MASS RP SPECTROMETRY. RC TISSUE=Prostatic carcinoma; RA Bienvenut W.V., Gao M., Leug H.; RL Submitted (JUN-2009) to UniProtKB. RN [14] RP INTERACTION WITH DNAJC3. RX PubMed=8576172; DOI=10.1074/jbc.271.3.1702; RA Polyak S.J., Tang N., Wambach M., Barber G.N., Katze M.G.; RT "The P58 cellular inhibitor complexes with the interferon-induced, double- RT stranded RNA-dependent protein kinase, PKR, to regulate its RT autophosphorylation and activity."; RL J. Biol. Chem. 271:1702-1707(1996). RN [15] RP INTERACTION WITH HIV-1 TAT. RX PubMed=9079663; DOI=10.1074/jbc.272.13.8388; RA Brand S.R., Kobayashi R., Mathews M.B.; RT "The Tat protein of human immunodeficiency virus type 1 is a substrate and RT inhibitor of the interferon-induced, virally activated protein kinase, RT PKR."; RL J. Biol. Chem. 272:8388-8395(1997). RN [16] RP INTERACTION WITH HCV NON-STRUCTURAL PROTEIN 5A (MICROBIAL INFECTION). RX PubMed=9143277; DOI=10.1006/viro.1997.8493; RA Gale M.J. Jr., Korth M.J., Tang N.M., Tan S.-L., Hopkins D.A., Dever T.E., RA Polyak S.J., Gretch D.R., Katze M.G.; RT "Evidence that hepatitis C virus resistance to interferon is mediated RT through repression of the PKR protein kinase by the nonstructural 5A RT protein."; RL Virology 230:217-227(1997). RN [17] RP INTERACTION WITH HCV NON-STRUCTURAL PROTEIN 5A (MICROBIAL INFECTION). RX PubMed=9710605; DOI=10.1128/mcb.18.9.5208; RA Gale M.J. Jr., Blakely C.M., Kwieciszewski B., Tan S.-L., Dossett M., RA Tang N.M., Korth M.J., Polyak S.J., Gretch D.R., Katze M.G.; RT "Control of PKR protein kinase by hepatitis C virus nonstructural 5A RT protein: molecular mechanisms of kinase regulation."; RL Mol. Cell. Biol. 18:5208-5218(1998). RN [18] RP INTERACTION WITH INFLUENZA A NS1 PROTEIN. RX PubMed=9781815; DOI=10.1089/jir.1998.18.757; RA Tan S.L., Katze M.G.; RT "Biochemical and genetic evidence for complex formation between the RT influenza A virus NS1 protein and the interferon-induced PKR protein RT kinase."; RL J. Interferon Cytokine Res. 18:757-766(1998). RN [19] RP INTERACTION WITH HCV ENVELOPE GLYCOPROTEIN E2 (MICROBIAL INFECTION). RX PubMed=10390359; DOI=10.1126/science.285.5424.107; RA Taylor D.R., Shi S.T., Romano P.R., Barber G.N., Lai M.M.C.; RT "Inhibition of the interferon-inducible protein kinase PKR by HCV E2 RT protein."; RL Science 285:107-110(1999). RN [20] RP FUNCTION, AND INTERACTION WITH IKBKB. RX PubMed=10848580; DOI=10.1128/mcb.20.13.4532-4542.2000; RA Bonnet M.C., Weil R., Dam E., Hovanessian A.G., Meurs E.F.; RT "PKR stimulates NF-kappaB irrespective of its kinase function by RT interacting with the IkappaB kinase complex."; RL Mol. Cell. Biol. 20:4532-4542(2000). RN [21] RP INTERACTION WITH TARBP2. RX PubMed=11438532; DOI=10.1074/jbc.m103584200; RA Daher A., Longuet M., Dorin D., Bois F., Segeral E., Bannwarth S., RA Battisti P.-L., Purcell D.F., Benarous R., Vaquero C., Meurs E.F., RA Gatignol A.; RT "Two dimerization domains in the trans-activation response RNA-binding RT protein (TRBP) individually reverse the protein kinase R inhibition of HIV- RT 1 long terminal repeat expression."; RL J. Biol. Chem. 276:33899-33905(2001). RN [22] RP PHOSPHORYLATION AT SER-83; THR-88; THR-89; THR-90; SER-242; THR-255 AND RP THR-258, MUTAGENESIS OF SER-83; THR-88; THR-89; THR-90; SER-242; THR-255; RP THR-258 AND LYS-296, AND INHIBITION BY HCV E2 ENVELOPE PROTEIN. RX PubMed=11152499; DOI=10.1128/jvi.75.3.1265-1273.2001; RA Taylor D.R., Tian B., Romano P.R., Hinnebusch A.G., Lai M.M.C., RA Mathews M.B.; RT "Hepatitis C virus envelope protein E2 does not inhibit PKR by simple RT competition with autophosphorylation sites in the RNA-binding domain."; RL J. Virol. 75:1265-1273(2001). RN [23] RP MUTAGENESIS OF LYS-60; ALA-67; THR-446 AND THR-451, AND PHOSPHORYLATION AT RP THR-446 AND THR-451. RX PubMed=11337501; DOI=10.1074/jbc.m102108200; RA Zhang F., Romano P.R., Nagamura-Inoue T., Tian B., Dever T.E., RA Mathews M.B., Ozato K., Hinnebusch A.G.; RT "Binding of double-stranded RNA to protein kinase PKR is required for RT dimerization and promotes critical autophosphorylation events in the RT activation loop."; RL J. Biol. Chem. 276:24946-24958(2001). RN [24] RP INTERACTION WITH HHV-8 PROTEIN VIRF2 (MICROBIAL INFECTION). RX PubMed=11160738; DOI=10.1128/jvi.75.5.2345-2352.2001; RA Burysek L., Pitha P.M.; RT "Latently expressed human herpesvirus 8-encoded interferon regulatory RT factor 2 inhibits double-stranded RNA-activated protein kinase."; RL J. Virol. 75:2345-2352(2001). RN [25] RP FUNCTION, AND INTERACTION WITH HHV-1 US11 (MICROBIAL INFECTION). RX PubMed=11836380; DOI=10.1128/jvi.76.5.2029-2035.2002; RA Cassady K.A., Gross M.; RT "The herpes simplex virus type 1 U(S)11 protein interacts with protein RT kinase R in infected cells and requires a 30-amino-acid sequence adjacent RT to a kinase substrate domain."; RL J. Virol. 76:2029-2035(2002). RN [26] RP INTERACTION WITH NPM1, AND ACTIVITY REGULATION. RX PubMed=12882984; DOI=10.1074/jbc.m301392200; RA Pang Q., Christianson T.A., Koretsky T., Carlson H., David L., Keeble W., RA Faulkner G.R., Speckhart A., Bagby G.C.; RT "Nucleophosmin interacts with and inhibits the catalytic function of RT eukaryotic initiation factor 2 kinase PKR."; RL J. Biol. Chem. 278:41709-41717(2003). RN [27] RP FUNCTION, AND INTERACTION WITH MAP2K6. RX PubMed=15229216; DOI=10.1074/jbc.m406554200; RA Silva A.M., Whitmore M., Xu Z., Jiang Z., Li X., Williams B.R.; RT "Protein kinase R (PKR) interacts with and activates mitogen-activated RT protein kinase kinase 6 (MKK6) in response to double-stranded RNA RT stimulation."; RL J. Biol. Chem. 279:37670-37676(2004). RN [28] RP IDENTIFICATION IN A COMPLEX WITH FANCA; FANCC; FANCG AND HSP70. RX PubMed=15299030; DOI=10.1074/jbc.m403884200; RA Zhang X., Li J., Sejas D.P., Rathbun K.R., Bagby G.C., Pang Q.; RT "The Fanconi anemia proteins functionally interact with the protein kinase RT regulated by RNA (PKR)."; RL J. Biol. Chem. 279:43910-43919(2004). RN [29] RP FUNCTION, INTERACTION WITH TRAF2; TRAF5 AND TRAF6, AND SUBCELLULAR RP LOCATION. RX PubMed=15121867; DOI=10.1128/mcb.24.10.4502-4512.2004; RA Gil J., Garcia M.A., Gomez-Puertas P., Guerra S., Rullas J., Nakano H., RA Alcami J., Esteban M.; RT "TRAF family proteins link PKR with NF-kappa B activation."; RL Mol. Cell. Biol. 24:4502-4512(2004). RN [30] RP INHIBITION BY VACCINIA VIRUS PROTEIN E3 (MICROBIAL INFECTION). RX PubMed=15207627; DOI=10.1016/j.virol.2004.03.012; RA Langland J.O., Jacobs B.L.; RT "Inhibition of PKR by vaccinia virus: role of the N- and C-terminal domains RT of E3L."; RL Virology 324:419-429(2004). RN [31] RP REVIEW. RX PubMed=17158706; DOI=10.1128/mmbr.00027-06; RA Garcia M.A., Gil J., Ventoso I., Guerra S., Domingo E., Rivas C., RA Esteban M.; RT "Impact of protein kinase PKR in cell biology: from antiviral to RT antiproliferative action."; RL Microbiol. Mol. Biol. Rev. 70:1032-1060(2006). RN [32] RP INTERACTION WITH HCMV TRS1 (MICROBIAL INFECTION). RX PubMed=16987971; DOI=10.1128/jvi.00957-06; RA Hakki M., Marshall E.E., De Niro K.L., Geballe A.P.; RT "Binding and nuclear relocalization of protein kinase R by human RT cytomegalovirus TRS1."; RL J. Virol. 80:11817-11826(2006). RN [33] RP PHOSPHORYLATION AT TYR-101; TYR-162 AND TYR-293. RX PubMed=16373505; DOI=10.1073/pnas.0508207103; RA Su Q., Wang S., Baltzis D., Qu L.K., Wong A.H., Koromilas A.E.; RT "Tyrosine phosphorylation acts as a molecular switch to full-scale RT activation of the eIF2alpha RNA-dependent protein kinase."; RL Proc. Natl. Acad. Sci. U.S.A. 103:63-68(2006). RN [34] RP INTERACTION WITH HCV NON-STRUCTURAL PROTEIN 5A (MICROBIAL INFECTION). RX PubMed=16951545; DOI=10.1016/s1016-8478(23)17385-7; RA Liang Y., Kang C.B., Yoon H.S.; RT "Molecular and structural characterization of the domain 2 of hepatitis C RT virus non-structural protein 5A."; RL Mol. Cells 22:13-20(2006). RN [35] RP INTERACTION WITH HCV NON-STRUCTURAL PROTEIN 5A (MICROBIAL INFECTION). RX PubMed=17451199; DOI=10.3748/wjg.v13.i8.1195; RA Veillon P., Payan C., Le Guillou-Guillemette H., Gaudy C., Lunel F.; RT "Quasispecies evolution in NS5A region of hepatitis C virus genotype 1b RT during interferon or combined interferon-ribavirin therapy."; RL World J. Gastroenterol. 13:1195-1203(2007). RN [36] RP INTERACTION WITH HCV MATURE CORE PROTEIN (MICROBIAL INFECTION). RX PubMed=17267064; DOI=10.1016/j.virusres.2006.12.010; RA Yan X.B., Battaglia S., Boucreux D., Chen Z., Brechot C., Pavio N.; RT "Mapping of the interacting domains of hepatitis C virus core protein and RT the double-stranded RNA-activated protein kinase PKR."; RL Virus Res. 125:79-87(2007). RN [37] RP INTERACTION WITH ADAR. RX PubMed=17079286; DOI=10.1128/jvi.01527-06; RA Nie Y., Hammond G.L., Yang J.H.; RT "Double-stranded RNA deaminase ADAR1 increases host susceptibility to virus RT infection."; RL J. Virol. 81:917-923(2007). RN [38] RP REVIEW ON ACTIVITY REGULATION. RX PubMed=17196820; DOI=10.1016/j.tibs.2006.12.003; RA Cole J.L.; RT "Activation of PKR: an open and shut case?"; RL Trends Biochem. Sci. 32:57-62(2007). RN [39] RP FUNCTION, INTERACTION WITH NCK1, AND ACTIVITY REGULATION. RX PubMed=18835251; DOI=10.1016/j.bbrc.2008.09.112; RA Cardin E., Larose L.; RT "Nck-1 interacts with PKR and modulates its activation by dsRNA."; RL Biochem. Biophys. Res. Commun. 377:231-235(2008). RN [40] RP INTERACTION WITH DUS2L, AND ACTIVITY REGULATION. RX PubMed=18096616; DOI=10.1093/nar/gkm1129; RA Mittelstadt M., Frump A., Khuu T., Fowlkes V., Handy I., Patel C.V., RA Patel R.C.; RT "Interaction of human tRNA-dihydrouridine synthase-2 with interferon- RT induced protein kinase PKR."; RL Nucleic Acids Res. 36:998-1008(2008). RN [41] RP PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-83 AND SER-456, AND RP IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS]. RC TISSUE=Cervix carcinoma; RX PubMed=18669648; DOI=10.1073/pnas.0805139105; RA Dephoure N., Zhou C., Villen J., Beausoleil S.A., Bakalarski C.E., RA Elledge S.J., Gygi S.P.; RT "A quantitative atlas of mitotic phosphorylation."; RL Proc. Natl. Acad. Sci. U.S.A. 105:10762-10767(2008). RN [42] RP MUTAGENESIS OF ASP-486, AND INTERACTION WITH VACCINIA VIRUS PROTEIN K3 RP (MICROBIAL INFECTION). RX PubMed=18971339; DOI=10.1073/pnas.0805524105; RA Seo E.J., Liu F., Kawagishi-Kobayashi M., Ung T.L., Cao C., Dar A.C., RA Sicheri F., Dever T.E.; RT "Protein kinase PKR mutants resistant to the poxvirus pseudosubstrate K3L RT protein."; RL Proc. Natl. Acad. Sci. U.S.A. 105:16894-16899(2008). RN [43] RP FUNCTION. RX PubMed=19507191; DOI=10.1002/jcp.21848; RA Blalock W.L., Grimaldi C., Fala F., Follo M., Horn S., Basecke J., RA Martinelli G., Cocco L., Martelli A.M.; RT "PKR activity is required for acute leukemic cell maintenance and growth: a RT role for PKR-mediated phosphatase activity to regulate GSK-3 RT phosphorylation."; RL J. Cell. Physiol. 221:232-241(2009). RN [44] RP FUNCTION, AND INTERACTION WITH DHX9. RX PubMed=19229320; DOI=10.1371/journal.ppat.1000311; RA Sadler A.J., Latchoumanin O., Hawkes D., Mak J., Williams B.R.; RT "An antiviral response directed by PKR phosphorylation of the RNA helicase RT A."; RL PLoS Pathog. 5:E1000311-E1000311(2009). RN [45] RP PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-83, AND IDENTIFICATION BY RP MASS SPECTROMETRY [LARGE SCALE ANALYSIS]. RC TISSUE=Leukemic T-cell; RX PubMed=19690332; DOI=10.1126/scisignal.2000007; RA Mayya V., Lundgren D.H., Hwang S.-I., Rezaul K., Wu L., Eng J.K., RA Rodionov V., Han D.K.; RT "Quantitative phosphoproteomic analysis of T cell receptor signaling RT reveals system-wide modulation of protein-protein interactions."; RL Sci. Signal. 2:RA46-RA46(2009). RN [46] RP FUNCTION IN HCV RESTRICTION. RX PubMed=19189853; DOI=10.1016/j.virusres.2009.01.007; RA Kang J.I., Kwon S.N., Park S.H., Kim Y.K., Choi S.Y., Kim J.P., Ahn B.Y.; RT "PKR protein kinase is activated by hepatitis C virus and inhibits viral RT replication through translational control."; RL Virus Res. 142:51-56(2009). RN [47] RP FUNCTION. RX PubMed=20171114; DOI=10.1016/j.cyto.2010.01.008; RA Lin S.S., Lee D.C., Law A.H., Fang J.W., Chua D.T., Lau A.S.; RT "A role for protein kinase PKR in the mediation of Epstein-Barr virus RT latent membrane protein-1-induced IL-6 and IL-10 expression."; RL Cytokine 50:210-219(2010). RN [48] RP FUNCTION AS CDK1 KINASE UPON DNA DAMAGE, AND FUNCTION AS TYROSINE-PROTEIN RP KINASE. RX PubMed=20395957; DOI=10.1038/embor.2010.45; RA Yoon C.-H., Miah M.A., Kim K.P., Bae Y.-S.; RT "New Cdc2 Tyr 4 phosphorylation by dsRNA-activated protein kinase triggers RT Cdc2 polyubiquitination and G2 arrest under genotoxic stresses."; RL EMBO Rep. 11:393-399(2010). RN [49] RP FUNCTION. RX PubMed=21123651; DOI=10.1101/gad.1965010; RA Harashima A., Guettouche T., Barber G.N.; RT "Phosphorylation of the NFAR proteins by the dsRNA-dependent protein kinase RT PKR constitutes a novel mechanism of translational regulation and cellular RT defense."; RL Genes Dev. 24:2640-2653(2010). RN [50] RP INTERACTION WITH HRSV NUCLEOPROTEIN (MICROBIAL INFECTION). RX PubMed=20519500; DOI=10.1074/jbc.m109.077321; RA Groskreutz D.J., Babor E.C., Monick M.M., Varga S.M., Hunninghake G.W.; RT "Respiratory syncytial virus limits alpha subunit of eukaryotic translation RT initiation factor 2 (eIF2alpha) phosphorylation to maintain translation and RT viral replication."; RL J. Biol. Chem. 285:24023-24031(2010). RN [51] RP FUNCTION IN HCV RESTRICTION. RX PubMed=19840259; DOI=10.1111/j.1478-3231.2009.02144.x; RA Chang J.H., Kato N., Muroyama R., Taniguchi H., Guleng B., Dharel N., RA Shao R.X., Tateishi K., Jazag A., Kawabe T., Omata M.; RT "Double-stranded RNA-activated protein kinase inhibits hepatitis C virus RT replication but may be not essential in interferon treatment."; RL Liver Int. 30:311-318(2010). RN [52] RP FUNCTION, AND PHOSPHORYLATION AT THR-451. RX PubMed=20685959; DOI=10.1091/mbc.e10-06-0481; RA Yang X., Nath A., Opperman M.J., Chan C.; RT "The double-stranded RNA-dependent protein kinase differentially regulates RT insulin receptor substrates 1 and 2 in HepG2 cells."; RL Mol. Biol. Cell 21:3449-3458(2010). RN [53] RP PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-83, AND IDENTIFICATION BY RP MASS SPECTROMETRY [LARGE SCALE ANALYSIS]. RC TISSUE=Cervix carcinoma; RX PubMed=20068231; DOI=10.1126/scisignal.2000475; RA Olsen J.V., Vermeulen M., Santamaria A., Kumar C., Miller M.L., RA Jensen L.J., Gnad F., Cox J., Jensen T.S., Nigg E.A., Brunak S., Mann M.; RT "Quantitative phosphoproteomics reveals widespread full phosphorylation RT site occupancy during mitosis."; RL Sci. Signal. 3:RA3-RA3(2010). RN [54] RP IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS]. RX PubMed=21269460; DOI=10.1186/1752-0509-5-17; RA Burkard T.R., Planyavsky M., Kaupe I., Breitwieser F.P., Buerckstuemmer T., RA Bennett K.L., Superti-Furga G., Colinge J.; RT "Initial characterization of the human central proteome."; RL BMC Syst. Biol. 5:17-17(2011). RN [55] RP SUBCELLULAR LOCATION, TISSUE SPECIFICITY, AND PHOSPHORYLATION. RX PubMed=21029237; DOI=10.1111/j.1750-3639.2010.00437.x; RA Bose A., Mouton-Liger F., Paquet C., Mazot P., Vigny M., Gray F., Hugon J.; RT "Modulation of tau phosphorylation by the kinase PKR: implications in RT Alzheimer's disease."; RL Brain Pathol. 21:189-200(2011). RN [56] RP REVIEW. RX PubMed=21924887; DOI=10.1016/j.coi.2011.08.009; RA Pfaller C.K., Li Z., George C.X., Samuel C.E.; RT "Protein kinase PKR and RNA adenosine deaminase ADAR1: new roles for old RT players as modulators of the interferon response."; RL Curr. Opin. Immunol. 23:573-582(2011). RN [57] RP REVIEW. RX PubMed=21166592; DOI=10.1089/jir.2010.0099; RA Pindel A., Sadler A.; RT "The role of protein kinase R in the interferon response."; RL J. Interferon Cytokine Res. 31:59-70(2011). RN [58] RP FUNCTION, SUBCELLULAR LOCATION, IDENTIFICATION BY MASS SPECTROMETRY, AND RP PHOSPHORYLATION. RX PubMed=21072047; DOI=10.1038/leu.2010.264; RA Blalock W.L., Bavelloni A., Piazzi M., Tagliavini F., Faenza I., RA Martelli A.M., Follo M.Y., Cocco L.; RT "Multiple forms of PKR present in the nuclei of acute leukemia cells RT represent an active kinase that is responsive to stress."; RL Leukemia 25:236-245(2011). RN [59] RP FUNCTION IN HBV RESTRICTION. RX PubMed=21710204; DOI=10.1007/s10059-011-1059-6; RA Park I.H., Baek K.W., Cho E.Y., Ahn B.Y.; RT "PKR-dependent mechanisms of interferon-? for inhibiting hepatitis B virus RT replication."; RL Mol. Cells 32:167-172(2011). RN [60] RP FUNCTION, AND SUBCELLULAR LOCATION. RX PubMed=22214662; DOI=10.4161/cc.11.2.18999; RA Bennett R.L., Pan Y., Christian J., Hui T., May W.S. Jr.; RT "The RAX/PACT-PKR stress response pathway promotes p53 sumoylation and RT activation, leading to G(1) arrest."; RL Cell Cycle 11:407-417(2012). RN [61] RP REVIEW. RX PubMed=22633454; DOI=10.1016/j.immuni.2012.05.010; RA Lacy-Hulbert A., Stuart L.M.; RT "Penetration resistance: PKR's other talent."; RL Immunity 36:695-696(2012). RN [62] RP FUNCTION. RX PubMed=22948139; DOI=10.1074/jbc.m112.390039; RA McAllister C.S., Taghavi N., Samuel C.E.; RT "Protein kinase PKR amplification of interferon beta induction occurs RT through initiation factor eIF-2alpha-mediated translational control."; RL J. Biol. Chem. 287:36384-36392(2012). RN [63] RP FUNCTION, AND INTERACTION WITH STAT3. RX PubMed=23084476; DOI=10.1016/j.molcel.2012.09.013; RA Shen S., Niso-Santano M., Adjemian S., Takehara T., Malik S.A., Minoux H., RA Souquere S., Marino G., Lachkar S., Senovilla L., Galluzzi L., Kepp O., RA Pierron G., Maiuri M.C., Hikita H., Kroemer R., Kroemer G.; RT "Cytoplasmic STAT3 represses autophagy by inhibiting PKR activity."; RL Mol. Cell 48:667-680(2012). RN [64] RP ACETYLATION [LARGE SCALE ANALYSIS] AT ALA-2, CLEAVAGE OF INITIATOR RP METHIONINE [LARGE SCALE ANALYSIS], AND IDENTIFICATION BY MASS SPECTROMETRY RP [LARGE SCALE ANALYSIS]. RX PubMed=22223895; DOI=10.1074/mcp.m111.015131; RA Bienvenut W.V., Sumpton D., Martinez A., Lilla S., Espagne C., Meinnel T., RA Giglione C.; RT "Comparative large-scale characterisation of plant vs. mammal proteins RT reveals similar and idiosyncratic N-alpha acetylation features."; RL Mol. Cell. Proteomics 11:M111.015131-M111.015131(2012). RN [65] RP FUNCTION, INTERACTION WITH NLRP1; NLRP3; NLRC4 AND AIM2, AND RP AUTOPHOSPHORYLATION. RX PubMed=22801494; DOI=10.1038/nature11290; RA Lu B., Nakamura T., Inouye K., Li J., Tang Y., Lundbaeck P., RA Valdes-Ferrer S.I., Olofsson P.S., Kalb T., Roth J., Zou Y., RA Erlandsson-Harris H., Yang H., Ting J.P., Wang H., Andersson U., RA Antoine D.J., Chavan S.S., Hotamisligil G.S., Tracey K.J.; RT "Novel role of PKR in inflammasome activation and HMGB1 release."; RL Nature 488:670-674(2012). RN [66] RP ACETYLATION [LARGE SCALE ANALYSIS] AT ALA-2, CLEAVAGE OF INITIATOR RP METHIONINE [LARGE SCALE ANALYSIS], AND IDENTIFICATION BY MASS SPECTROMETRY RP [LARGE SCALE ANALYSIS]. RX PubMed=22814378; DOI=10.1073/pnas.1210303109; RA Van Damme P., Lasa M., Polevoda B., Gazquez C., Elosegui-Artola A., RA Kim D.S., De Juan-Pardo E., Demeyer K., Hole K., Larrea E., Timmerman E., RA Prieto J., Arnesen T., Sherman F., Gevaert K., Aldabe R.; RT "N-terminal acetylome analyses and functional insights of the N-terminal RT acetyltransferase NatB."; RL Proc. Natl. Acad. Sci. U.S.A. 109:12449-12454(2012). RN [67] RP REVIEW. RX PubMed=23092889; DOI=10.1126/scisignal.2003511; RA Kang R., Tang D.; RT "PKR-dependent inflammatory signals."; RL Sci. Signal. 5:PE47-PE47(2012). RN [68] RP FUNCTION. RX PubMed=22381929; DOI=10.1016/j.virol.2012.01.029; RA Taghavi N., Samuel C.E.; RT "Protein kinase PKR catalytic activity is required for the PKR-dependent RT activation of mitogen-activated protein kinases and amplification of RT interferon beta induction following virus infection."; RL Virology 427:208-216(2012). RN [69] RP REVIEW. RX PubMed=23202496; DOI=10.3390/v4112598; RA Dabo S., Meurs E.F.; RT "dsRNA-dependent protein kinase PKR and its role in stress, signaling and RT HCV infection."; RL Viruses 4:2598-2635(2012). RN [70] RP TISSUE SPECIFICITY. RX PubMed=23403623; DOI=10.1182/blood-2012-09-456400; RA Liu X., Bennett R.L., Cheng X., Byrne M., Reinhard M.K., May W.S. Jr.; RT "PKR regulates proliferation, differentiation and survival of murine RT hematopoietic stem/progenitor cells."; RL Blood 121:3364-3374(2013). RN [71] RP REVIEW. RX PubMed=23354059; DOI=10.1007/s00018-012-1252-6; RA Donnelly N., Gorman A.M., Gupta S., Samali A.; RT "The eIF2alpha kinases: their structures and functions."; RL Cell. Mol. Life Sci. 70:3493-3511(2013). RN [72] RP FUNCTION, ISGYLATION AT LYS-69 AND LYS-159, AND ACTIVITY REGULATION. RX PubMed=23229543; DOI=10.1074/jbc.m112.401851; RA Okumura F., Okumura A.J., Uematsu K., Hatakeyama S., Zhang D.E., Kamura T.; RT "Activation of double-stranded RNA-activated protein kinase (PKR) by RT interferon-stimulated gene 15 (ISG15) modification down-regulates protein RT translation."; RL J. Biol. Chem. 288:2839-2847(2013). RN [73] RP PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-542, AND IDENTIFICATION BY RP MASS SPECTROMETRY [LARGE SCALE ANALYSIS]. RC TISSUE=Cervix carcinoma, and Erythroleukemia; RX PubMed=23186163; DOI=10.1021/pr300630k; RA Zhou H., Di Palma S., Preisinger C., Peng M., Polat A.N., Heck A.J., RA Mohammed S.; RT "Toward a comprehensive characterization of a human cancer cell RT phosphoproteome."; RL J. Proteome Res. 12:260-271(2013). RN [74] RP INTERACTION WITH TOSCANA VIRUS PROTEIN NSS (MICROBIAL INFECTION), AND RP ACTIVITY REGULATION. RX PubMed=23325696; DOI=10.1128/jvi.02506-12; RA Kalveram B., Ikegami T.; RT "Toscana virus NSs protein promotes degradation of double-stranded RNA- RT dependent protein kinase."; RL J. Virol. 87:3710-3718(2013). RN [75] RP FUNCTION IN MV RESTRICTION. RX PubMed=23115276; DOI=10.1128/jvi.02270-12; RA Okonski K.M., Samuel C.E.; RT "Stress granule formation induced by measles virus is protein kinase PKR RT dependent and impaired by RNA adenosine deaminase ADAR1."; RL J. Virol. 87:756-766(2013). RN [76] RP FUNCTION. RX PubMed=23372823; DOI=10.1371/journal.pone.0055108; RA Li Y., Xie J., Wu S., Xia J., Zhang P., Liu C., Zhang P., Huang X.; RT "Protein kinase regulated by dsRNA downregulates the interferon production RT in dengue virus- and dsrna-stimulated human lung epithelial cells."; RL PLoS ONE 8:E55108-E55108(2013). RN [77] RP FUNCTION IN HCV RESTRICTION. RX PubMed=23399035; DOI=10.1016/j.virol.2013.01.015; RA Zhang L., Alter H.J., Wang H., Jia S., Wang E., Marincola F.M., Shih J.W., RA Wang R.Y.; RT "The modulation of hepatitis C virus 1a replication by PKR is dependent on RT NF-kB mediated interferon beta response in Huh7.5.1 cells."; RL Virology 438:28-36(2013). RN [78] RP IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS]. RC TISSUE=Liver; RX PubMed=24275569; DOI=10.1016/j.jprot.2013.11.014; RA Bian Y., Song C., Cheng K., Dong M., Wang F., Huang J., Sun D., Wang L., RA Ye M., Zou H.; RT "An enzyme assisted RP-RPLC approach for in-depth analysis of human liver RT phosphoproteome."; RL J. Proteomics 96:253-262(2014). RN [79] RP INTERACTION WITH VACCINIA VIRUS PROTEIN E3 (MICROBIAL INFECTION). RX PubMed=25740987; DOI=10.1128/jvi.03288-14; RA Dueck K.J., Hu Y.S., Chen P., Deschambault Y., Lee J., Varga J., Cao J.; RT "Mutational analysis of vaccinia virus E3 protein: the biological functions RT do not correlate with its biochemical capacity to bind double-stranded RT RNA."; RL J. Virol. 89:5382-5394(2015). RN [80] RP INTERACTION WITH MBIP AND MOCS2B, SUBCELLULAR LOCATION, AND RP PHOSPHORYLATION. RX PubMed=26705305; DOI=10.1093/jmcb/mjv070; RA Suganuma T., Swanson S.K., Florens L., Washburn M.P., Workman J.L.; RT "Moco biosynthesis and the ATAC acetyltransferase engage translation RT initiation by inhibiting latent PKR activity."; RL J. Mol. Cell Biol. 8:44-50(2016). RN [81] RP MUTAGENESIS OF PHE-489; THR-496; ILE-502; LYS-510 AND GLN-516, RP CHARACTERIZATION OF VARIANT VAL-506, AND INTERACTION WITH HCMV TRS1 RP (MICROBIAL INFECTION). RX PubMed=27780231; DOI=10.1371/journal.ppat.1005966; RA Carpentier K.S., Esparo N.M., Child S.J., Geballe A.P.; RT "A Single Amino Acid Dictates Protein Kinase R Susceptibility to Unrelated RT Viral Antagonists."; RL PLoS Pathog. 12:e1005966-e1005966(2016). RN [82] RP INTERACTION WITH HUMAN HERPES VIRUS 8 PROTEIN KTA/ORF57 (MICROBIAL RP INFECTION). RX PubMed=29084250; DOI=10.1371/journal.ppat.1006677; RA Sharma N.R., Majerciak V., Kruhlak M.J., Zheng Z.M.; RT "KSHV inhibits stress granule formation by viral ORF57 blocking PKR RT activation."; RL PLoS Pathog. 13:e1006677-e1006677(2017). RN [83] {ECO:0007744|PDB:1QU6} RP STRUCTURE BY NMR OF 1-170, AND DOMAIN. RX PubMed=9736623; DOI=10.1093/emboj/17.18.5458; RA Nanduri S., Carpick B.W., Yang Y., Williams B.R.G., Qin J.; RT "Structure of the double-stranded RNA-binding domain of the protein kinase RT PKR reveals the molecular basis of its dsRNA-mediated activation."; RL EMBO J. 17:5458-5465(1998). RN [84] {ECO:0007744|PDB:2A19, ECO:0007744|PDB:2A1A} RP X-RAY CRYSTALLOGRAPHY (2.50 ANGSTROMS) OF 258-550 IN COMPLEX WITH RP EIF2S1/EIF-2ALPHA, PHOSPHORYLATION AT THR-446, DOMAIN, SUBUNIT, COFACTOR, RP AND INTERACTION WITH EIF2S1/EIF-2ALPHA. RX PubMed=16179258; DOI=10.1016/j.cell.2005.06.044; RA Dar A.C., Dever T.E., Sicheri F.; RT "Higher-order substrate recognition of eIF2alpha by the RNA-dependent RT protein kinase PKR."; RL Cell 122:887-900(2005). RN [85] {ECO:0007744|PDB:6D3K, ECO:0007744|PDB:6D3L} RP X-RAY CRYSTALLOGRAPHY (2.60 ANGSTROMS) OF 229-551, AND SUBUNIT. RX PubMed=31246429; DOI=10.1021/acs.biochem.9b00161; RA Mayo C.B., Erlandsen H., Mouser D.J., Feinstein A.G., Robinson V.L., RA May E.R., Cole J.L.; RT "Structural Basis of Protein Kinase R Autophosphorylation."; RL Biochemistry 58:2967-2977(2019). RN [86] RP INVOLVEMENT IN LEUDEN, FUNCTION, VARIANTS LEUDEN LEU-11; SER-32; PHE-97; RP SER-109; VAL-109; PHE-133; SER-325 AND CYS-461, CHARACTERIZATION OF RP VARIANTS LEUDEN LEU-11; PHE-133 AND CYS-461, AND VARIANT GLN-114. RX PubMed=32197074; DOI=10.1016/j.ajhg.2020.02.016; RG Undiagnosed Diseases Network; RA Mao D., Reuter C.M., Ruzhnikov M.R.Z., Beck A.E., Farrow E.G., Emrick L.T., RA Rosenfeld J.A., Mackenzie K.M., Robak L., Wheeler M.T., Burrage L.C., RA Jain M., Liu P., Calame D., Kuery S., Sillesen M., Schmitz-Abe K., RA Tonduti D., Spaccini L., Iascone M., Genetti C.A., Koenig M.K., Graf M., RA Tran A., Alejandro M., Lee B.H., Thiffault I., Agrawal P.B., RA Bernstein J.A., Bellen H.J., Chao H.T.; RT "De novo EIF2AK1 and EIF2AK2 variants are associated with developmental RT delay, leukoencephalopathy, and neurologic decompensation."; RL Am. J. Hum. Genet. 106:570-583(2020). RN [87] RP VARIANTS [LARGE SCALE ANALYSIS] GLU-428; VAL-439 AND VAL-506. RX PubMed=17344846; DOI=10.1038/nature05610; RA Greenman C., Stephens P., Smith R., Dalgliesh G.L., Hunter C., Bignell G., RA Davies H., Teague J., Butler A., Stevens C., Edkins S., O'Meara S., RA Vastrik I., Schmidt E.E., Avis T., Barthorpe S., Bhamra G., Buck G., RA Choudhury B., Clements J., Cole J., Dicks E., Forbes S., Gray K., RA Halliday K., Harrison R., Hills K., Hinton J., Jenkinson A., Jones D., RA Menzies A., Mironenko T., Perry J., Raine K., Richardson D., Shepherd R., RA Small A., Tofts C., Varian J., Webb T., West S., Widaa S., Yates A., RA Cahill D.P., Louis D.N., Goldstraw P., Nicholson A.G., Brasseur F., RA Looijenga L., Weber B.L., Chiew Y.-E., DeFazio A., Greaves M.F., RA Green A.R., Campbell P., Birney E., Easton D.F., Chenevix-Trench G., RA Tan M.-H., Khoo S.K., Teh B.T., Yuen S.T., Leung S.Y., Wooster R., RA Futreal P.A., Stratton M.R.; RT "Patterns of somatic mutation in human cancer genomes."; RL Nature 446:153-158(2007). RN [88] RP VARIANTS DYT33 THR-32; ARG-130 AND ALA-138, CHARACTERIZATION OF VARIANTS RP DYT33 THR-32 AND ARG-130, AND INVOLVEMENT IN DYT33. RX PubMed=33236446; DOI=10.1002/ana.25973; RA Kuipers D.J.S., Mandemakers W., Lu C.S., Olgiati S., Breedveld G.J., RA Fevga C., Tadic V., Carecchio M., Osterman B., Sagi-Dain L., Wu-Chou Y.H., RA Chen C.C., Chang H.C., Wu S.L., Yeh T.H., Weng Y.H., Elia A.E., RA Panteghini C., Marotta N., Pauly M.G., Kuehn A.A., Volkmann J., Lace B., RA Meijer I.A., Kandaswamy K., Quadri M., Garavaglia B., Lohmann K., Bauer P., RA Mencacci N.E., Lubbe S.J., Klein C., Bertoli-Avella A.M., Bonifati V.; RT "EIF2AK2 Missense Variants Associated with Early Onset Generalized RT Dystonia."; RL Ann. Neurol. 89:485-497(2021). RN [89] RP VARIANT DYT33 ARG-130, AND INVOLVEMENT IN DYT33. RX PubMed=33866603; DOI=10.1002/ana.26081; RA Musacchio T., Zech M., Reich M.M., Winkelmann J., Volkmann J.; RT "A Recurrent EIF2AK2 Missense Variant Causes Autosomal-Dominant Isolated RT Dystonia."; RL Ann. Neurol. 89:1257-1258(2021). RN [90] RP VARIANT DYT33 ARG-130. RX PubMed=35146068; DOI=10.1002/mdc3.13371; RA Magrinelli F., Moualek D., Tazir M., Pacha L.A., Verghese A., Bhatia K.P., RA Maroofian R., Houlden H.; RT "Heterozygous EIF2AK2 Variant Causes Adolescence-Onset Generalized Dystonia RT Partially Responsive to DBS."; RL Mov. Disord. Clin. Pract. 9:268-271(2022). CC -!- FUNCTION: IFN-induced dsRNA-dependent serine/threonine-protein kinase CC that phosphorylates the alpha subunit of eukaryotic translation CC initiation factor 2 (EIF2S1/eIF-2-alpha) and plays a key role in the CC innate immune response to viral infection (PubMed:18835251, CC PubMed:19189853, PubMed:19507191, PubMed:21072047, PubMed:21123651, CC PubMed:22381929, PubMed:22948139, PubMed:23229543). Inhibits viral CC replication via the integrated stress response (ISR): EIF2S1/eIF-2- CC alpha phosphorylation in response to viral infection converts CC EIF2S1/eIF-2-alpha in a global protein synthesis inhibitor, resulting CC to a shutdown of cellular and viral protein synthesis, while CC concomitantly initiating the preferential translation of ISR-specific CC mRNAs, such as the transcriptional activator ATF4 (PubMed:19189853, CC PubMed:21123651, PubMed:22948139, PubMed:23229543). Exerts its CC antiviral activity on a wide range of DNA and RNA viruses including CC hepatitis C virus (HCV), hepatitis B virus (HBV), measles virus (MV) CC and herpes simplex virus 1 (HHV-1) (PubMed:11836380, PubMed:19189853, CC PubMed:19840259, PubMed:20171114, PubMed:21710204, PubMed:23115276, CC PubMed:23399035). Also involved in the regulation of signal CC transduction, apoptosis, cell proliferation and differentiation: CC phosphorylates other substrates including p53/TP53, PPP2R5A, DHX9, CC ILF3, IRS1 and the HHV-1 viral protein US11 (PubMed:11836380, CC PubMed:19229320, PubMed:22214662). In addition to serine/threonine- CC protein kinase activity, also has tyrosine-protein kinase activity and CC phosphorylates CDK1 at 'Tyr-4' upon DNA damage, facilitating its CC ubiquitination and proteasomal degradation (PubMed:20395957). Either as CC an adapter protein and/or via its kinase activity, can regulate various CC signaling pathways (p38 MAP kinase, NF-kappa-B and insulin signaling CC pathways) and transcription factors (JUN, STAT1, STAT3, IRF1, ATF3) CC involved in the expression of genes encoding pro-inflammatory cytokines CC and IFNs (PubMed:22948139, PubMed:23084476, PubMed:23372823). Activates CC the NF-kappa-B pathway via interaction with IKBKB and TRAF family of CC proteins and activates the p38 MAP kinase pathway via interaction with CC MAP2K6 (PubMed:10848580, PubMed:15121867, PubMed:15229216). Can act as CC both a positive and negative regulator of the insulin signaling pathway CC (ISP) (PubMed:20685959). Negatively regulates ISP by inducing the CC inhibitory phosphorylation of insulin receptor substrate 1 (IRS1) at CC 'Ser-312' and positively regulates ISP via phosphorylation of PPP2R5A CC which activates FOXO1, which in turn up-regulates the expression of CC insulin receptor substrate 2 (IRS2) (PubMed:20685959). Can regulate CC NLRP3 inflammasome assembly and the activation of NLRP3, NLRP1, AIM2 CC and NLRC4 inflammasomes (PubMed:22801494). Plays a role in the CC regulation of the cytoskeleton by binding to gelsolin (GSN), CC sequestering the protein in an inactive conformation away from actin CC (By similarity). {ECO:0000250|UniProtKB:Q03963, CC ECO:0000269|PubMed:10848580, ECO:0000269|PubMed:11836380, CC ECO:0000269|PubMed:15121867, ECO:0000269|PubMed:15229216, CC ECO:0000269|PubMed:18835251, ECO:0000269|PubMed:19189853, CC ECO:0000269|PubMed:19229320, ECO:0000269|PubMed:19507191, CC ECO:0000269|PubMed:19840259, ECO:0000269|PubMed:20171114, CC ECO:0000269|PubMed:20395957, ECO:0000269|PubMed:20685959, CC ECO:0000269|PubMed:21072047, ECO:0000269|PubMed:21123651, CC ECO:0000269|PubMed:21710204, ECO:0000269|PubMed:22214662, CC ECO:0000269|PubMed:22381929, ECO:0000269|PubMed:22801494, CC ECO:0000269|PubMed:22948139, ECO:0000269|PubMed:23084476, CC ECO:0000269|PubMed:23115276, ECO:0000269|PubMed:23229543, CC ECO:0000269|PubMed:23372823, ECO:0000269|PubMed:23399035, CC ECO:0000269|PubMed:32197074}. CC -!- CATALYTIC ACTIVITY: CC Reaction=L-seryl-[protein] + ATP = O-phospho-L-seryl-[protein] + ADP + CC H(+); Xref=Rhea:RHEA:17989, Rhea:RHEA-COMP:9863, Rhea:RHEA- CC COMP:11604, ChEBI:CHEBI:15378, ChEBI:CHEBI:29999, ChEBI:CHEBI:30616, CC ChEBI:CHEBI:83421, ChEBI:CHEBI:456216; EC=2.7.11.1; CC -!- CATALYTIC ACTIVITY: CC Reaction=L-threonyl-[protein] + ATP = O-phospho-L-threonyl-[protein] + CC ADP + H(+); Xref=Rhea:RHEA:46608, Rhea:RHEA-COMP:11060, Rhea:RHEA- CC COMP:11605, ChEBI:CHEBI:15378, ChEBI:CHEBI:30013, ChEBI:CHEBI:30616, CC ChEBI:CHEBI:61977, ChEBI:CHEBI:456216; EC=2.7.11.1; CC -!- CATALYTIC ACTIVITY: CC Reaction=L-tyrosyl-[protein] + ATP = O-phospho-L-tyrosyl-[protein] + CC ADP + H(+); Xref=Rhea:RHEA:10596, Rhea:RHEA-COMP:10136, Rhea:RHEA- CC COMP:20101, ChEBI:CHEBI:15378, ChEBI:CHEBI:30616, ChEBI:CHEBI:46858, CC ChEBI:CHEBI:61978, ChEBI:CHEBI:456216; EC=2.7.10.2; CC Evidence={ECO:0000255|PROSITE-ProRule:PRU10027}; CC -!- COFACTOR: CC Name=Mg(2+); Xref=ChEBI:CHEBI:18420; CC Evidence={ECO:0000269|PubMed:16179258, ECO:0000303|PubMed:31246429}; CC -!- ACTIVITY REGULATION: Initially produced in an inactive form and is CC activated by binding to viral dsRNA, which causes dimerization and CC autophosphorylation in the activation loop and stimulation of function. CC ISGylation can activate it in the absence of viral infection. Can also CC be activated by heparin, pro-inflammatory stimuli, growth factors, CC cytokines, oxidative stress and the cellular protein PRKRA. Activity is CC markedly stimulated by manganese ions. Activation is blocked by the CC viral components HIV-1 Tat protein and large amounts of HIV-1 trans- CC activation response (TAR) RNA element as well as by the cellular CC proteins TARBP2, DUS2L, NPM1, NCK1 and ADAR. Down-regulated by Toscana CC virus (TOS) and Rift valley fever virus (RVFV) NSS which promote its CC proteasomal degradation. Inhibited by vaccinia virus protein E3, CC probably via dsRNA sequestering. {ECO:0000269|PubMed:12882984, CC ECO:0000269|PubMed:18096616, ECO:0000269|PubMed:18835251, CC ECO:0000269|PubMed:23229543, ECO:0000269|PubMed:23325696}. CC -!- SUBUNIT: Homodimer (PubMed:16179258, PubMed:31246429). Interacts with CC STRBP (By similarity). Interacts with DNAJC3. Forms a complex with CC FANCA, FANCC, FANCG and HSP70. Interacts with ADAR/ADAR1. Interacts CC with IRS1 (By similarity). The inactive form interacts with NCK1 and CC GSN. Interacts (via the kinase catalytic domain) with STAT3 (via SH2 CC domain), TRAF2 (C-terminus), TRAF5 (C-terminus) and TRAF6 (C-terminus). CC Interacts with MAP2K6, IKBKB/IKKB, NPM1, TARBP2, NLRP1, NLRP3, NLRC4 CC and AIM2. Interacts (via DRBM 1 domain) with DUS2L (via DRBM domain). CC Interacts with DHX9 (via N-terminus) and this interaction is dependent CC upon activation of the kinase. Interacts with EIF2S1/EIF-2ALPHA; this CC interaction induces a conformational change in EIF2S1 and its CC phosphorylation by EIF2AK2 (PubMed:16179258). Interacts with MBIP; the CC interaction is direct and leads to inhibition of EIF2AK2 self- CC activating autophosphorylation (PubMed:26705305). Interacts with the CC molybdopterin synthase complex subunit MOCS2B; the interaction is CC direct and enhances the interaction between EIF2AK2 and MBIP CC (PubMed:26705305). {ECO:0000250|UniProtKB:Q03963, CC ECO:0000269|PubMed:10390359, ECO:0000269|PubMed:10848580, CC ECO:0000269|PubMed:11438532, ECO:0000269|PubMed:12882984, CC ECO:0000269|PubMed:15121867, ECO:0000269|PubMed:15229216, CC ECO:0000269|PubMed:15299030, ECO:0000269|PubMed:16179258, CC ECO:0000269|PubMed:17079286, ECO:0000269|PubMed:18096616, CC ECO:0000269|PubMed:18835251, ECO:0000269|PubMed:19229320, CC ECO:0000269|PubMed:22801494, ECO:0000269|PubMed:23084476, CC ECO:0000269|PubMed:25740987, ECO:0000269|PubMed:26705305, CC ECO:0000269|PubMed:31246429, ECO:0000269|PubMed:8576172, CC ECO:0000269|PubMed:9079663, ECO:0000269|PubMed:9143277, CC ECO:0000269|PubMed:9781815}. CC -!- SUBUNIT: (Microbial infection) Interacts with human cytomegalovirus CC (HCMV) TRS1; this interaction retains EIF2AK2 to the nucleus and CC prevents its activation. {ECO:0000269|PubMed:16987971, CC ECO:0000269|PubMed:27780231}. CC -!- SUBUNIT: (Microbial infection) Interacts with vaccinia virus protein K3 CC (K3L); this interaction inhibits EIF2AK2. CC {ECO:0000269|PubMed:18971339}. CC -!- SUBUNIT: (Microbial infection) Interacts with human herpes simplex CC virus 1 (HHV-1) protein US11 in an RNA-dependent manner. CC {ECO:0000269|PubMed:11836380}. CC -!- SUBUNIT: (Microbial infection) The inactive form interacts with Toscana CC virus (TOS) NSS. {ECO:0000269|PubMed:23325696}. CC -!- SUBUNIT: (Microbial infection) Interacts with herpes virus 8 protein v- CC IRF2; this interaction inhibits EIF2AK2 activation. CC {ECO:0000269|PubMed:11160738}. CC -!- SUBUNIT: (Microbial infection) Interacts with vaccinia protein E3. CC {ECO:0000269|PubMed:25740987}. CC -!- SUBUNIT: (Microbial infection) Interacts (via N-terminus) with CC Hepatitis C virus (HCV) mature core protein (via N-terminus); this CC interaction induces the autophosphorylation of EIF2AK2. CC {ECO:0000269|PubMed:17267064}. CC -!- SUBUNIT: (Microbial infection) Interacts with Hepatitis C virus (HCV) CC non-structural protein 5A (NS5A); this interaction leads to disruption CC of EIF2AK2 dimerization by NS5A. {ECO:0000269|PubMed:16951545, CC ECO:0000269|PubMed:17451199, ECO:0000269|PubMed:9143277, CC ECO:0000269|PubMed:9710605}. CC -!- SUBUNIT: (Microbial infection) Interacts with Hepatitis C virus (HCV) CC envelope glycoprotein E2; this interaction inhibits EIF2AK2 and blocks CC its inhibitory effect on protein synthesis and cell growth. CC {ECO:0000269|PubMed:9143277}. CC -!- SUBUNIT: (Microbial infection) Interacts with human respiratory CC syncytial virus (HRSV) nucleoprotein; this interaction inhibits EIF2AK2 CC phosphorylation of EIF2S1 and blocks EIF2AK2-mediated translation CC shutoff. {ECO:0000269|PubMed:20519500}. CC -!- SUBUNIT: (Microbial infection) Interacts with human herpesvirus 8 CC protein MTA/ORF57; this interaction inhibits stress granule formation. CC {ECO:0000269|PubMed:29084250}. CC -!- INTERACTION: CC P19525; P78563-4: ADARB1; NbExp=3; IntAct=EBI-640775, EBI-12002366; CC P19525; P06493: CDK1; NbExp=4; IntAct=EBI-640775, EBI-444308; CC P19525; Q7L2E3: DHX30; NbExp=4; IntAct=EBI-640775, EBI-1211456; CC P19525; Q96C10: DHX58; NbExp=2; IntAct=EBI-640775, EBI-744193; CC P19525; Q08211: DHX9; NbExp=4; IntAct=EBI-640775, EBI-352022; CC P19525; Q9UPY3: DICER1; NbExp=2; IntAct=EBI-640775, EBI-395506; CC P19525; Q6P2E9: EDC4; NbExp=2; IntAct=EBI-640775, EBI-1006038; CC P19525; P19525: EIF2AK2; NbExp=2; IntAct=EBI-640775, EBI-640775; CC P19525; P05198: EIF2S1; NbExp=5; IntAct=EBI-640775, EBI-1056162; CC P19525; P56537: EIF6; NbExp=2; IntAct=EBI-640775, EBI-372243; CC P19525; Q8IY81: FTSJ3; NbExp=3; IntAct=EBI-640775, EBI-744088; CC P19525; Q9HCE1: MOV10; NbExp=3; IntAct=EBI-640775, EBI-1055820; CC P19525; Q96P20: NLRP3; NbExp=6; IntAct=EBI-640775, EBI-6253230; CC P19525; P06748: NPM1; NbExp=4; IntAct=EBI-640775, EBI-78579; CC P19525; O75569: PRKRA; NbExp=6; IntAct=EBI-640775, EBI-713955; CC P19525; O75569-1: PRKRA; NbExp=3; IntAct=EBI-640775, EBI-15588172; CC P19525; Q9NUL3: STAU2; NbExp=3; IntAct=EBI-640775, EBI-722938; CC P19525; Q15633: TARBP2; NbExp=2; IntAct=EBI-640775, EBI-978581; CC P19525; Q9H0E2: TOLLIP; NbExp=2; IntAct=EBI-640775, EBI-74615; CC P19525; Q9UL40: ZNF346; NbExp=4; IntAct=EBI-640775, EBI-2462313; CC P19525; Q27968: DNAJC3; Xeno; NbExp=5; IntAct=EBI-640775, EBI-640793; CC P19525; P0DTC9: N; Xeno; NbExp=8; IntAct=EBI-640775, EBI-25475856; CC P19525; P20639: OPG041; Xeno; NbExp=3; IntAct=EBI-640775, EBI-8674942; CC P19525; P04487: US11; Xeno; NbExp=3; IntAct=EBI-640775, EBI-6150681; CC P19525; Q2HR71: vIRF-2; Xeno; NbExp=2; IntAct=EBI-640775, EBI-8876177; CC P19525; PRO_0000278746 [O92972]; Xeno; NbExp=2; IntAct=EBI-640775, EBI-6918883; CC P19525; PRO_0000037570 [P27958]; Xeno; NbExp=4; IntAct=EBI-640775, EBI-6904269; CC P19525; PRO_0000037576 [P27958]; Xeno; NbExp=5; IntAct=EBI-640775, EBI-8753518; CC -!- SUBCELLULAR LOCATION: Cytoplasm {ECO:0000269|PubMed:15121867, CC ECO:0000269|PubMed:21029237, ECO:0000269|PubMed:22214662, CC ECO:0000269|PubMed:26705305}. Nucleus {ECO:0000269|PubMed:21029237, CC ECO:0000269|PubMed:21072047, ECO:0000269|PubMed:26705305}. Cytoplasm, CC perinuclear region {ECO:0000269|PubMed:15121867}. Note=Nuclear CC localization is elevated in acute leukemia, myelodysplastic syndrome CC (MDS), melanoma, breast, colon, prostate and lung cancer patient CC samples or cell lines as well as neurocytes from advanced Creutzfeldt- CC Jakob disease patients. {ECO:0000269|PubMed:21072047}. CC -!- ALTERNATIVE PRODUCTS: CC Event=Alternative splicing; Named isoforms=2; CC Name=1; CC IsoId=P19525-1; Sequence=Displayed; CC Name=2; CC IsoId=P19525-2; Sequence=VSP_046177; CC -!- TISSUE SPECIFICITY: Highly expressed in thymus, spleen and bone marrow CC compared to non-hematopoietic tissues such as small intestine, liver, CC or kidney tissues. Colocalizes with GSK3B and TAU in the Alzheimer CC disease (AD) brain. Elevated levels seen in breast and colon CC carcinomas, and which correlates with tumor progression and CC invasiveness or risk of progression. {ECO:0000269|PubMed:21029237, CC ECO:0000269|PubMed:23403623}. CC -!- INDUCTION: By type I interferons. {ECO:0000269|PubMed:1695551}. CC -!- DOMAIN: Contains 2 dsRNA-binding domain (DRBM) (PubMed:9736623). The N- CC terminus contains the catalytic domain dimerization. The C-terminus CC binds EIF2S1/EIF2-alpha (PubMed:16179258). CC {ECO:0000269|PubMed:16179258, ECO:0000269|PubMed:9736623}. CC -!- PTM: Autophosphorylated on several Ser, Thr and Tyr residues. CC Autophosphorylation of Thr-451 is dependent on Thr-446 and is CC stimulated by dsRNA binding and dimerization. Autophosphorylation CC apparently leads to the activation of the kinase. Tyrosine CC autophosphorylation is essential for efficient dsRNA-binding, CC dimerization, and kinase activation. Autophosphorylation is inhibited CC by the concerted action of ATAC complex subunit MBIP and molybdopterin CC synthase complex subunit MOCS2B (PubMed:26705305). CC {ECO:0000269|PubMed:11152499, ECO:0000269|PubMed:11337501, CC ECO:0000269|PubMed:16179258, ECO:0000269|PubMed:16373505, CC ECO:0000269|PubMed:20685959, ECO:0000269|PubMed:21029237, CC ECO:0000269|PubMed:21072047, ECO:0000269|PubMed:26705305}. CC -!- DISEASE: Leukoencephalopathy, developmental delay, and episodic CC neurologic regression syndrome (LEUDEN) [MIM:618877]: An autosomal CC dominant disorder characterized by global developmental delay apparent CC in early childhood, cognitive impairment, ataxia, poor or absent speech CC with dysarthria, hypotonia, hypertonia, extrapyramidal signs, tremor, CC and abnormal involuntary movements. Affected individuals also exhibit CC neurological regression in the setting of febrile illness or infection. CC Many patients have seizures. Brain imaging shows diffuse white matter CC abnormalities with poor myelination. {ECO:0000269|PubMed:32197074}. CC Note=The disease may be caused by variants affecting the gene CC represented in this entry. CC -!- DISEASE: Dystonia 33 (DYT33) [MIM:619687]: A form of dystonia, a CC disorder defined by the presence of sustained involuntary muscle CC contraction, often leading to abnormal postures. DYT33 is a slowly CC progressive form characterized by onset of focal or generalized CC dystonia in the first decades of life. Disease manifestations are CC variable. Some patients show ambulation difficulties, dysarthria, or CC dysphagia. Some affected individuals may manifest motor delay, lower CC limb spasticity, and mild developmental delay with intellectual CC disability. DYT33 penetrance is incomplete. Inheritance can be CC autosomal dominant or recessive. {ECO:0000269|PubMed:33236446, CC ECO:0000269|PubMed:33866603, ECO:0000269|PubMed:35146068}. Note=The CC disease is caused by variants affecting the gene represented in this CC entry. CC -!- SIMILARITY: Belongs to the protein kinase superfamily. Ser/Thr protein CC kinase family. GCN2 subfamily. {ECO:0000255|PROSITE-ProRule:PRU00159}. CC -!- WEB RESOURCE: Name=Atlas of Genetics and Cytogenetics in Oncology and CC Haematology; CC URL="https://atlasgeneticsoncology.org/gene/41866/EIF2AK2"; CC --------------------------------------------------------------------------- CC Copyrighted by the UniProt Consortium, see https://www.uniprot.org/terms CC Distributed under the Creative Commons Attribution (CC BY 4.0) License CC --------------------------------------------------------------------------- DR EMBL; M35663; AAA36409.1; -; mRNA. DR EMBL; M85294; AAA18253.1; -; mRNA. DR EMBL; U50648; AAC50768.1; -; Genomic_DNA. DR EMBL; U50634; AAC50768.1; JOINED; Genomic_DNA. DR EMBL; U50635; AAC50768.1; JOINED; Genomic_DNA. DR EMBL; U50636; AAC50768.1; JOINED; Genomic_DNA. DR EMBL; U50637; AAC50768.1; JOINED; Genomic_DNA. DR EMBL; U50638; AAC50768.1; JOINED; Genomic_DNA. DR EMBL; U50639; AAC50768.1; JOINED; Genomic_DNA. DR EMBL; U50640; AAC50768.1; JOINED; Genomic_DNA. DR EMBL; U50641; AAC50768.1; JOINED; Genomic_DNA. DR EMBL; U50642; AAC50768.1; JOINED; Genomic_DNA. DR EMBL; U50643; AAC50768.1; JOINED; Genomic_DNA. DR EMBL; U50644; AAC50768.1; JOINED; Genomic_DNA. DR EMBL; U50645; AAC50768.1; JOINED; Genomic_DNA. DR EMBL; U50646; AAC50768.1; JOINED; Genomic_DNA. DR EMBL; U50647; AAC50768.1; JOINED; Genomic_DNA. DR EMBL; AF167472; AAF13156.1; -; Genomic_DNA. DR EMBL; AF167460; AAF13156.1; JOINED; Genomic_DNA. DR EMBL; AF167462; AAF13156.1; JOINED; Genomic_DNA. DR EMBL; AF167463; AAF13156.1; JOINED; Genomic_DNA. DR EMBL; AF167464; AAF13156.1; JOINED; Genomic_DNA. DR EMBL; AF167465; AAF13156.1; JOINED; Genomic_DNA. DR EMBL; AF167466; AAF13156.1; JOINED; Genomic_DNA. DR EMBL; AF167468; AAF13156.1; JOINED; Genomic_DNA. DR EMBL; AF167470; AAF13156.1; JOINED; Genomic_DNA. DR EMBL; AY302136; AAP57628.1; -; mRNA. DR EMBL; AK290655; BAF83344.1; -; mRNA. DR EMBL; AK313818; BAG36554.1; -; mRNA. DR EMBL; AY228338; AAO38055.1; -; Genomic_DNA. DR EMBL; AC007899; AAY24317.1; -; Genomic_DNA. DR EMBL; CH471053; EAX00407.1; -; Genomic_DNA. DR EMBL; CH471053; EAX00408.1; -; Genomic_DNA. DR EMBL; CH471053; EAX00409.1; -; Genomic_DNA. DR EMBL; BC093676; AAH93676.1; -; mRNA. DR EMBL; BC101475; AAI01476.1; -; mRNA. DR CCDS; CCDS1786.1; -. [P19525-1] DR CCDS; CCDS46259.1; -. [P19525-2] DR PIR; JC5225; JC5225. DR RefSeq; NP_001129123.1; NM_001135651.3. [P19525-1] DR RefSeq; NP_001129124.1; NM_001135652.2. [P19525-2] DR RefSeq; NP_002750.1; NM_002759.4. [P19525-1] DR RefSeq; XP_011531289.1; XM_011532987.3. [P19525-1] DR RefSeq; XP_054198993.1; XM_054343018.1. [P19525-1] DR PDB; 1QU6; NMR; -; A=1-170. DR PDB; 2A19; X-ray; 2.50 A; B/C=258-550. DR PDB; 2A1A; X-ray; 2.80 A; B=258-550. DR PDB; 3UIU; X-ray; 2.90 A; A/B=254-551. DR PDB; 6D3K; X-ray; 2.60 A; A/B/C=229-551. DR PDB; 6D3L; X-ray; 3.10 A; A=229-551. DR PDB; 7OBK; X-ray; 1.80 A; B=541-551. DR PDB; 7OBL; X-ray; 1.80 A; B=541-551. DR PDB; 8BI7; X-ray; 1.40 A; B=541-551. DR PDB; 8I9J; EM; 6.39 A; A=1-170. DR PDB; 8IZN; EM; 6.67 A; A=1-170. DR PDBsum; 1QU6; -. DR PDBsum; 2A19; -. DR PDBsum; 2A1A; -. DR PDBsum; 3UIU; -. DR PDBsum; 6D3K; -. DR PDBsum; 6D3L; -. DR PDBsum; 7OBK; -. DR PDBsum; 7OBL; -. DR PDBsum; 8BI7; -. DR PDBsum; 8I9J; -. DR PDBsum; 8IZN; -. DR AlphaFoldDB; P19525; -. DR BMRB; P19525; -. DR EMDB; EMD-35274; -. DR EMDB; EMD-35866; -. DR SMR; P19525; -. DR BioGRID; 111596; 395. DR DIP; DIP-2657N; -. DR FunCoup; P19525; 998. DR IntAct; P19525; 176. DR MINT; P19525; -. DR STRING; 9606.ENSP00000233057; -. DR BindingDB; P19525; -. DR ChEMBL; CHEMBL5785; -. DR DrugBank; DB12010; Fostamatinib. DR DrugBank; DB07995; H-89. DR DrugBank; DB00328; Indomethacin. DR DrugCentral; P19525; -. DR GuidetoPHARMACOLOGY; 2016; -. DR GlyGen; P19525; 2 sites, 1 N-linked glycan (1 site), 1 O-linked glycan (1 site). DR iPTMnet; P19525; -. DR PhosphoSitePlus; P19525; -. DR SwissPalm; P19525; -. DR BioMuta; EIF2AK2; -. DR DMDM; 125527; -. DR jPOST; P19525; -. DR MassIVE; P19525; -. DR PaxDb; 9606-ENSP00000233057; -. DR PeptideAtlas; P19525; -. DR ProteomicsDB; 19391; -. DR ProteomicsDB; 53670; -. [P19525-1] DR Pumba; P19525; -. DR TopDownProteomics; P19525-1; -. [P19525-1] DR Antibodypedia; 3548; 1196 antibodies from 44 providers. DR DNASU; 5610; -. DR Ensembl; ENST00000233057.9; ENSP00000233057.4; ENSG00000055332.20. [P19525-1] DR Ensembl; ENST00000395127.6; ENSP00000378559.2; ENSG00000055332.20. [P19525-1] DR Ensembl; ENST00000405334.5; ENSP00000385014.1; ENSG00000055332.20. [P19525-2] DR Ensembl; ENST00000647926.1; ENSP00000497534.1; ENSG00000055332.20. [P19525-1] DR Ensembl; ENST00000679507.1; ENSP00000506024.1; ENSG00000055332.20. [P19525-1] DR Ensembl; ENST00000681463.1; ENSP00000505138.1; ENSG00000055332.20. [P19525-1] DR Ensembl; ENST00000681507.1; ENSP00000505772.1; ENSG00000055332.20. [P19525-1] DR GeneID; 5610; -. DR KEGG; hsa:5610; -. DR MANE-Select; ENST00000233057.9; ENSP00000233057.4; NM_001135651.3; NP_001129123.1. DR UCSC; uc010fab.3; human. [P19525-1] DR AGR; HGNC:9437; -. DR ClinPGx; PA33779; -. DR CTD; 5610; -. DR DisGeNET; 5610; -. DR GeneCards; EIF2AK2; -. DR HGNC; HGNC:9437; EIF2AK2. DR HPA; ENSG00000055332; Low tissue specificity. DR MalaCards; EIF2AK2; -. DR MIM; 176871; gene. DR MIM; 618877; phenotype. DR MIM; 619687; phenotype. DR OpenTargets; ENSG00000055332; -. DR Orphanet; 256; Early-onset generalized limb-onset dystonia. DR VEuPathDB; HostDB:ENSG00000055332; -. DR eggNOG; KOG1033; Eukaryota. DR GeneTree; ENSGT00940000160736; -. DR HOGENOM; CLU_023682_1_0_1; -. DR InParanoid; P19525; -. DR OMA; KIACEMM; -. DR OrthoDB; 341578at2759; -. DR PAN-GO; P19525; 2 GO annotations based on evolutionary models. DR PhylomeDB; P19525; -. DR PathwayCommons; P19525; -. DR Reactome; R-HSA-1169408; ISG15 antiviral mechanism. DR Reactome; R-HSA-169131; Inhibition of PKR. DR Reactome; R-HSA-4755510; SUMOylation of immune response proteins. DR Reactome; R-HSA-909733; Interferon alpha/beta signaling. DR Reactome; R-HSA-9833109; Evasion by RSV of host interferon responses. DR Reactome; R-HSA-9833482; PKR-mediated signaling. DR SignaLink; P19525; -. DR SIGNOR; P19525; -. DR Agora; ENSG00000055332; -. DR BioGRID-ORCS; 5610; 13 hits in 1193 CRISPR screens. DR CD-CODE; 91857CE7; Nucleolus. DR CD-CODE; DEE660B4; Stress granule. DR CD-CODE; FB4E32DD; Presynaptic clusters and postsynaptic densities. DR ChiTaRS; EIF2AK2; human. DR EvolutionaryTrace; P19525; -. DR GeneWiki; Protein_kinase_R; -. DR GenomeRNAi; 5610; -. DR Pharos; P19525; Tchem. DR PRO; PR:P19525; -. DR Proteomes; UP000005640; Chromosome 2. DR RNAct; P19525; protein. DR Bgee; ENSG00000055332; Expressed in endometrium epithelium and 211 other cell types or tissues. DR GO; GO:0005737; C:cytoplasm; IDA:UniProtKB. DR GO; GO:0005829; C:cytosol; IDA:HPA. DR GO; GO:0016020; C:membrane; HDA:UniProtKB. DR GO; GO:0005654; C:nucleoplasm; TAS:Reactome. DR GO; GO:0005634; C:nucleus; IBA:GO_Central. DR GO; GO:0048471; C:perinuclear region of cytoplasm; IDA:UniProtKB. DR GO; GO:0005840; C:ribosome; TAS:AgBase. DR GO; GO:0005524; F:ATP binding; IEA:UniProtKB-KW. DR GO; GO:0003725; F:double-stranded RNA binding; IDA:MGI. DR GO; GO:0004694; F:eukaryotic translation initiation factor 2alpha kinase activity; IMP:UniProtKB. DR GO; GO:0042802; F:identical protein binding; IPI:IntAct. DR GO; GO:0016301; F:kinase activity; IDA:UniProt. DR GO; GO:0004715; F:non-membrane spanning protein tyrosine kinase activity; IEA:UniProtKB-EC. DR GO; GO:0004672; F:protein kinase activity; IDA:UniProtKB. DR GO; GO:0019888; F:protein phosphatase regulator activity; TAS:ProtInc. DR GO; GO:0106310; F:protein serine kinase activity; IEA:RHEA. DR GO; GO:0004674; F:protein serine/threonine kinase activity; IDA:UniProt. DR GO; GO:0003723; F:RNA binding; HDA:UniProtKB. DR GO; GO:0140374; P:antiviral innate immune response; IDA:UniProt. DR GO; GO:0034198; P:cellular response to amino acid starvation; IMP:UniProtKB. DR GO; GO:0051607; P:defense response to virus; IEP:ARUK-UCL. DR GO; GO:0030968; P:endoplasmic reticulum unfolded protein response; IEA:Ensembl. DR GO; GO:0043066; P:negative regulation of apoptotic process; IEA:Ensembl. DR GO; GO:0008285; P:negative regulation of cell population proliferation; TAS:ProtInc. DR GO; GO:0033689; P:negative regulation of osteoblast proliferation; IMP:UniProtKB. DR GO; GO:0017148; P:negative regulation of translation; IDA:UniProtKB. DR GO; GO:0045071; P:negative regulation of viral genome replication; IMP:UniProtKB. DR GO; GO:0032722; P:positive regulation of chemokine production; ISS:UniProtKB. DR GO; GO:0001819; P:positive regulation of cytokine production; ISS:UniProtKB. DR GO; GO:0043410; P:positive regulation of MAPK cascade; IMP:UniProtKB. DR GO; GO:0051092; P:positive regulation of NF-kappaB transcription factor activity; IDA:UniProtKB. DR GO; GO:1901224; P:positive regulation of non-canonical NF-kappaB signal transduction; ISS:UniProtKB. DR GO; GO:0032874; P:positive regulation of stress-activated MAPK cascade; ISS:UniProtKB. DR GO; GO:0046777; P:protein autophosphorylation; IDA:UniProtKB. DR GO; GO:0006468; P:protein phosphorylation; IDA:UniProtKB. DR GO; GO:1901532; P:regulation of hematopoietic progenitor cell differentiation; ISS:UniProtKB. DR GO; GO:1902036; P:regulation of hematopoietic stem cell differentiation; ISS:UniProtKB. DR GO; GO:1902033; P:regulation of hematopoietic stem cell proliferation; ISS:UniProtKB. DR GO; GO:1900225; P:regulation of NLRP3 inflammasome complex assembly; ISS:UniProtKB. DR GO; GO:0006446; P:regulation of translational initiation; IBA:GO_Central. DR GO; GO:0035455; P:response to interferon-alpha; IDA:UniProtKB. DR GO; GO:0009615; P:response to virus; IMP:UniProtKB. DR GO; GO:0006412; P:translation; IEA:Ensembl. DR CDD; cd19903; DSRM_EIF2AK2_rpt1; 1. DR CDD; cd19904; DSRM_EIF2AK2_rpt2; 1. DR CDD; cd14047; STKc_EIF2AK2_PKR; 1. DR DisProt; DP03944; -. DR FunFam; 3.30.160.20:FF:000045; Eukaryotic translation initiation factor 2-alpha kinase 2; 1. DR FunFam; 3.30.160.20:FF:000062; Eukaryotic translation initiation factor 2-alpha kinase 2; 1. DR FunFam; 3.30.200.20:FF:000536; Eukaryotic translation initiation factor 2-alpha kinase 2; 1. DR FunFam; 1.10.510.10:FF:000251; eukaryotic translation initiation factor 2-alpha kinase 3; 1. DR Gene3D; 3.30.160.20; -; 2. DR Gene3D; 3.30.200.20; Phosphorylase Kinase, domain 1; 1. DR Gene3D; 1.10.510.10; Transferase(Phosphotransferase) domain 1; 1. DR IDEAL; IID00443; -. DR InterPro; IPR050339; CC_SR_Kinase. DR InterPro; IPR014720; dsRBD_dom. DR InterPro; IPR044452; EIF2AK2_DSRM_1. DR InterPro; IPR044453; EIF2AK2_DSRM_2. DR InterPro; IPR011009; Kinase-like_dom_sf. DR InterPro; IPR000719; Prot_kinase_dom. DR InterPro; IPR017441; Protein_kinase_ATP_BS. DR InterPro; IPR008271; Ser/Thr_kinase_AS. DR PANTHER; PTHR11042; EUKARYOTIC TRANSLATION INITIATION FACTOR 2-ALPHA KINASE EIF2-ALPHA KINASE -RELATED; 1. DR PANTHER; PTHR11042:SF163; INTERFERON-INDUCED, DOUBLE-STRANDED RNA-ACTIVATED PROTEIN KINASE; 1. DR Pfam; PF00035; dsrm; 2. DR Pfam; PF00069; Pkinase; 1. DR SMART; SM00358; DSRM; 2. DR SMART; SM00220; S_TKc; 1. DR SUPFAM; SSF54768; dsRNA-binding domain-like; 2. DR SUPFAM; SSF56112; Protein kinase-like (PK-like); 1. DR PROSITE; PS50137; DS_RBD; 2. DR PROSITE; PS00107; PROTEIN_KINASE_ATP; 1. DR PROSITE; PS50011; PROTEIN_KINASE_DOM; 1. DR PROSITE; PS00108; PROTEIN_KINASE_ST; 1. PE 1: Evidence at protein level; KW 3D-structure; Acetylation; Alternative splicing; Antiviral defense; KW ATP-binding; Cytoplasm; Direct protein sequencing; Disease variant; KW Dystonia; Host-virus interaction; Immunity; Innate immunity; KW Isopeptide bond; Kinase; Magnesium; Nucleotide-binding; Nucleus; KW Phosphoprotein; Proteomics identification; Reference proteome; Repeat; KW RNA-binding; Serine/threonine-protein kinase; Transcription; KW Transcription regulation; Transferase; Tyrosine-protein kinase; KW Ubl conjugation. FT INIT_MET 1 FT /note="Removed" FT /evidence="ECO:0000269|Ref.13, ECO:0007744|PubMed:22223895, FT ECO:0007744|PubMed:22814378" FT CHAIN 2..551 FT /note="Interferon-induced, double-stranded RNA-activated FT protein kinase" FT /id="PRO_0000085945" FT DOMAIN 9..77 FT /note="DRBM 1" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00266, FT ECO:0000269|PubMed:9736623" FT DOMAIN 100..167 FT /note="DRBM 2" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00266, FT ECO:0000269|PubMed:9736623" FT DOMAIN 267..538 FT /note="Protein kinase" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00159" FT REPEAT 331..343 FT /note="1" FT REPEAT 345..357 FT /note="2" FT REGION 2..180 FT /note="(Microbial infection) Interaction with HCV NS5A" FT /evidence="ECO:0000269|PubMed:17267064" FT REGION 202..222 FT /note="Disordered" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT REGION 266..551 FT /note="Interaction with TRAF5" FT /evidence="ECO:0000269|PubMed:15121867" FT REGION 266..362 FT /note="Dimerization" FT /evidence="ECO:0000269|PubMed:16179258" FT REGION 331..357 FT /note="2 X 13 AA approximate repeats" FT REGION 379..496 FT /note="Interaction with EIF2S1/EIF-2ALPHA" FT /evidence="ECO:0000269|PubMed:16179258" FT COMPBIAS 202..215 FT /note="Polar residues" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT ACT_SITE 414 FT /note="Proton acceptor" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00159, FT ECO:0000255|PROSITE-ProRule:PRU10027" FT BINDING 273..281 FT /ligand="ATP" FT /ligand_id="ChEBI:CHEBI:30616" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00159" FT BINDING 296 FT /ligand="ATP" FT /ligand_id="ChEBI:CHEBI:30616" FT BINDING 432 FT /ligand="Mg(2+)" FT /ligand_id="ChEBI:CHEBI:18420" FT /evidence="ECO:0000305|PubMed:16179258, FT ECO:0000305|PubMed:31246429" FT MOD_RES 2 FT /note="N-acetylalanine" FT /evidence="ECO:0000269|Ref.13, ECO:0007744|PubMed:22223895, FT ECO:0007744|PubMed:22814378" FT MOD_RES 83 FT /note="Phosphoserine" FT /evidence="ECO:0000269|PubMed:11152499, FT ECO:0007744|PubMed:18669648, ECO:0007744|PubMed:19690332, FT ECO:0007744|PubMed:20068231" FT MOD_RES 88 FT /note="Phosphothreonine; by autocatalysis" FT /evidence="ECO:0000305|PubMed:11152499" FT MOD_RES 89 FT /note="Phosphothreonine; by autocatalysis" FT /evidence="ECO:0000305|PubMed:11152499" FT MOD_RES 90 FT /note="Phosphothreonine; by autocatalysis" FT /evidence="ECO:0000305|PubMed:11152499" FT MOD_RES 101 FT /note="Phosphotyrosine; by autocatalysis" FT /evidence="ECO:0000269|PubMed:16373505" FT MOD_RES 162 FT /note="Phosphotyrosine; by autocatalysis" FT /evidence="ECO:0000269|PubMed:16373505" FT MOD_RES 242 FT /note="Phosphoserine; by autocatalysis" FT /evidence="ECO:0000305|PubMed:11152499" FT MOD_RES 255 FT /note="Phosphothreonine; by autocatalysis" FT /evidence="ECO:0000305|PubMed:11152499" FT MOD_RES 258 FT /note="Phosphothreonine; by autocatalysis" FT /evidence="ECO:0000305|PubMed:11152499" FT MOD_RES 293 FT /note="Phosphotyrosine; by autocatalysis" FT /evidence="ECO:0000269|PubMed:16373505" FT MOD_RES 446 FT /note="Phosphothreonine; by autocatalysis" FT /evidence="ECO:0000269|PubMed:11337501, FT ECO:0000269|PubMed:16179258" FT MOD_RES 451 FT /note="Phosphothreonine; by autocatalysis" FT /evidence="ECO:0000269|PubMed:11337501, FT ECO:0000269|PubMed:20685959" FT MOD_RES 456 FT /note="Phosphoserine" FT /evidence="ECO:0007744|PubMed:18669648" FT MOD_RES 542 FT /note="Phosphoserine" FT /evidence="ECO:0007744|PubMed:23186163" FT CROSSLNK 69 FT /note="Glycyl lysine isopeptide (Lys-Gly) (interchain with FT G-Cter in ISG15)" FT /evidence="ECO:0000269|PubMed:23229543" FT CROSSLNK 159 FT /note="Glycyl lysine isopeptide (Lys-Gly) (interchain with FT G-Cter in ISG15)" FT /evidence="ECO:0000269|PubMed:23229543" FT VAR_SEQ 263..303 FT /note="Missing (in isoform 2)" FT /evidence="ECO:0000303|Ref.7" FT /id="VSP_046177" FT VARIANT 11 FT /note="M -> L (in LEUDEN; uncertain significance; reduced FT phosphorylation of eukaryotic translation initiation factor FT 2-alpha in patient cells)" FT /evidence="ECO:0000269|PubMed:32197074" FT /id="VAR_084260" FT VARIANT 32 FT /note="N -> S (in LEUDEN; uncertain significance)" FT /evidence="ECO:0000269|PubMed:32197074" FT /id="VAR_084261" FT VARIANT 32 FT /note="N -> T (in DYT33; uncertain significance; gain-of- FT function variant resulting in increased levels of FT phosphorylated EIF2AK2 and EIF2A in patient cells compared FT to controls)" FT /evidence="ECO:0000269|PubMed:33236446" FT /id="VAR_086715" FT VARIANT 97 FT /note="S -> F (in LEUDEN; uncertain significance)" FT /evidence="ECO:0000269|PubMed:32197074" FT /id="VAR_084262" FT VARIANT 109 FT /note="A -> S (in LEUDEN; uncertain significance)" FT /evidence="ECO:0000269|PubMed:32197074" FT /id="VAR_084263" FT VARIANT 109 FT /note="A -> V (in LEUDEN; uncertain significance)" FT /evidence="ECO:0000269|PubMed:32197074" FT /id="VAR_084264" FT VARIANT 114 FT /note="L -> Q (found in a patient with dysmorphic facies, FT syndactyly, congenital microcephaly and global FT developmental delay; uncertain significance)" FT /evidence="ECO:0000269|PubMed:32197074" FT /id="VAR_084265" FT VARIANT 130 FT /note="G -> R (in DYT33; gain-of-function variant resulting FT in increased levels of phosphorylated EIF2AK2 and EIF2A in FT patient cells compared to controls)" FT /evidence="ECO:0000269|PubMed:33236446, FT ECO:0000269|PubMed:33866603, ECO:0000269|PubMed:35146068" FT /id="VAR_086716" FT VARIANT 133 FT /note="Y -> F (in LEUDEN; uncertain significance; reduced FT phosphorylation of eukaryotic translation initiation factor FT 2-alpha in patient cells)" FT /evidence="ECO:0000269|PubMed:32197074" FT /id="VAR_084266" FT VARIANT 138 FT /note="G -> A (in DYT33; uncertain significance)" FT /evidence="ECO:0000269|PubMed:33236446" FT /id="VAR_086717" FT VARIANT 325 FT /note="G -> S (in LEUDEN; uncertain significance)" FT /evidence="ECO:0000269|PubMed:32197074" FT /id="VAR_084267" FT VARIANT 428 FT /note="V -> E (in dbSNP:rs56219559)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_040474" FT VARIANT 439 FT /note="L -> V (in a lung adenocarcinoma sample; somatic FT mutation)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_040475" FT VARIANT 461 FT /note="S -> C (in LEUDEN; uncertain significance; reduced FT phosphorylation of eukaryotic translation initiation factor FT 2-alpha in patient cells)" FT /evidence="ECO:0000269|PubMed:32197074" FT /id="VAR_084268" FT VARIANT 506 FT /note="I -> V (no effect on PKR inhibition by HCMV protein FT TRS1; dbSNP:rs34821155)" FT /evidence="ECO:0000269|PubMed:17344846, FT ECO:0000269|PubMed:27780231" FT /id="VAR_040476" FT MUTAGEN 59..60 FT /note="SK->AA: In FL-PKR-2AI; moderate loss of activity but FT no effect on dsRNA binding." FT /evidence="ECO:0000269|PubMed:11337501" FT MUTAGEN 60 FT /note="K->A: Impairs dsRNA binding but not dimerization or FT activity." FT /evidence="ECO:0000269|PubMed:11337501" FT MUTAGEN 67 FT /note="A->E: Significant loss of activity; loss of dsRNA FT binding and dimerization." FT /evidence="ECO:0000269|PubMed:11337501" FT MUTAGEN 83 FT /note="S->A: No effect on enzymatic activity; when FT associated with A-88; A-89 and A-90." FT /evidence="ECO:0000269|PubMed:11152499" FT MUTAGEN 88 FT /note="T->A: No effect on enzymatic activity; when FT associated with A-83; A-89 and A-90." FT /evidence="ECO:0000269|PubMed:11152499" FT MUTAGEN 89 FT /note="T->A: No effect on enzymatic activity; when FT associated with A-83; A-88 and A-90." FT /evidence="ECO:0000269|PubMed:11152499" FT MUTAGEN 90 FT /note="T->A: No effect on enzymatic activity; when FT associated with A-83; A-88 and A-89." FT /evidence="ECO:0000269|PubMed:11152499" FT MUTAGEN 149..150 FT /note="TK->AA: In FL-PKR-2AII; no effect on activity." FT /evidence="ECO:0000269|PubMed:11337501" FT MUTAGEN 242 FT /note="S->A: Moderate loss of activity; when associated FT with A-255 and A-258." FT /evidence="ECO:0000269|PubMed:11152499" FT MUTAGEN 244..296 FT /note="Missing: Loss of activity." FT /evidence="ECO:0000269|PubMed:11337501" FT MUTAGEN 255 FT /note="T->A: Moderate loss of activity; when associated FT with A-242 and A-255." FT /evidence="ECO:0000269|PubMed:11152499" FT MUTAGEN 258 FT /note="T->A: Moderate loss of activity." FT /evidence="ECO:0000269|PubMed:11152499" FT MUTAGEN 296 FT /note="K->R: Loss of activity." FT /evidence="ECO:0000269|PubMed:11152499" FT MUTAGEN 446 FT /note="T->A: Significant loss of activity and impairs FT autophosphorylation of T-451." FT /evidence="ECO:0000269|PubMed:11337501" FT MUTAGEN 451 FT /note="T->A: Loss of activity." FT /evidence="ECO:0000269|PubMed:11337501" FT MUTAGEN 486 FT /note="D->V: 15-fold decrease in K3L binding affinity and FT thus resistance of mutated PKR to K3L inhibition." FT /evidence="ECO:0000269|PubMed:18971339" FT MUTAGEN 489 FT /note="F->S: Loss of PKR inhibition by HCMV protein TRS1." FT /evidence="ECO:0000269|PubMed:27780231" FT MUTAGEN 496 FT /note="T->K: No effect on PKR inhibition by HCMV protein FT TRS1." FT /evidence="ECO:0000269|PubMed:27780231" FT MUTAGEN 502 FT /note="I->T: No effect on PKR inhibition by HCMV protein FT TRS1." FT /evidence="ECO:0000269|PubMed:27780231" FT MUTAGEN 510 FT /note="K->R: No effect on PKR inhibition by HCMV protein FT TRS1." FT /evidence="ECO:0000269|PubMed:27780231" FT MUTAGEN 516 FT /note="Q->E: No effect on PKR inhibition by HCMV protein FT TRS1." FT /evidence="ECO:0000269|PubMed:27780231" FT CONFLICT 102 FT /note="I -> M (in Ref. 7; AAP57628)" FT /evidence="ECO:0000305" FT CONFLICT 224 FT /note="S -> R (in Ref. 7; AAP57628)" FT /evidence="ECO:0000305" FT CONFLICT 512 FT /note="K -> E (in Ref. 6; AAF13156)" FT /evidence="ECO:0000305" FT STRAND 5..7 FT /evidence="ECO:0007829|PDB:1QU6" FT HELIX 10..21 FT /evidence="ECO:0007829|PDB:1QU6" FT STRAND 26..32 FT /evidence="ECO:0007829|PDB:1QU6" FT TURN 35..37 FT /evidence="ECO:0007829|PDB:1QU6" FT STRAND 41..50 FT /evidence="ECO:0007829|PDB:1QU6" FT STRAND 54..56 FT /evidence="ECO:0007829|PDB:1QU6" FT HELIX 61..76 FT /evidence="ECO:0007829|PDB:1QU6" FT HELIX 102..111 FT /evidence="ECO:0007829|PDB:1QU6" FT STRAND 115..123 FT /evidence="ECO:0007829|PDB:1QU6" FT STRAND 125..138 FT /evidence="ECO:0007829|PDB:1QU6" FT STRAND 144..149 FT /evidence="ECO:0007829|PDB:1QU6" FT HELIX 150..167 FT /evidence="ECO:0007829|PDB:1QU6" FT HELIX 261..266 FT /evidence="ECO:0007829|PDB:2A19" FT STRAND 267..274 FT /evidence="ECO:0007829|PDB:2A19" FT STRAND 276..278 FT /evidence="ECO:0007829|PDB:2A19" FT STRAND 281..286 FT /evidence="ECO:0007829|PDB:2A19" FT TURN 287..289 FT /evidence="ECO:0007829|PDB:2A19" FT STRAND 292..299 FT /evidence="ECO:0007829|PDB:2A19" FT HELIX 303..305 FT /evidence="ECO:0007829|PDB:2A19" FT HELIX 306..314 FT /evidence="ECO:0007829|PDB:2A19" FT STRAND 323..332 FT /evidence="ECO:0007829|PDB:2A19" FT STRAND 358..366 FT /evidence="ECO:0007829|PDB:2A19" FT HELIX 374..380 FT /evidence="ECO:0007829|PDB:2A19" FT HELIX 381..383 FT /evidence="ECO:0007829|PDB:2A19" FT HELIX 388..407 FT /evidence="ECO:0007829|PDB:2A19" FT STRAND 410..412 FT /evidence="ECO:0007829|PDB:2A1A" FT HELIX 417..419 FT /evidence="ECO:0007829|PDB:2A19" FT STRAND 420..424 FT /evidence="ECO:0007829|PDB:2A19" FT STRAND 427..430 FT /evidence="ECO:0007829|PDB:2A19" FT HELIX 433..435 FT /evidence="ECO:0007829|PDB:6D3L" FT STRAND 437..440 FT /evidence="ECO:0007829|PDB:2A19" FT HELIX 457..461 FT /evidence="ECO:0007829|PDB:2A19" FT HELIX 468..482 FT /evidence="ECO:0007829|PDB:2A19" FT HELIX 488..499 FT /evidence="ECO:0007829|PDB:2A19" FT STRAND 505..507 FT /evidence="ECO:0007829|PDB:3UIU" FT HELIX 509..518 FT /evidence="ECO:0007829|PDB:2A19" FT HELIX 523..525 FT /evidence="ECO:0007829|PDB:2A19" FT HELIX 529..539 FT /evidence="ECO:0007829|PDB:2A19" SQ SEQUENCE 551 AA; 62094 MW; 815AD83ACAB45DA3 CRC64; MAGDLSAGFF MEELNTYRQK QGVVLKYQEL PNSGPPHDRR FTFQVIIDGR EFPEGEGRSK KEAKNAAAKL AVEILNKEKK AVSPLLLTTT NSSEGLSMGN YIGLINRIAQ KKRLTVNYEQ CASGVHGPEG FHYKCKMGQK EYSIGTGSTK QEAKQLAAKL AYLQILSEET SVKSDYLSSG SFATTCESQS NSLVTSTLAS ESSSEGDFSA DTSEINSNSD SLNSSSLLMN GLRNNQRKAK RSLAPRFDLP DMKETKYTVD KRFGMDFKEI ELIGSGGFGQ VFKAKHRIDG KTYVIKRVKY NNEKAEREVK ALAKLDHVNI VHYNGCWDGF DYDPETSDDS LESSDYDPEN SKNSSRSKTK CLFIQMEFCD KGTLEQWIEK RRGEKLDKVL ALELFEQITK GVDYIHSKKL IHRDLKPSNI FLVDTKQVKI GDFGLVTSLK NDGKRTRSKG TLRYMSPEQI SSQDYGKEVD LYALGLILAE LLHVCDTAFE TSKFFTDLRD GIISDIFDKK EKTLLQKLLS KKPEDRPNTS EILRTLTVWK KSPEKNERHT C // ID GLT12_HUMAN Reviewed; 581 AA. AC Q8IXK2; Q5TCF7; Q8NG54; Q96CT9; Q9H771; DT 16-AUG-2004, integrated into UniProtKB/Swiss-Prot. DT 20-DEC-2005, sequence version 3. DT 28-JAN-2026, entry version 192. DE RecName: Full=Polypeptide N-acetylgalactosaminyltransferase 12; DE EC=2.4.1.41; DE AltName: Full=Polypeptide GalNAc transferase 12; DE Short=GalNAc-T12; DE Short=pp-GaNTase 12; DE AltName: Full=Protein-UDP acetylgalactosaminyltransferase 12; DE AltName: Full=UDP-GalNAc:polypeptide N-acetylgalactosaminyltransferase 12; GN Name=GALNT12; OS Homo sapiens (Human). OC Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia; OC Eutheria; Euarchontoglires; Primates; Haplorrhini; Catarrhini; Hominidae; OC Homo. OX NCBI_TaxID=9606; RN [1] RP NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 1), ENZYME ACTIVITY, TISSUE RP SPECIFICITY, AND VARIANT VAL-119. RC TISSUE=Lung; RX PubMed=12135769; DOI=10.1016/s0014-5793(02)03007-7; RA Guo J.-M., Zhang Y., Cheng L., Iwasaki H., Wang H., Kubota T., RA Tachibana K., Narimatsu H.; RT "Molecular cloning and characterization of a novel member of the UDP- RT GalNAc:polypeptide N-acetylgalactosaminyltransferase family, pp-GalNAc- RT T12(1)."; RL FEBS Lett. 524:211-218(2002). RN [2] RP NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 1). RA Bennett E.P.; RL Submitted (JAN-1999) to the EMBL/GenBank/DDBJ databases. RN [3] RP NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA]. RX PubMed=15164053; DOI=10.1038/nature02465; RA Humphray S.J., Oliver K., Hunt A.R., Plumb R.W., Loveland J.E., Howe K.L., RA Andrews T.D., Searle S., Hunt S.E., Scott C.E., Jones M.C., Ainscough R., RA Almeida J.P., Ambrose K.D., Ashwell R.I.S., Babbage A.K., Babbage S., RA Bagguley C.L., Bailey J., Banerjee R., Barker D.J., Barlow K.F., Bates K., RA Beasley H., Beasley O., Bird C.P., Bray-Allen S., Brown A.J., Brown J.Y., RA Burford D., Burrill W., Burton J., Carder C., Carter N.P., Chapman J.C., RA Chen Y., Clarke G., Clark S.Y., Clee C.M., Clegg S., Collier R.E., RA Corby N., Crosier M., Cummings A.T., Davies J., Dhami P., Dunn M., RA Dutta I., Dyer L.W., Earthrowl M.E., Faulkner L., Fleming C.J., RA Frankish A., Frankland J.A., French L., Fricker D.G., Garner P., RA Garnett J., Ghori J., Gilbert J.G.R., Glison C., Grafham D.V., Gribble S., RA Griffiths C., Griffiths-Jones S., Grocock R., Guy J., Hall R.E., RA Hammond S., Harley J.L., Harrison E.S.I., Hart E.A., Heath P.D., RA Henderson C.D., Hopkins B.L., Howard P.J., Howden P.J., Huckle E., RA Johnson C., Johnson D., Joy A.A., Kay M., Keenan S., Kershaw J.K., RA Kimberley A.M., King A., Knights A., Laird G.K., Langford C., Lawlor S., RA Leongamornlert D.A., Leversha M., Lloyd C., Lloyd D.M., Lovell J., RA Martin S., Mashreghi-Mohammadi M., Matthews L., McLaren S., McLay K.E., RA McMurray A., Milne S., Nickerson T., Nisbett J., Nordsiek G., Pearce A.V., RA Peck A.I., Porter K.M., Pandian R., Pelan S., Phillimore B., Povey S., RA Ramsey Y., Rand V., Scharfe M., Sehra H.K., Shownkeen R., Sims S.K., RA Skuce C.D., Smith M., Steward C.A., Swarbreck D., Sycamore N., Tester J., RA Thorpe A., Tracey A., Tromans A., Thomas D.W., Wall M., Wallis J.M., RA West A.P., Whitehead S.L., Willey D.L., Williams S.A., Wilming L., RA Wray P.W., Young L., Ashurst J.L., Coulson A., Blocker H., Durbin R.M., RA Sulston J.E., Hubbard T., Jackson M.J., Bentley D.R., Beck S., Rogers J., RA Dunham I.; RT "DNA sequence and analysis of human chromosome 9."; RL Nature 429:369-374(2004). RN [4] RP NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM 2). RC TISSUE=Bone marrow; RX PubMed=15489334; DOI=10.1101/gr.2596504; RG The MGC Project Team; RT "The status, quality, and expansion of the NIH full-length cDNA project: RT the Mammalian Gene Collection (MGC)."; RL Genome Res. 14:2121-2127(2004). RN [5] RP NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] OF 144-581 (ISOFORM 1). RC TISSUE=Colon; RX PubMed=14702039; DOI=10.1038/ng1285; RA Ota T., Suzuki Y., Nishikawa T., Otsuki T., Sugiyama T., Irie R., RA Wakamatsu A., Hayashi K., Sato H., Nagai K., Kimura K., Makita H., RA Sekine M., Obayashi M., Nishi T., Shibahara T., Tanaka T., Ishii S., RA Yamamoto J., Saito K., Kawai Y., Isono Y., Nakamura Y., Nagahari K., RA Murakami K., Yasuda T., Iwayanagi T., Wagatsuma M., Shiratori A., Sudo H., RA Hosoiri T., Kaku Y., Kodaira H., Kondo H., Sugawara M., Takahashi M., RA Kanda K., Yokoi T., Furuya T., Kikkawa E., Omura Y., Abe K., Kamihara K., RA Katsuta N., Sato K., Tanikawa M., Yamazaki M., Ninomiya K., Ishibashi T., RA Yamashita H., Murakawa K., Fujimori K., Tanai H., Kimata M., Watanabe M., RA Hiraoka S., Chiba Y., Ishida S., Ono Y., Takiguchi S., Watanabe S., RA Yosida M., Hotuta T., Kusano J., Kanehori K., Takahashi-Fujii A., Hara H., RA Tanase T.-O., Nomura Y., Togiya S., Komai F., Hara R., Takeuchi K., RA Arita M., Imose N., Musashino K., Yuuki H., Oshima A., Sasaki N., RA Aotsuka S., Yoshikawa Y., Matsunawa H., Ichihara T., Shiohata N., Sano S., RA Moriya S., Momiyama H., Satoh N., Takami S., Terashima Y., Suzuki O., RA Nakagawa S., Senoh A., Mizoguchi H., Goto Y., Shimizu F., Wakebe H., RA Hishigaki H., Watanabe T., Sugiyama A., Takemoto M., Kawakami B., RA Yamazaki M., Watanabe K., Kumagai A., Itakura S., Fukuzumi Y., Fujimori Y., RA Komiyama M., Tashiro H., Tanigami A., Fujiwara T., Ono T., Yamada K., RA Fujii Y., Ozaki K., Hirao M., Ohmori Y., Kawabata A., Hikiji T., RA Kobatake N., Inagaki H., Ikema Y., Okamoto S., Okitani R., Kawakami T., RA Noguchi S., Itoh T., Shigeta K., Senba T., Matsumura K., Nakajima Y., RA Mizuno T., Morinaga M., Sasaki M., Togashi T., Oyama M., Hata H., RA Watanabe M., Komatsu T., Mizushima-Sugano J., Satoh T., Shirai Y., RA Takahashi Y., Nakagawa K., Okumura K., Nagase T., Nomura N., Kikuchi H., RA Masuho Y., Yamashita R., Nakai K., Yada T., Nakamura Y., Ohara O., RA Isogai T., Sugano S.; RT "Complete sequencing and characterization of 21,243 full-length human RT cDNAs."; RL Nat. Genet. 36:40-45(2004). RN [6] RP VARIANTS CRCS1 TRP-297; ASN-303; ASP-341; HIS-373; HIS-382; PHE-479 AND RP MET-491, CHARACTERIZATION OF VARIANTS CRCS1 TRP-297; ASN-303; ASP-341; RP HIS-373; HIS-382; PHE-479 AND MET-491, AND VARIANTS GLU-3; ARG-46; VAL-119; RP ASN-261; ARG-272 AND LYS-552. RX PubMed=19617566; DOI=10.1073/pnas.0901454106; RA Guda K., Moinova H., He J., Jamison O., Ravi L., Natale L., Lutterbaugh J., RA Lawrence E., Lewis S., Willson J.K., Lowe J.B., Wiesner G.L., RA Parmigiani G., Barnholtz-Sloan J., Dawson D.W., Velculescu V.E., RA Kinzler K.W., Papadopoulos N., Vogelstein B., Willis J., Gerken T.A., RA Markowitz S.D.; RT "Inactivating germ-line and somatic mutations in polypeptide N- RT acetylgalactosaminyltransferase 12 in human colon cancers."; RL Proc. Natl. Acad. Sci. U.S.A. 106:12921-12925(2009). RN [7] RP VARIANTS CRCS1 ASN-303 AND CYS-396. RX PubMed=22461326; DOI=10.1002/humu.22088; RA Clarke E., Green R.C., Green J.S., Mahoney K., Parfrey P.S., RA Younghusband H.B., Woods M.O.; RT "Inherited deleterious variants in GALNT12 are associated with CRC RT susceptibility."; RL Hum. Mutat. 33:1056-1058(2012). RN [8] RP INVOLVEMENT IN CRCS1. RX PubMed=24115450; DOI=10.1002/humu.22454; RA Segui N., Pineda M., Navarro M., Lazaro C., Brunet J., Infante M., RA Duran M., Soto J.L., Blanco I., Capella G., Valle L.; RT "GALNT12 is not a major contributor of familial colorectal cancer type X."; RL Hum. Mutat. 35:50-52(2014). CC -!- FUNCTION: Catalyzes the initial reaction in O-linked oligosaccharide CC biosynthesis, the transfer of an N-acetyl-D-galactosamine residue to a CC serine or threonine residue on the protein receptor. Has activity CC toward non-glycosylated peptides such as Muc5AC, Muc1a and EA2, and no CC detectable activity with Muc2 and Muc7. Displays enzymatic activity CC toward the Gal-NAc-Muc5AC glycopeptide, but no detectable activity to CC mono-GalNAc-glycosylated Muc1a, Muc2, Muc7 and EA2. May play an CC important role in the initial step of mucin-type oligosaccharide CC biosynthesis in digestive organs. CC -!- CATALYTIC ACTIVITY: CC Reaction=L-seryl-[protein] + UDP-N-acetyl-alpha-D-galactosamine = a 3- CC O-[N-acetyl-alpha-D-galactosaminyl]-L-seryl-[protein] + UDP + H(+); CC Xref=Rhea:RHEA:23956, Rhea:RHEA-COMP:9863, Rhea:RHEA-COMP:12788, CC ChEBI:CHEBI:15378, ChEBI:CHEBI:29999, ChEBI:CHEBI:53604, CC ChEBI:CHEBI:58223, ChEBI:CHEBI:67138; EC=2.4.1.41; CC Evidence={ECO:0000269|PubMed:12135769}; CC -!- CATALYTIC ACTIVITY: CC Reaction=L-threonyl-[protein] + UDP-N-acetyl-alpha-D-galactosamine = a CC 3-O-[N-acetyl-alpha-D-galactosaminyl]-L-threonyl-[protein] + UDP + CC H(+); Xref=Rhea:RHEA:52424, Rhea:RHEA-COMP:11060, Rhea:RHEA- CC COMP:11689, ChEBI:CHEBI:15378, ChEBI:CHEBI:30013, ChEBI:CHEBI:58223, CC ChEBI:CHEBI:67138, ChEBI:CHEBI:87075; EC=2.4.1.41; CC Evidence={ECO:0000269|PubMed:12135769}; CC -!- COFACTOR: CC Name=Mn(2+); Xref=ChEBI:CHEBI:29035; Evidence={ECO:0000250}; CC -!- PATHWAY: Protein modification; protein glycosylation. CC -!- INTERACTION: CC Q8IXK2; P02790: HPX; NbExp=3; IntAct=EBI-8995375, EBI-1223791; CC -!- SUBCELLULAR LOCATION: Golgi apparatus membrane {ECO:0000250}; Single- CC pass type II membrane protein {ECO:0000250}. CC -!- ALTERNATIVE PRODUCTS: CC Event=Alternative splicing; Named isoforms=2; CC Name=1; CC IsoId=Q8IXK2-1; Sequence=Displayed; CC Name=2; CC IsoId=Q8IXK2-2; Sequence=VSP_011217; CC -!- TISSUE SPECIFICITY: Widely expressed at different levels of expression. CC Highly expressed in digestive organs such as small intestine, stomach, CC pancreas and colon. Expressed at intermediate level in testis, thyroid CC gland and spleen. Weakly expressed in whole brain, cerebral cortex, CC cerebellum, fetal brain, bone marrow, thymus, leukocytes, heart, CC skeletal muscle, liver, lung, esophagus, kidney, adrenal gland, mammary CC gland, uterus, placenta, ovary and prostate. CC {ECO:0000269|PubMed:12135769}. CC -!- DOMAIN: There are two conserved domains in the glycosyltransferase CC region: the N-terminal domain (domain A, also called GT1 motif), which CC is probably involved in manganese coordination and substrate binding CC and the C-terminal domain (domain B, also called Gal/GalNAc-T motif), CC which is probably involved in catalytic reaction and UDP-Gal binding. CC {ECO:0000250}. CC -!- DOMAIN: The ricin B-type lectin domain binds to GalNAc and contributes CC to the glycopeptide specificity. {ECO:0000250}. CC -!- DISEASE: Colorectal cancer 1 (CRCS1) [MIM:608812]: A complex disease CC characterized by malignant lesions arising from the inner wall of the CC large intestine (the colon) and the rectum. Genetic alterations are CC often associated with progression from premalignant lesion (adenoma) to CC invasive adenocarcinoma. Risk factors for cancer of the colon and CC rectum include colon polyps, long-standing ulcerative colitis, and CC genetic family history. {ECO:0000269|PubMed:19617566, CC ECO:0000269|PubMed:22461326, ECO:0000269|PubMed:24115450}. Note=Disease CC susceptibility is associated with variants affecting the gene CC represented in this entry. The role of GALNT12 in colon cancer CC susceptibility is however subject to discussion: studies on 103 CC probants with colorectal cancer 1 (CRCS1) suggest that it does not act CC as a major contributor of CRCS1 (PubMed:24115450). CC {ECO:0000269|PubMed:24115450}. CC -!- SIMILARITY: Belongs to the glycosyltransferase 2 family. GalNAc-T CC subfamily. {ECO:0000305}. CC -!- SEQUENCE CAUTION: CC Sequence=BAB15027.1; Type=Erroneous initiation; Evidence={ECO:0000305}; CC -!- WEB RESOURCE: Name=Functional Glycomics Gateway - GTase; CC Note=Polypeptide N-acetylgalactosaminyltransferase 12; CC URL="http://www.functionalglycomics.org/glycomics/molecule/jsp/glycoEnzyme/viewGlycoEnzyme.jsp?gbpId=gt_hum_495"; CC --------------------------------------------------------------------------- CC Copyrighted by the UniProt Consortium, see https://www.uniprot.org/terms CC Distributed under the Creative Commons Attribution (CC BY 4.0) License CC --------------------------------------------------------------------------- DR EMBL; AB078146; BAC07181.1; -; mRNA. DR EMBL; AJ132365; CAC80100.2; -; mRNA. DR EMBL; AL136084; -; NOT_ANNOTATED_CDS; Genomic_DNA. DR EMBL; BC013945; AAH13945.1; -; mRNA. DR EMBL; AK024865; BAB15027.1; ALT_INIT; mRNA. DR CCDS; CCDS6737.1; -. [Q8IXK2-1] DR RefSeq; NP_078918.3; NM_024642.4. [Q8IXK2-1] DR RefSeq; XP_006717350.1; XM_006717287.1. DR PDB; 6PXU; X-ray; 2.01 A; A/B=39-581. DR PDBsum; 6PXU; -. DR AlphaFoldDB; Q8IXK2; -. DR SMR; Q8IXK2; -. DR BioGRID; 122816; 129. DR FunCoup; Q8IXK2; 763. DR IntAct; Q8IXK2; 92. DR MINT; Q8IXK2; -. DR STRING; 9606.ENSP00000364150; -. DR CAZy; CBM13; Carbohydrate-Binding Module Family 13. DR CAZy; GT27; Glycosyltransferase Family 27. DR UniLectin; Q8IXK2; -. DR GlyGen; Q8IXK2; 3 sites, 1 O-linked glycan (3 sites). DR iPTMnet; Q8IXK2; -. DR PhosphoSitePlus; Q8IXK2; -. DR SwissPalm; Q8IXK2; -. DR BioMuta; GALNT12; -. DR DMDM; 84028209; -. DR jPOST; Q8IXK2; -. DR MassIVE; Q8IXK2; -. DR PaxDb; 9606-ENSP00000364150; -. DR PeptideAtlas; Q8IXK2; -. DR ProteomicsDB; 71019; -. [Q8IXK2-1] DR ProteomicsDB; 71020; -. [Q8IXK2-2] DR Pumba; Q8IXK2; -. DR Antibodypedia; 29005; 88 antibodies from 14 providers. DR DNASU; 79695; -. DR Ensembl; ENST00000375011.4; ENSP00000364150.3; ENSG00000119514.8. [Q8IXK2-1] DR GeneID; 79695; -. DR KEGG; hsa:79695; -. DR MANE-Select; ENST00000375011.4; ENSP00000364150.3; NM_024642.5; NP_078918.3. DR UCSC; uc004ayz.3; human. [Q8IXK2-1] DR AGR; HGNC:19877; -. DR ClinPGx; PA134929192; -. DR CTD; 79695; -. DR DisGeNET; 79695; -. DR GeneCards; GALNT12; -. DR HGNC; HGNC:19877; GALNT12. DR HPA; ENSG00000119514; Tissue enhanced (epididymis, intestine, stomach). DR MalaCards; GALNT12; -. DR MIM; 608812; phenotype. DR MIM; 610290; gene. DR OpenTargets; ENSG00000119514; -. DR VEuPathDB; HostDB:ENSG00000119514; -. DR eggNOG; KOG3736; Eukaryota. DR GeneTree; ENSGT00940000157173; -. DR HOGENOM; CLU_013477_0_3_1; -. DR InParanoid; Q8IXK2; -. DR OMA; SKSYFHY; -. DR OrthoDB; 416652at2759; -. DR PAN-GO; Q8IXK2; 3 GO annotations based on evolutionary models. DR PhylomeDB; Q8IXK2; -. DR BRENDA; 2.4.1.41; 2681. DR PathwayCommons; Q8IXK2; -. DR Reactome; R-HSA-5083636; Defective GALNT12 causes CRCS1. DR Reactome; R-HSA-913709; O-linked glycosylation of mucins. DR SignaLink; Q8IXK2; -. DR UniPathway; UPA00378; -. DR Agora; ENSG00000119514; -. DR BioGRID-ORCS; 79695; 10 hits in 1155 CRISPR screens. DR ChiTaRS; GALNT12; human. DR GenomeRNAi; 79695; -. DR Pharos; Q8IXK2; Tbio. DR PRO; PR:Q8IXK2; -. DR Proteomes; UP000005640; Chromosome 9. DR RNAct; Q8IXK2; protein. DR Bgee; ENSG00000119514; Expressed in palpebral conjunctiva and 153 other cell types or tissues. DR ExpressionAtlas; Q8IXK2; baseline and differential. DR GO; GO:0005794; C:Golgi apparatus; IBA:GO_Central. DR GO; GO:0000139; C:Golgi membrane; TAS:Reactome. DR GO; GO:0030246; F:carbohydrate binding; IEA:UniProtKB-KW. DR GO; GO:0046872; F:metal ion binding; IEA:UniProtKB-KW. DR GO; GO:0004653; F:polypeptide N-acetylgalactosaminyltransferase activity; IBA:GO_Central. DR GO; GO:0006493; P:protein O-linked glycosylation; IBA:GO_Central. DR GO; GO:0016266; P:protein O-linked glycosylation via N-acetyl-galactosamine; TAS:Reactome. DR CDD; cd23471; beta-trefoil_Ricin_GALNT12; 1. DR CDD; cd02510; pp-GalNAc-T; 1. DR FunFam; 2.80.10.50:FF:000057; Polypeptide N-acetylgalactosaminyltransferase; 1. DR FunFam; 3.90.550.10:FF:000021; Polypeptide N-acetylgalactosaminyltransferase; 1. DR Gene3D; 2.80.10.50; -; 1. DR Gene3D; 3.90.550.10; Spore Coat Polysaccharide Biosynthesis Protein SpsA, Chain A; 1. DR InterPro; IPR045885; GalNAc-T. DR InterPro; IPR001173; Glyco_trans_2-like. DR InterPro; IPR029044; Nucleotide-diphossugar_trans. DR InterPro; IPR035992; Ricin_B-like_lectins. DR InterPro; IPR000772; Ricin_B_lectin. DR PANTHER; PTHR11675; N-ACETYLGALACTOSAMINYLTRANSFERASE; 1. DR PANTHER; PTHR11675:SF18; POLYPEPTIDE N-ACETYLGALACTOSAMINYLTRANSFERASE 12; 1. DR Pfam; PF00535; Glycos_transf_2; 1. DR Pfam; PF00652; Ricin_B_lectin; 1. DR SMART; SM00458; RICIN; 1. DR SUPFAM; SSF53448; Nucleotide-diphospho-sugar transferases; 1. DR SUPFAM; SSF50370; Ricin B-like lectins; 1. DR PROSITE; PS50231; RICIN_B_LECTIN; 1. PE 1: Evidence at protein level; KW 3D-structure; Alternative splicing; Disease variant; Disulfide bond; KW Glycosyltransferase; Golgi apparatus; Lectin; Manganese; Membrane; KW Metal-binding; Proteomics identification; Reference proteome; KW Signal-anchor; Transferase; Transmembrane; Transmembrane helix. FT CHAIN 1..581 FT /note="Polypeptide N-acetylgalactosaminyltransferase 12" FT /id="PRO_0000059128" FT TOPO_DOM 1..19 FT /note="Cytoplasmic" FT /evidence="ECO:0000255" FT TRANSMEM 20..37 FT /note="Helical; Signal-anchor for type II membrane protein" FT /evidence="ECO:0000255" FT TOPO_DOM 38..581 FT /note="Lumenal" FT /evidence="ECO:0000255" FT DOMAIN 445..577 FT /note="Ricin B-type lectin" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00174" FT REGION 43..67 FT /note="Disordered" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT REGION 135..244 FT /note="Catalytic subdomain A" FT REGION 304..366 FT /note="Catalytic subdomain B" FT BINDING 176 FT /ligand="substrate" FT /evidence="ECO:0000250" FT BINDING 205 FT /ligand="substrate" FT /evidence="ECO:0000250" FT BINDING 228 FT /ligand="Mn(2+)" FT /ligand_id="ChEBI:CHEBI:29035" FT /evidence="ECO:0000250" FT BINDING 230 FT /ligand="Mn(2+)" FT /ligand_id="ChEBI:CHEBI:29035" FT /evidence="ECO:0000250" FT BINDING 335 FT /ligand="substrate" FT /evidence="ECO:0000250" FT BINDING 363 FT /ligand="Mn(2+)" FT /ligand_id="ChEBI:CHEBI:29035" FT /evidence="ECO:0000250" FT BINDING 371 FT /ligand="substrate" FT /evidence="ECO:0000250" FT DISULFID 125..358 FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00174" FT DISULFID 349..422 FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00174" FT DISULFID 458..479 FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00174" FT DISULFID 506..521 FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00174" FT DISULFID 547..566 FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00174" FT VAR_SEQ 1..309 FT /note="Missing (in isoform 2)" FT /evidence="ECO:0000303|PubMed:15489334" FT /id="VSP_011217" FT VARIANT 3 FT /note="G -> E (in dbSNP:rs1356894484)" FT /evidence="ECO:0000269|PubMed:19617566" FT /id="VAR_064352" FT VARIANT 46 FT /note="G -> R (in dbSNP:rs10987768)" FT /evidence="ECO:0000269|PubMed:19617566" FT /id="VAR_064353" FT VARIANT 119 FT /note="E -> V (in dbSNP:rs1137654)" FT /evidence="ECO:0000269|PubMed:12135769, FT ECO:0000269|PubMed:19617566" FT /id="VAR_064354" FT VARIANT 261 FT /note="D -> N (in dbSNP:rs41306504)" FT /evidence="ECO:0000269|PubMed:19617566" FT /id="VAR_064355" FT VARIANT 272 FT /note="G -> R (in dbSNP:rs367645298)" FT /evidence="ECO:0000269|PubMed:19617566" FT /id="VAR_064356" FT VARIANT 297 FT /note="R -> W (in CRCS1; germline mutation; partial loss of FT activity; dbSNP:rs149726976)" FT /evidence="ECO:0000269|PubMed:19617566" FT /id="VAR_064357" FT VARIANT 303 FT /note="D -> N (in CRCS1; germline mutation; reduction of FT activity; dbSNP:rs145236923)" FT /evidence="ECO:0000269|PubMed:19617566, FT ECO:0000269|PubMed:22461326" FT /id="VAR_064358" FT VARIANT 341 FT /note="E -> D (in CRCS1; somatic mutation; loss of FT activity)" FT /evidence="ECO:0000269|PubMed:19617566" FT /id="VAR_064359" FT VARIANT 373 FT /note="R -> H (in CRCS1; germline mutation; partial loss of FT activity; dbSNP:rs920049418)" FT /evidence="ECO:0000269|PubMed:19617566" FT /id="VAR_064360" FT VARIANT 382 FT /note="R -> H (in CRCS1; germline mutation; loss of FT activity; dbSNP:rs868590153)" FT /evidence="ECO:0000269|PubMed:19617566" FT /id="VAR_064361" FT VARIANT 396 FT /note="Y -> C (in CRCS1; dbSNP:rs1272530441)" FT /evidence="ECO:0000269|PubMed:22461326" FT /id="VAR_068509" FT VARIANT 479 FT /note="C -> F (in CRCS1; somatic mutation; loss of FT activity)" FT /evidence="ECO:0000269|PubMed:19617566" FT /id="VAR_064362" FT VARIANT 491 FT /note="T -> M (in CRCS1; germline mutation; loss of FT activity; dbSNP:rs267606840)" FT /evidence="ECO:0000269|PubMed:19617566" FT /id="VAR_064363" FT VARIANT 552 FT /note="R -> K (in dbSNP:rs1285871027)" FT /evidence="ECO:0000269|PubMed:19617566" FT /id="VAR_064364" FT STRAND 61..65 FT /evidence="ECO:0007829|PDB:6PXU" FT TURN 75..78 FT /evidence="ECO:0007829|PDB:6PXU" FT HELIX 88..101 FT /evidence="ECO:0007829|PDB:6PXU" FT HELIX 105..108 FT /evidence="ECO:0007829|PDB:6PXU" FT HELIX 123..127 FT /evidence="ECO:0007829|PDB:6PXU" FT TURN 132..134 FT /evidence="ECO:0007829|PDB:6PXU" FT STRAND 138..146 FT /evidence="ECO:0007829|PDB:6PXU" FT HELIX 149..162 FT /evidence="ECO:0007829|PDB:6PXU" FT HELIX 165..167 FT /evidence="ECO:0007829|PDB:6PXU" FT STRAND 168..175 FT /evidence="ECO:0007829|PDB:6PXU" FT HELIX 181..183 FT /evidence="ECO:0007829|PDB:6PXU" FT HELIX 185..191 FT /evidence="ECO:0007829|PDB:6PXU" FT STRAND 197..201 FT /evidence="ECO:0007829|PDB:6PXU" FT HELIX 207..218 FT /evidence="ECO:0007829|PDB:6PXU" FT STRAND 221..226 FT /evidence="ECO:0007829|PDB:6PXU" FT STRAND 229..233 FT /evidence="ECO:0007829|PDB:6PXU" FT HELIX 238..247 FT /evidence="ECO:0007829|PDB:6PXU" FT STRAND 251..260 FT /evidence="ECO:0007829|PDB:6PXU" FT TURN 262..264 FT /evidence="ECO:0007829|PDB:6PXU" FT STRAND 276..279 FT /evidence="ECO:0007829|PDB:6PXU" FT STRAND 285..288 FT /evidence="ECO:0007829|PDB:6PXU" FT HELIX 292..297 FT /evidence="ECO:0007829|PDB:6PXU" FT STRAND 315..318 FT /evidence="ECO:0007829|PDB:6PXU" FT HELIX 319..324 FT /evidence="ECO:0007829|PDB:6PXU" FT STRAND 334..337 FT /evidence="ECO:0007829|PDB:6PXU" FT HELIX 338..348 FT /evidence="ECO:0007829|PDB:6PXU" FT STRAND 352..364 FT /evidence="ECO:0007829|PDB:6PXU" FT HELIX 376..387 FT /evidence="ECO:0007829|PDB:6PXU" FT HELIX 389..391 FT /evidence="ECO:0007829|PDB:6PXU" FT HELIX 392..398 FT /evidence="ECO:0007829|PDB:6PXU" FT HELIX 400..404 FT /evidence="ECO:0007829|PDB:6PXU" FT HELIX 411..419 FT /evidence="ECO:0007829|PDB:6PXU" FT HELIX 425..431 FT /evidence="ECO:0007829|PDB:6PXU" FT STRAND 445..454 FT /evidence="ECO:0007829|PDB:6PXU" FT STRAND 457..460 FT /evidence="ECO:0007829|PDB:6PXU" FT STRAND 464..467 FT /evidence="ECO:0007829|PDB:6PXU" FT STRAND 475..478 FT /evidence="ECO:0007829|PDB:6PXU" FT HELIX 484..486 FT /evidence="ECO:0007829|PDB:6PXU" FT STRAND 488..490 FT /evidence="ECO:0007829|PDB:6PXU" FT STRAND 496..498 FT /evidence="ECO:0007829|PDB:6PXU" FT STRAND 500..503 FT /evidence="ECO:0007829|PDB:6PXU" FT STRAND 505..508 FT /evidence="ECO:0007829|PDB:6PXU" FT STRAND 517..520 FT /evidence="ECO:0007829|PDB:6PXU" FT HELIX 527..529 FT /evidence="ECO:0007829|PDB:6PXU" FT STRAND 531..533 FT /evidence="ECO:0007829|PDB:6PXU" FT STRAND 537..541 FT /evidence="ECO:0007829|PDB:6PXU" FT TURN 542..545 FT /evidence="ECO:0007829|PDB:6PXU" FT STRAND 546..551 FT /evidence="ECO:0007829|PDB:6PXU" FT TURN 554..556 FT /evidence="ECO:0007829|PDB:6PXU" FT STRAND 560..564 FT /evidence="ECO:0007829|PDB:6PXU" FT HELIX 570..572 FT /evidence="ECO:0007829|PDB:6PXU" FT STRAND 573..579 FT /evidence="ECO:0007829|PDB:6PXU" SQ SEQUENCE 581 AA; 66938 MW; 8C001D58E103A523 CRC64; MWGRTARRRC PRELRRGREA LLVLLALLAL AGLGSVLRAQ RGAGAGAAEP GPPRTPRPGR REPVMPRPPV PANALGARGE AVRLQLQGEE LRLQEESVRL HQINIYLSDR ISLHRRLPER WNPLCKEKKY DYDNLPRTSV IIAFYNEAWS TLLRTVYSVL ETSPDILLEE VILVDDYSDR EHLKERLANE LSGLPKVRLI RANKREGLVR ARLLGASAAR GDVLTFLDCH CECHEGWLEP LLQRIHEEES AVVCPVIDVI DWNTFEYLGN SGEPQIGGFD WRLVFTWHTV PERERIRMQS PVDVIRSPTM AGGLFAVSKK YFEYLGSYDT GMEVWGGENL EFSFRIWQCG GVLETHPCSH VGHVFPKQAP YSRNKALANS VRAAEVWMDE FKELYYHRNP RARLEPFGDV TERKQLRDKL QCKDFKWFLE TVYPELHVPE DRPGFFGMLQ NKGLTDYCFD YNPPDENQIV GHQVILYLCH GMGQNQFFEY TSQKEIRYNT HQPEGCIAVE AGMDTLIMHL CEETAPENQK FILQEDGSLF HEQSKKCVQA ARKESSDSFV PLLRDCTNSD HQKWFFKERM L // ID RN5A_HUMAN Reviewed; 741 AA. AC Q05823; Q5W0L2; Q6AI46; DT 01-NOV-1995, integrated into UniProtKB/Swiss-Prot. DT 01-FEB-1996, sequence version 2. DT 28-JAN-2026, entry version 218. DE RecName: Full=2-5A-dependent ribonuclease; DE Short=2-5A-dependent RNase; DE EC=3.1.26.-; DE AltName: Full=Ribonuclease 4; DE AltName: Full=Ribonuclease L; DE Short=RNase L; GN Name=RNASEL {ECO:0000303|PubMed:40010341}; Synonyms=RNS4; OS Homo sapiens (Human). OC Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia; OC Eutheria; Euarchontoglires; Primates; Haplorrhini; Catarrhini; Hominidae; OC Homo. OX NCBI_TaxID=9606; RN [1] RP NUCLEOTIDE SEQUENCE [GENOMIC DNA], AND MUTAGENESIS OF LYS-240 AND LYS-274. RC TISSUE=Kidney; RX PubMed=7680958; DOI=10.1016/0092-8674(93)90403-d; RA Zhou A., Hassel B.A., Silverman R.H.; RT "Expression cloning of 2-5A-dependent RNAase: a uniquely regulated mediator RT of interferon action."; RL Cell 72:753-765(1993). RN [2] RP NUCLEOTIDE SEQUENCE [GENOMIC DNA]. RC TISSUE=Placenta; RX PubMed=11063255; DOI=10.1007/s003350010194; RA Zhou A., Nie H., Silverman R.H.; RT "Analysis and origins of the human and mouse RNase L genes: mediators of RT interferon action."; RL Mamm. Genome 11:989-992(2000). RN [3] RP NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM 2). RC TISSUE=Colon carcinoma; RX PubMed=17974005; DOI=10.1186/1471-2164-8-399; RA Bechtel S., Rosenfelder H., Duda A., Schmidt C.P., Ernst U., RA Wellenreuther R., Mehrle A., Schuster C., Bahr A., Bloecker H., Heubner D., RA Hoerlein A., Michel G., Wedler H., Koehrer K., Ottenwaelder B., Poustka A., RA Wiemann S., Schupp I.; RT "The full-ORF clone resource of the German cDNA consortium."; RL BMC Genomics 8:399-399(2007). RN [4] RP NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA]. RX PubMed=16710414; DOI=10.1038/nature04727; RA Gregory S.G., Barlow K.F., McLay K.E., Kaul R., Swarbreck D., Dunham A., RA Scott C.E., Howe K.L., Woodfine K., Spencer C.C.A., Jones M.C., Gillson C., RA Searle S., Zhou Y., Kokocinski F., McDonald L., Evans R., Phillips K., RA Atkinson A., Cooper R., Jones C., Hall R.E., Andrews T.D., Lloyd C., RA Ainscough R., Almeida J.P., Ambrose K.D., Anderson F., Andrew R.W., RA Ashwell R.I.S., Aubin K., Babbage A.K., Bagguley C.L., Bailey J., RA Beasley H., Bethel G., Bird C.P., Bray-Allen S., Brown J.Y., Brown A.J., RA Buckley D., Burton J., Bye J., Carder C., Chapman J.C., Clark S.Y., RA Clarke G., Clee C., Cobley V., Collier R.E., Corby N., Coville G.J., RA Davies J., Deadman R., Dunn M., Earthrowl M., Ellington A.G., Errington H., RA Frankish A., Frankland J., French L., Garner P., Garnett J., Gay L., RA Ghori M.R.J., Gibson R., Gilby L.M., Gillett W., Glithero R.J., RA Grafham D.V., Griffiths C., Griffiths-Jones S., Grocock R., Hammond S., RA Harrison E.S.I., Hart E., Haugen E., Heath P.D., Holmes S., Holt K., RA Howden P.J., Hunt A.R., Hunt S.E., Hunter G., Isherwood J., James R., RA Johnson C., Johnson D., Joy A., Kay M., Kershaw J.K., Kibukawa M., RA Kimberley A.M., King A., Knights A.J., Lad H., Laird G., Lawlor S., RA Leongamornlert D.A., Lloyd D.M., Loveland J., Lovell J., Lush M.J., RA Lyne R., Martin S., Mashreghi-Mohammadi M., Matthews L., Matthews N.S.W., RA McLaren S., Milne S., Mistry S., Moore M.J.F., Nickerson T., O'Dell C.N., RA Oliver K., Palmeiri A., Palmer S.A., Parker A., Patel D., Pearce A.V., RA Peck A.I., Pelan S., Phelps K., Phillimore B.J., Plumb R., Rajan J., RA Raymond C., Rouse G., Saenphimmachak C., Sehra H.K., Sheridan E., RA Shownkeen R., Sims S., Skuce C.D., Smith M., Steward C., Subramanian S., RA Sycamore N., Tracey A., Tromans A., Van Helmond Z., Wall M., Wallis J.M., RA White S., Whitehead S.L., Wilkinson J.E., Willey D.L., Williams H., RA Wilming L., Wray P.W., Wu Z., Coulson A., Vaudin M., Sulston J.E., RA Durbin R.M., Hubbard T., Wooster R., Dunham I., Carter N.P., McVean G., RA Ross M.T., Harrow J., Olson M.V., Beck S., Rogers J., Bentley D.R.; RT "The DNA sequence and biological annotation of human chromosome 1."; RL Nature 441:315-321(2006). RN [5] RP NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA]. RA Mural R.J., Istrail S., Sutton G., Florea L., Halpern A.L., Mobarry C.M., RA Lippert R., Walenz B., Shatkay H., Dew I., Miller J.R., Flanigan M.J., RA Edwards N.J., Bolanos R., Fasulo D., Halldorsson B.V., Hannenhalli S., RA Turner R., Yooseph S., Lu F., Nusskern D.R., Shue B.C., Zheng X.H., RA Zhong F., Delcher A.L., Huson D.H., Kravitz S.A., Mouchard L., Reinert K., RA Remington K.A., Clark A.G., Waterman M.S., Eichler E.E., Adams M.D., RA Hunkapiller M.W., Myers E.W., Venter J.C.; RL Submitted (JUL-2005) to the EMBL/GenBank/DDBJ databases. RN [6] RP NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORMS 1 AND 2). RC TISSUE=Lymph; RX PubMed=15489334; DOI=10.1101/gr.2596504; RG The MGC Project Team; RT "The status, quality, and expansion of the NIH full-length cDNA project: RT the Mammalian Gene Collection (MGC)."; RL Genome Res. 14:2121-2127(2004). RN [7] RP CHARACTERIZATION OF RNASEL ACTIVITY. RX PubMed=7514601; DOI=10.1016/s0021-9258(17)36767-4; RA Dong B., Xu L., Zhou A., Hassel B.A., Lee X., Torrence P.F., RA Silverman R.H.; RT "Intrinsic molecular activities of the interferon-induced 2-5A-dependent RT RNase."; RL J. Biol. Chem. 269:14153-14158(1994). RN [8] RP INTERACTION WITH ABCE1. RX PubMed=7539425; DOI=10.1074/jbc.270.22.13308; RA Bisbal C., Martinand C., Silhol M., Lebleu B., Salehzada T.; RT "Cloning and characterization of a RNase L inhibitor. A new component of RT the interferon-regulated 2-5A pathway."; RL J. Biol. Chem. 270:13308-13317(1995). RN [9] RP FUNCTION, AND SUBCELLULAR LOCATION. RX PubMed=11585831; DOI=10.1074/jbc.m107482200; RA Le Roy F., Bisbal C., Silhol M., Martinand C., Lebleu B., Salehzada T.; RT "The 2-5A/RNase L/RNase L inhibitor (RNI) pathway regulates mitochondrial RT mRNAs stability in interferon alpha-treated H9 cells."; RL J. Biol. Chem. 276:48473-48482(2001). RN [10] RP ERRATUM OF PUBMED:11585831. RA Le Roy F., Bisbal C., Silhol M., Martinand C., Lebleu B., Salehzada T.; RL J. Biol. Chem. 277:13354-13354(2002). RN [11] RP REVIEW. RX PubMed=9856285; DOI=10.1016/s0753-3322(99)80006-7; RA Castelli J., Wood K.A., Youle R.J.; RT "The 2-5A system in viral infection and apoptosis."; RL Biomed. Pharmacother. 52:386-390(1998). RN [12] RP MUTAGENESIS OF LYS-392. RX PubMed=9862963; DOI=10.1093/nar/27.2.439; RA Dong B., Silverman R.H.; RT "Alternative function of a protein kinase homology domain in 2', 5'- RT oligoadenylate dependent RNase L."; RL Nucleic Acids Res. 27:439-445(1999). RN [13] RP MUTAGENESIS OF HIS-583; PRO-584; TRP-632; ASP-661; ARG-667 AND HIS-672. RX PubMed=11333017; DOI=10.1017/s1355838201002230; RA Dong B., Niwa M., Walter P., Silverman R.H.; RT "Basis for regulated RNA cleavage by functional analysis of RNase L and RT Ire1p."; RL RNA 7:361-373(2001). RN [14] RP ACETYLATION [LARGE SCALE ANALYSIS] AT LYS-684, AND IDENTIFICATION BY MASS RP SPECTROMETRY [LARGE SCALE ANALYSIS]. RX PubMed=19608861; DOI=10.1126/science.1175371; RA Choudhary C., Kumar C., Gnad F., Nielsen M.L., Rehman M., Walther T.C., RA Olsen J.V., Mann M.; RT "Lysine acetylation targets protein complexes and co-regulates major RT cellular functions."; RL Science 325:834-840(2009). RN [15] RP FUNCTION. RX PubMed=26263979; DOI=10.3390/ijms160817611; RA Siddiqui M.A., Mukherjee S., Manivannan P., Malathi K.; RT "RNase L cleavage products promote switch from autophagy to apoptosis by RT caspase-mediated cleavage of beclin-1."; RL Int. J. Mol. Sci. 16:17611-17636(2015). RN [16] RP FUNCTION. RX PubMed=40010341; DOI=10.1016/j.immuni.2025.01.016; RA Huai W., Yang K., Xing C., Song K., Lyu H., Williams N.S., Wu J., Yan N.; RT "OAS cross-activates RNase L intercellularly through cell-to-cell transfer RT of 2-5A to spread innate immunity."; RL Immunity 58:797-810.e6(2025). RN [17] RP X-RAY CRYSTALLOGRAPHY (1.8 ANGSTROMS) OF 21-305 IN COMPLEX WITH THE RP ACTIVATOR 2-5A. RX PubMed=15385955; DOI=10.1038/sj.emboj.7600420; RA Tanaka N., Nakanishi M., Kusakabe Y., Goto Y., Kitade Y., Nakamura K.T.; RT "Structural basis for recognition of 2',5'-linked oligoadenylates by human RT ribonuclease L."; RL EMBO J. 23:3929-3938(2004). RN [18] RP VARIANTS SER-59; PHE-406; GLN-462 AND GLU-541. RX PubMed=11941539; DOI=10.1086/340450; RA Roekman A., Ikonen T., Seppaelae E.H., Nupponen N., Autio V., Mononen N., RA Bailey-Wilson J., Trent J., Carpten J., Matikainen M.P., Koivisto P.A., RA Tammela T.L.J., Kallioniemi O.-P., Schleutker J.; RT "Germline alterations of the RNASEL gene, a candidate HPC1 gene at 1q25, in RT patients and families with prostate cancer."; RL Am. J. Hum. Genet. 70:1299-1304(2002). RN [19] RP VARIANTS SER-59; GLN-462 AND GLU-541. RX PubMed=11799394; DOI=10.1038/ng823; RA Carpten J., Nupponen N., Isaacs S., Sood R., Robbins C., Xu J., Faruque M., RA Moses T., Ewing C., Gillanders E., Hu P., Bujnovszky P., Makalowska I., RA Baffoe-Bonnie A., Faith D., Smith J., Stephan D., Wiley K., Brownstein M., RA Gildea D., Kelly B., Jenkins R., Hostetter G., Matikainen M., RA Schleutker J., Klinger K., Connors T., Xiang Y., Wang Z., De Marzo A., RA Papadopoulos N., Kallioniemi O.-P., Burk R., Meyers D., Groenberg H., RA Meltzer P., Silverman R., Bailey-Wilson J., Walsh P., Isaacs W., Trent J.; RT "Germline mutations in the ribonuclease L gene in families showing linkage RT with HPC1."; RL Nat. Genet. 30:181-184(2002). RN [20] RP CHARACTERIZATION OF VARIANTS GLN-462 AND GLU-541. RX PubMed=12415269; DOI=10.1038/ng1021; RA Casey G., Neville P.J., Plummer S.J., Xiang Y., Krumroy L.M., Klein E.A., RA Catalona W.J., Nupponen N., Carpten J.D., Trent J.M., Silverman R.H., RA Witte J.S.; RT "RNASEL Arg462Gln variant is implicated in up to 13% of prostate cancer RT cases."; RL Nat. Genet. 32:581-583(2002). RN [21] RP VARIANTS [LARGE SCALE ANALYSIS] LEU-97; THR-289; GLN-462; GLU-541 AND RP HIS-592. RX PubMed=17344846; DOI=10.1038/nature05610; RA Greenman C., Stephens P., Smith R., Dalgliesh G.L., Hunter C., Bignell G., RA Davies H., Teague J., Butler A., Stevens C., Edkins S., O'Meara S., RA Vastrik I., Schmidt E.E., Avis T., Barthorpe S., Bhamra G., Buck G., RA Choudhury B., Clements J., Cole J., Dicks E., Forbes S., Gray K., RA Halliday K., Harrison R., Hills K., Hinton J., Jenkinson A., Jones D., RA Menzies A., Mironenko T., Perry J., Raine K., Richardson D., Shepherd R., RA Small A., Tofts C., Varian J., Webb T., West S., Widaa S., Yates A., RA Cahill D.P., Louis D.N., Goldstraw P., Nicholson A.G., Brasseur F., RA Looijenga L., Weber B.L., Chiew Y.-E., DeFazio A., Greaves M.F., RA Green A.R., Campbell P., Birney E., Easton D.F., Chenevix-Trench G., RA Tan M.-H., Khoo S.K., Teh B.T., Yuen S.T., Leung S.Y., Wooster R., RA Futreal P.A., Stratton M.R.; RT "Patterns of somatic mutation in human cancer genomes."; RL Nature 446:153-158(2007). CC -!- FUNCTION: Endoribonuclease that functions in the interferon (IFN) CC antiviral response (PubMed:11585831, PubMed:26263979). In INF treated CC and virus infected cells, RNASEL probably mediates its antiviral CC effects through a combination of direct cleavage of single-stranded CC viral RNAs, inhibition of protein synthesis through the degradation of CC rRNA, induction of apoptosis, and induction of other antiviral genes CC (PubMed:11585831, PubMed:26263979). RNASEL mediated apoptosis is the CC result of a JNK-dependent stress-response pathway leading to cytochrome CC c release from mitochondria and caspase-dependent apoptosis CC (PubMed:11585831, PubMed:26263979). Therefore, activation of RNASEL CC could lead to elimination of virus infected cells under some CC circumstances (PubMed:11585831, PubMed:26263979). In the crosstalk CC between autophagy and apoptosis proposed to induce autophagy as an CC early stress response to small double-stranded RNA and at later stages CC of prolonged stress to activate caspase-dependent proteolytic cleavage CC of BECN1 to terminate autophagy and promote apoptosis CC (PubMed:26263979). Might play a central role in the regulation of mRNA CC turnover (PubMed:11585831). Cleaves 3' of UpNp dimers, with preference CC for UU and UA sequences, to sets of discrete products ranging from CC between 4 and 22 nucleotides in length. Involved in intercellular CC immune signaling (PubMed:40010341). Cross-activated by 2',5'- CC oligoadenylates (2-5A) previously generated in RNA virus-infected CC cells, triggers type I interferon signaling in uninfected neighboring CC cells to limit local spread of infection (PubMed:40010341). CC {ECO:0000269|PubMed:11585831, ECO:0000269|PubMed:26263979, CC ECO:0000269|PubMed:40010341}. CC -!- COFACTOR: CC Name=Mn(2+); Xref=ChEBI:CHEBI:29035; CC Name=Mg(2+); Xref=ChEBI:CHEBI:18420; CC Note=Manganese or magnesium. Required for optimal RNA cleavage rates.; CC -!- ACTIVITY REGULATION: After binding to 2-5A (5'-phosphorylated 2',5'- CC linked oligoadenylates) the homodimerization and subsequent activation CC occurs. Inhibited by RNASEL inhibitor ABCE1/RLI, a cytoplasmic member CC of the ATP-binding cassette (ABC) transporter family. CC -!- SUBUNIT: Monomer (inactive form) or homodimer. Interacts with ABCE1; CC this interaction inhibits the RNASEL. {ECO:0000269|PubMed:15385955, CC ECO:0000269|PubMed:7539425}. CC -!- INTERACTION: CC Q05823; P46940: IQGAP1; NbExp=2; IntAct=EBI-8390477, EBI-297509; CC Q05823-1; Q05823-1: RNASEL; NbExp=2; IntAct=EBI-16094551, EBI-16094551; CC -!- SUBCELLULAR LOCATION: Cytoplasm {ECO:0000269|PubMed:11585831}. CC Mitochondrion {ECO:0000269|PubMed:11585831}. CC -!- ALTERNATIVE PRODUCTS: CC Event=Alternative splicing; Named isoforms=2; CC Name=1; CC IsoId=Q05823-1; Sequence=Displayed; CC Name=2; CC IsoId=Q05823-2; Sequence=VSP_056272, VSP_056273; CC -!- TISSUE SPECIFICITY: Highly expressed in spleen and thymus followed by CC prostate, testis, uterus, small intestine, colon and peripheral blood CC leukocytes. CC -!- INDUCTION: By interferons. Virus replication in higher vertebrates is CC restrained by IFNs that cause cells to transcribe genes encoding CC antiviral proteins, such as 2'-5' oligoadenylate synthetases (OASs). CC oligoadenylate synthetase is stimulated by dsRNA to produce 5'- CC phosphorylated, 2'-5'-linked oligoadenylates (2-5A), whose function is CC to activate RNASEL. CC -!- DOMAIN: The nine ankyrin repeats also called 2-5A sensor constitute the CC N-terminus 2-5A binding domain. CC -!- DOMAIN: The protein kinase domain is predicted to be catalytically CC inactive. It allows the homodimerization. CC -!- DOMAIN: The ribonuclease domain is located in the C-terminus. A single CC active nuclease domain in a dimer is sufficient for ribonuclease CC activity (By similarity). {ECO:0000250}. CC -!- DISEASE: Prostate cancer, hereditary, 1 (HPC1) [MIM:601518]: A CC condition associated with familial predisposition to cancer of the CC prostate. Most prostate cancers are adenocarcinomas that develop in the CC acini of the prostatic ducts. Other rare histopathologic types of CC prostate cancer that occur in approximately 5% of patients include CC small cell carcinoma, mucinous carcinoma, prostatic ductal carcinoma, CC transitional cell carcinoma, squamous cell carcinoma, basal cell CC carcinoma, adenoid cystic carcinoma (basaloid), signet-ring cell CC carcinoma and neuroendocrine carcinoma. {ECO:0000305|PubMed:11799394, CC ECO:0000305|PubMed:11941539, ECO:0000305|PubMed:12415269, CC ECO:0000305|PubMed:17344846}. Note=Disease susceptibility is associated CC with variants affecting the gene represented in this entry. CC -!- SIMILARITY: Belongs to the protein kinase superfamily. {ECO:0000305}. CC --------------------------------------------------------------------------- CC Copyrighted by the UniProt Consortium, see https://www.uniprot.org/terms CC Distributed under the Creative Commons Attribution (CC BY 4.0) License CC --------------------------------------------------------------------------- DR EMBL; L10381; AAA18032.1; -; Genomic_DNA. DR EMBL; CR627369; CAH10468.1; -; mRNA. DR EMBL; AL138776; -; NOT_ANNOTATED_CDS; Genomic_DNA. DR EMBL; CH471067; EAW91128.1; -; Genomic_DNA. DR EMBL; BC090934; AAH90934.1; -; mRNA. DR EMBL; BC114433; AAI14434.1; -; mRNA. DR CCDS; CCDS1347.1; -. [Q05823-1] DR PIR; A45771; A45771. DR RefSeq; NP_066956.1; NM_021133.4. [Q05823-1] DR RefSeq; XP_047283062.1; XM_047427106.1. [Q05823-2] DR RefSeq; XP_054194044.1; XM_054338069.1. [Q05823-2] DR PDB; 1WDY; X-ray; 1.80 A; A=21-305. DR PDB; 4G8K; X-ray; 2.40 A; A/B=1-337. DR PDB; 4G8L; X-ray; 2.80 A; A/B/C/D=1-337. DR PDB; 4OAU; X-ray; 2.60 A; C=21-719. DR PDB; 4OAV; X-ray; 2.10 A; B/D=21-719. DR PDBsum; 1WDY; -. DR PDBsum; 4G8K; -. DR PDBsum; 4G8L; -. DR PDBsum; 4OAU; -. DR PDBsum; 4OAV; -. DR AlphaFoldDB; Q05823; -. DR SMR; Q05823; -. DR BioGRID; 111969; 43. DR CORUM; Q05823; -. DR DIP; DIP-61367N; -. DR FunCoup; Q05823; 673. DR IntAct; Q05823; 42. DR MINT; Q05823; -. DR STRING; 9606.ENSP00000356530; -. DR BindingDB; Q05823; -. DR ChEMBL; CHEMBL3575; -. DR GlyGen; Q05823; 2 sites, 1 O-linked glycan (1 site). DR iPTMnet; Q05823; -. DR PhosphoSitePlus; Q05823; -. DR BioMuta; RNASEL; -. DR DMDM; 1350802; -. DR jPOST; Q05823; -. DR MassIVE; Q05823; -. DR PaxDb; 9606-ENSP00000356530; -. DR PeptideAtlas; Q05823; -. DR ProteomicsDB; 58353; -. [Q05823-1] DR ProteomicsDB; 66189; -. DR Pumba; Q05823; -. DR Antibodypedia; 1127; 232 antibodies from 30 providers. DR DNASU; 6041; -. DR Ensembl; ENST00000367559.7; ENSP00000356530.3; ENSG00000135828.12. [Q05823-1] DR Ensembl; ENST00000539397.1; ENSP00000440844.1; ENSG00000135828.12. [Q05823-2] DR GeneID; 6041; -. DR KEGG; hsa:6041; -. DR MANE-Select; ENST00000367559.7; ENSP00000356530.3; NM_021133.4; NP_066956.1. DR UCSC; uc001gpk.4; human. [Q05823-1] DR AGR; HGNC:10050; -. DR ClinPGx; PA34418; -. DR CTD; 6041; -. DR DisGeNET; 6041; -. DR GeneCards; RNASEL; -. DR HGNC; HGNC:10050; RNASEL. DR HPA; ENSG00000135828; Low tissue specificity. DR MalaCards; RNASEL; -. DR MIM; 176807; phenotype. DR MIM; 180435; gene. DR MIM; 601518; phenotype. DR OpenTargets; ENSG00000135828; -. DR Orphanet; 1331; Familial prostate cancer. DR VEuPathDB; HostDB:ENSG00000135828; -. DR eggNOG; KOG1027; Eukaryota. DR eggNOG; KOG4177; Eukaryota. DR GeneTree; ENSGT00940000161114; -. DR HOGENOM; CLU_022542_0_0_1; -. DR InParanoid; Q05823; -. DR OMA; YGSESHK; -. DR OrthoDB; 194358at2759; -. DR PAN-GO; Q05823; 5 GO annotations based on evolutionary models. DR PhylomeDB; Q05823; -. DR BioCyc; MetaCyc:HS06069-MONOMER; -. DR BRENDA; 4.6.1.19; 2681. DR PathwayCommons; Q05823; -. DR Reactome; R-HSA-8983711; OAS antiviral response. DR Reactome; R-HSA-909733; Interferon alpha/beta signaling. DR SignaLink; Q05823; -. DR SIGNOR; Q05823; -. DR Agora; ENSG00000135828; -. DR BioGRID-ORCS; 6041; 9 hits in 1192 CRISPR screens. DR CD-CODE; DEE660B4; Stress granule. DR ChiTaRS; RNASEL; human. DR EvolutionaryTrace; Q05823; -. DR GeneWiki; Ribonuclease_L; -. DR GeneWiki; RNASEL; -. DR GenomeRNAi; 6041; -. DR Pharos; Q05823; Tchem. DR PRO; PR:Q05823; -. DR Proteomes; UP000005640; Chromosome 1. DR RNAct; Q05823; protein. DR Bgee; ENSG00000135828; Expressed in amniotic fluid and 174 other cell types or tissues. DR GO; GO:0005829; C:cytosol; TAS:Reactome. DR GO; GO:0005759; C:mitochondrial matrix; TAS:Reactome. DR GO; GO:0016363; C:nuclear matrix; IEA:Ensembl. DR GO; GO:0005524; F:ATP binding; IEA:UniProtKB-KW. DR GO; GO:0016787; F:hydrolase activity; IEA:UniProtKB-KW. DR GO; GO:0042802; F:identical protein binding; IPI:IntAct. DR GO; GO:0004672; F:protein kinase activity; IEA:InterPro. DR GO; GO:0043021; F:ribonucleoprotein complex binding; IEA:Ensembl. DR GO; GO:0003723; F:RNA binding; IDA:UniProtKB. DR GO; GO:0004521; F:RNA endonuclease activity; NAS:UniProtKB. DR GO; GO:0004540; F:RNA nuclease activity; IDA:ARUK-UCL. DR GO; GO:0019843; F:rRNA binding; IEA:Ensembl. DR GO; GO:0008270; F:zinc ion binding; IEA:UniProtKB-KW. DR GO; GO:0051607; P:defense response to virus; IDA:UniProtKB. DR GO; GO:0045444; P:fat cell differentiation; IEA:Ensembl. DR GO; GO:0006397; P:mRNA processing; IEA:InterPro. DR GO; GO:0045071; P:negative regulation of viral genome replication; IDA:UniProtKB. DR GO; GO:0046326; P:positive regulation of D-glucose import; IEA:Ensembl. DR GO; GO:0045944; P:positive regulation of transcription by RNA polymerase II; IDA:UniProtKB. DR GO; GO:0006468; P:protein phosphorylation; NAS:UniProtKB. DR GO; GO:0043488; P:regulation of mRNA stability; IEA:Ensembl. DR GO; GO:0006396; P:RNA processing; IBA:GO_Central. DR GO; GO:0006364; P:rRNA processing; IEA:Ensembl. DR CDD; cd10423; RNase_RNase-L; 1. DR FunFam; 1.25.40.20:FF:000231; 2-5A-dependent ribonuclease; 1. DR FunFam; 1.10.510.10:FF:000618; Ribonuclease L; 1. DR FunFam; 1.20.1440.180:FF:000003; Ribonuclease L; 1. DR Gene3D; 1.25.40.20; Ankyrin repeat-containing domain; 1. DR Gene3D; 1.20.1440.180; KEN domain; 1. DR Gene3D; 1.10.510.10; Transferase(Phosphotransferase) domain 1; 1. DR InterPro; IPR002110; Ankyrin_rpt. DR InterPro; IPR036770; Ankyrin_rpt-contain_sf. DR InterPro; IPR010513; KEN_dom. DR InterPro; IPR038357; KEN_sf. DR InterPro; IPR011009; Kinase-like_dom_sf. DR InterPro; IPR000719; Prot_kinase_dom. DR InterPro; IPR042745; RNase-L_RNase. DR PANTHER; PTHR24141; 2-5A-DEPENDENT RIBONUCLEASE; 1. DR PANTHER; PTHR24141:SF1; 2-5A-DEPENDENT RIBONUCLEASE; 1. DR Pfam; PF12796; Ank_2; 3. DR Pfam; PF13857; Ank_5; 1. DR Pfam; PF00069; Pkinase; 1. DR Pfam; PF06479; Ribonuc_2-5A; 1. DR PRINTS; PR01415; ANKYRIN. DR SMART; SM00248; ANK; 8. DR SMART; SM00580; PUG; 1. DR SMART; SM00220; S_TKc; 1. DR SUPFAM; SSF48403; Ankyrin repeat; 1. DR SUPFAM; SSF56112; Protein kinase-like (PK-like); 1. DR PROSITE; PS50297; ANK_REP_REGION; 1. DR PROSITE; PS50088; ANK_REPEAT; 6. DR PROSITE; PS51392; KEN; 1. DR PROSITE; PS50011; PROTEIN_KINASE_DOM; 1. PE 1: Evidence at protein level; KW 3D-structure; Acetylation; Alternative splicing; ANK repeat; KW Antiviral defense; ATP-binding; Cytoplasm; Endonuclease; Hydrolase; KW Immunity; Innate immunity; Metal-binding; Mitochondrion; Nuclease; KW Nucleotide-binding; Proteomics identification; Reference proteome; Repeat; KW RNA-binding; Zinc; Zinc-finger. FT CHAIN 1..741 FT /note="2-5A-dependent ribonuclease" FT /id="PRO_0000067051" FT REPEAT 24..53 FT /note="ANK 1" FT REPEAT 58..87 FT /note="ANK 2" FT REPEAT 91..120 FT /note="ANK 3" FT REPEAT 124..153 FT /note="ANK 4" FT REPEAT 167..197 FT /note="ANK 5" FT REPEAT 201..234 FT /note="ANK 6" FT REPEAT 238..268 FT /note="ANK 7" FT REPEAT 272..301 FT /note="ANK 8" FT REPEAT 303..329 FT /note="ANK 9" FT DOMAIN 365..586 FT /note="Protein kinase" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00159" FT DOMAIN 589..723 FT /note="KEN" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00725" FT ZN_FING 395..444 FT /note="C6-type; atypical" FT REGION 1..21 FT /note="Disordered" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT REGION 229..242 FT /note="2-5A binding (P-loop) 1" FT REGION 253..275 FT /note="2-5A binding (P-loop) 2" FT REGION 715..741 FT /note="Disordered" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT COMPBIAS 9..18 FT /note="Polar residues" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT MOD_RES 684 FT /note="N6-acetyllysine" FT /evidence="ECO:0007744|PubMed:19608861" FT VAR_SEQ 636..652 FT /note="INECVMKKMNKFYEKRG -> MSKLRHRQIIFPTTQNQ (in isoform FT 2)" FT /evidence="ECO:0000303|PubMed:15489334, FT ECO:0000303|PubMed:17974005" FT /id="VSP_056272" FT VAR_SEQ 653..741 FT /note="Missing (in isoform 2)" FT /evidence="ECO:0000303|PubMed:15489334, FT ECO:0000303|PubMed:17974005" FT /id="VSP_056273" FT VARIANT 59 FT /note="G -> S (in dbSNP:rs151296858)" FT /evidence="ECO:0000269|PubMed:11799394, FT ECO:0000269|PubMed:11941539" FT /id="VAR_013509" FT VARIANT 97 FT /note="I -> L (in dbSNP:rs56250729)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_042358" FT VARIANT 289 FT /note="A -> T (in dbSNP:rs35553278)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_042359" FT VARIANT 406 FT /note="S -> F (in dbSNP:rs145787003)" FT /evidence="ECO:0000269|PubMed:11941539" FT /id="VAR_013510" FT VARIANT 462 FT /note="R -> Q (risk factor for prostate cancer; reduced FT enzymatic activity; dbSNP:rs486907)" FT /evidence="ECO:0000269|PubMed:11799394, FT ECO:0000269|PubMed:11941539, ECO:0000269|PubMed:12415269, FT ECO:0000269|PubMed:17344846" FT /id="VAR_012056" FT VARIANT 541 FT /note="D -> E (no change in enzymatic activity; FT dbSNP:rs627928)" FT /evidence="ECO:0000269|PubMed:11799394, FT ECO:0000269|PubMed:11941539, ECO:0000269|PubMed:12415269, FT ECO:0000269|PubMed:17344846" FT /id="VAR_012057" FT VARIANT 592 FT /note="R -> H (in dbSNP:rs35896902)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_042360" FT MUTAGEN 240 FT /note="K->N: Reduced 2-5A binding activity; almost complete FT loss of 2-5A binding activity; when associated with N-274." FT /evidence="ECO:0000269|PubMed:7680958" FT MUTAGEN 274 FT /note="K->N: Reduced 2-5A binding activity; almost complete FT loss of 2-5A binding activity; when associated with N-240." FT /evidence="ECO:0000269|PubMed:7680958" FT MUTAGEN 392 FT /note="K->R: Complete loss of enzymatic activity and enzyme FT dimerization. No change in binding to 2-5A and RNA." FT /evidence="ECO:0000269|PubMed:9862963" FT MUTAGEN 583 FT /note="H->A: No change in enzymatic activity." FT /evidence="ECO:0000269|PubMed:11333017" FT MUTAGEN 584 FT /note="P->A: No change in enzymatic activity." FT /evidence="ECO:0000269|PubMed:11333017" FT MUTAGEN 632 FT /note="W->A: No change in enzymatic activity." FT /evidence="ECO:0000269|PubMed:11333017" FT MUTAGEN 661 FT /note="D->A: Complete loss of enzymatic activity." FT /evidence="ECO:0000269|PubMed:11333017" FT MUTAGEN 667 FT /note="R->A: Complete loss of enzymatic activity. No change FT in 2-5A binding and enzyme dimerization." FT /evidence="ECO:0000269|PubMed:11333017" FT MUTAGEN 672 FT /note="H->A: Complete loss of enzymatic activity. No change FT in 2-5A binding activity and enzyme dimerization." FT /evidence="ECO:0000269|PubMed:11333017" FT HELIX 22..34 FT /evidence="ECO:0007829|PDB:1WDY" FT HELIX 38..46 FT /evidence="ECO:0007829|PDB:1WDY" FT TURN 56..58 FT /evidence="ECO:0007829|PDB:1WDY" FT HELIX 62..68 FT /evidence="ECO:0007829|PDB:1WDY" FT HELIX 72..80 FT /evidence="ECO:0007829|PDB:1WDY" FT HELIX 95..102 FT /evidence="ECO:0007829|PDB:1WDY" FT HELIX 105..113 FT /evidence="ECO:0007829|PDB:1WDY" FT HELIX 128..134 FT /evidence="ECO:0007829|PDB:1WDY" FT HELIX 138..146 FT /evidence="ECO:0007829|PDB:1WDY" FT HELIX 159..163 FT /evidence="ECO:0007829|PDB:1WDY" FT HELIX 171..178 FT /evidence="ECO:0007829|PDB:1WDY" FT HELIX 181..189 FT /evidence="ECO:0007829|PDB:1WDY" FT HELIX 205..211 FT /evidence="ECO:0007829|PDB:1WDY" FT TURN 215..217 FT /evidence="ECO:0007829|PDB:1WDY" FT HELIX 218..227 FT /evidence="ECO:0007829|PDB:1WDY" FT HELIX 237..239 FT /evidence="ECO:0007829|PDB:4G8K" FT HELIX 242..248 FT /evidence="ECO:0007829|PDB:1WDY" FT HELIX 252..260 FT /evidence="ECO:0007829|PDB:1WDY" FT STRAND 261..263 FT /evidence="ECO:0007829|PDB:1WDY" FT HELIX 276..282 FT /evidence="ECO:0007829|PDB:1WDY" FT HELIX 286..295 FT /evidence="ECO:0007829|PDB:1WDY" FT STRAND 301..303 FT /evidence="ECO:0007829|PDB:4OAV" FT HELIX 304..310 FT /evidence="ECO:0007829|PDB:4OAV" FT HELIX 314..322 FT /evidence="ECO:0007829|PDB:4OAV" FT STRAND 341..344 FT /evidence="ECO:0007829|PDB:4OAV" FT HELIX 345..352 FT /evidence="ECO:0007829|PDB:4OAV" FT STRAND 361..363 FT /evidence="ECO:0007829|PDB:4OAV" FT HELIX 367..369 FT /evidence="ECO:0007829|PDB:4OAV" FT STRAND 370..374 FT /evidence="ECO:0007829|PDB:4OAV" FT STRAND 377..395 FT /evidence="ECO:0007829|PDB:4OAV" FT HELIX 399..409 FT /evidence="ECO:0007829|PDB:4OAV" FT STRAND 420..425 FT /evidence="ECO:0007829|PDB:4OAV" FT STRAND 427..435 FT /evidence="ECO:0007829|PDB:4OAV" FT STRAND 438..440 FT /evidence="ECO:0007829|PDB:4OAV" FT HELIX 441..445 FT /evidence="ECO:0007829|PDB:4OAV" FT HELIX 459..477 FT /evidence="ECO:0007829|PDB:4OAV" FT HELIX 488..490 FT /evidence="ECO:0007829|PDB:4OAV" FT STRAND 491..493 FT /evidence="ECO:0007829|PDB:4OAV" FT STRAND 495..497 FT /evidence="ECO:0007829|PDB:4OAV" FT STRAND 499..501 FT /evidence="ECO:0007829|PDB:4OAV" FT HELIX 514..532 FT /evidence="ECO:0007829|PDB:4OAV" FT TURN 533..535 FT /evidence="ECO:0007829|PDB:4OAV" FT HELIX 539..544 FT /evidence="ECO:0007829|PDB:4OAV" FT HELIX 547..551 FT /evidence="ECO:0007829|PDB:4OAV" FT HELIX 557..567 FT /evidence="ECO:0007829|PDB:4OAV" FT HELIX 576..580 FT /evidence="ECO:0007829|PDB:4OAV" FT HELIX 584..586 FT /evidence="ECO:0007829|PDB:4OAV" FT HELIX 589..600 FT /evidence="ECO:0007829|PDB:4OAV" FT HELIX 603..606 FT /evidence="ECO:0007829|PDB:4OAV" FT HELIX 613..618 FT /evidence="ECO:0007829|PDB:4OAV" FT TURN 628..631 FT /evidence="ECO:0007829|PDB:4OAV" FT HELIX 632..634 FT /evidence="ECO:0007829|PDB:4OAV" FT HELIX 638..645 FT /evidence="ECO:0007829|PDB:4OAV" FT HELIX 646..648 FT /evidence="ECO:0007829|PDB:4OAV" FT TURN 649..652 FT /evidence="ECO:0007829|PDB:4OAV" FT HELIX 659..672 FT /evidence="ECO:0007829|PDB:4OAV" FT HELIX 681..685 FT /evidence="ECO:0007829|PDB:4OAV" FT HELIX 688..695 FT /evidence="ECO:0007829|PDB:4OAV" FT HELIX 699..707 FT /evidence="ECO:0007829|PDB:4OAV" FT HELIX 711..715 FT /evidence="ECO:0007829|PDB:4OAV" SQ SEQUENCE 741 AA; 83533 MW; 91385EA307E3CE1D CRC64; MESRDHNNPQ EGPTSSSGRR AAVEDNHLLI KAVQNEDVDL VQQLLEGGAN VNFQEEEGGW TPLHNAVQMS REDIVELLLR HGADPVLRKK NGATPFILAA IAGSVKLLKL FLSKGADVNE CDFYGFTAFM EAAVYGKVKA LKFLYKRGAN VNLRRKTKED QERLRKGGAT ALMDAAEKGH VEVLKILLDE MGADVNACDN MGRNALIHAL LSSDDSDVEA ITHLLLDHGA DVNVRGERGK TPLILAVEKK HLGLVQRLLE QEHIEINDTD SDGKTALLLA VELKLKKIAE LLCKRGASTD CGDLVMTARR NYDHSLVKVL LSHGAKEDFH PPAEDWKPQS SHWGAALKDL HRIYRPMIGK LKFFIDEKYK IADTSEGGIY LGFYEKQEVA VKTFCEGSPR AQREVSCLQS SRENSHLVTF YGSESHRGHL FVCVTLCEQT LEACLDVHRG EDVENEEDEF ARNVLSSIFK AVQELHLSCG YTHQDLQPQN ILIDSKKAAH LADFDKSIKW AGDPQEVKRD LEDLGRLVLY VVKKGSISFE DLKAQSNEEV VQLSPDEETK DLIHRLFHPG EHVRDCLSDL LGHPFFWTWE SRYRTLRNVG NESDIKTRKS ESEILRLLQP GPSEHSKSFD KWTTKINECV MKKMNKFYEK RGNFYQNTVG DLLKFIRNLG EHIDEEKHKK MKLKIGDPSL YFQKTFPDLV IYVYTKLQNT EYRKHFPQTH SPNKPQCDGA GGASGLASPG C // ID SLN11_HUMAN Reviewed; 901 AA. AC Q7Z7L1; E1P643; Q8N3S8; Q8N762; Q8TEE0; DT 03-APR-2007, integrated into UniProtKB/Swiss-Prot. DT 30-NOV-2010, sequence version 2. DT 28-JAN-2026, entry version 167. DE RecName: Full=Schlafen family member 11 {ECO:0000305}; DE EC=3.1.-.- {ECO:0000269|PubMed:29395061, ECO:0000269|PubMed:36115853}; GN Name=SLFN11 {ECO:0000312|HGNC:HGNC:26633}; OS Homo sapiens (Human). OC Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia; OC Eutheria; Euarchontoglires; Primates; Haplorrhini; Catarrhini; Hominidae; OC Homo. OX NCBI_TaxID=9606; RN [1] RP NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA], AND VARIANTS PHE-121 AND ASP-301. RC TISSUE=Spleen; RX PubMed=14702039; DOI=10.1038/ng1285; RA Ota T., Suzuki Y., Nishikawa T., Otsuki T., Sugiyama T., Irie R., RA Wakamatsu A., Hayashi K., Sato H., Nagai K., Kimura K., Makita H., RA Sekine M., Obayashi M., Nishi T., Shibahara T., Tanaka T., Ishii S., RA Yamamoto J., Saito K., Kawai Y., Isono Y., Nakamura Y., Nagahari K., RA Murakami K., Yasuda T., Iwayanagi T., Wagatsuma M., Shiratori A., Sudo H., RA Hosoiri T., Kaku Y., Kodaira H., Kondo H., Sugawara M., Takahashi M., RA Kanda K., Yokoi T., Furuya T., Kikkawa E., Omura Y., Abe K., Kamihara K., RA Katsuta N., Sato K., Tanikawa M., Yamazaki M., Ninomiya K., Ishibashi T., RA Yamashita H., Murakawa K., Fujimori K., Tanai H., Kimata M., Watanabe M., RA Hiraoka S., Chiba Y., Ishida S., Ono Y., Takiguchi S., Watanabe S., RA Yosida M., Hotuta T., Kusano J., Kanehori K., Takahashi-Fujii A., Hara H., RA Tanase T.-O., Nomura Y., Togiya S., Komai F., Hara R., Takeuchi K., RA Arita M., Imose N., Musashino K., Yuuki H., Oshima A., Sasaki N., RA Aotsuka S., Yoshikawa Y., Matsunawa H., Ichihara T., Shiohata N., Sano S., RA Moriya S., Momiyama H., Satoh N., Takami S., Terashima Y., Suzuki O., RA Nakagawa S., Senoh A., Mizoguchi H., Goto Y., Shimizu F., Wakebe H., RA Hishigaki H., Watanabe T., Sugiyama A., Takemoto M., Kawakami B., RA Yamazaki M., Watanabe K., Kumagai A., Itakura S., Fukuzumi Y., Fujimori Y., RA Komiyama M., Tashiro H., Tanigami A., Fujiwara T., Ono T., Yamada K., RA Fujii Y., Ozaki K., Hirao M., Ohmori Y., Kawabata A., Hikiji T., RA Kobatake N., Inagaki H., Ikema Y., Okamoto S., Okitani R., Kawakami T., RA Noguchi S., Itoh T., Shigeta K., Senba T., Matsumura K., Nakajima Y., RA Mizuno T., Morinaga M., Sasaki M., Togashi T., Oyama M., Hata H., RA Watanabe M., Komatsu T., Mizushima-Sugano J., Satoh T., Shirai Y., RA Takahashi Y., Nakagawa K., Okumura K., Nagase T., Nomura N., Kikuchi H., RA Masuho Y., Yamashita R., Nakai K., Yada T., Nakamura Y., Ohara O., RA Isogai T., Sugano S.; RT "Complete sequencing and characterization of 21,243 full-length human RT cDNAs."; RL Nat. Genet. 36:40-45(2004). RN [2] RP NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA], AND VARIANT ASP-301. RC TISSUE=Skeletal muscle; RX PubMed=17974005; DOI=10.1186/1471-2164-8-399; RA Bechtel S., Rosenfelder H., Duda A., Schmidt C.P., Ernst U., RA Wellenreuther R., Mehrle A., Schuster C., Bahr A., Bloecker H., Heubner D., RA Hoerlein A., Michel G., Wedler H., Koehrer K., Ottenwaelder B., Poustka A., RA Wiemann S., Schupp I.; RT "The full-ORF clone resource of the German cDNA consortium."; RL BMC Genomics 8:399-399(2007). RN [3] RP NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA]. RX PubMed=16625196; DOI=10.1038/nature04689; RA Zody M.C., Garber M., Adams D.J., Sharpe T., Harrow J., Lupski J.R., RA Nicholson C., Searle S.M., Wilming L., Young S.K., Abouelleil A., RA Allen N.R., Bi W., Bloom T., Borowsky M.L., Bugalter B.E., Butler J., RA Chang J.L., Chen C.-K., Cook A., Corum B., Cuomo C.A., de Jong P.J., RA DeCaprio D., Dewar K., FitzGerald M., Gilbert J., Gibson R., Gnerre S., RA Goldstein S., Grafham D.V., Grocock R., Hafez N., Hagopian D.S., Hart E., RA Norman C.H., Humphray S., Jaffe D.B., Jones M., Kamal M., Khodiyar V.K., RA LaButti K., Laird G., Lehoczky J., Liu X., Lokyitsang T., Loveland J., RA Lui A., Macdonald P., Major J.E., Matthews L., Mauceli E., McCarroll S.A., RA Mihalev A.H., Mudge J., Nguyen C., Nicol R., O'Leary S.B., Osoegawa K., RA Schwartz D.C., Shaw-Smith C., Stankiewicz P., Steward C., Swarbreck D., RA Venkataraman V., Whittaker C.A., Yang X., Zimmer A.R., Bradley A., RA Hubbard T., Birren B.W., Rogers J., Lander E.S., Nusbaum C.; RT "DNA sequence of human chromosome 17 and analysis of rearrangement in the RT human lineage."; RL Nature 440:1045-1049(2006). RN [4] RP NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA], AND VARIANT ASP-301. RA Mural R.J., Istrail S., Sutton G.G., Florea L., Halpern A.L., Mobarry C.M., RA Lippert R., Walenz B., Shatkay H., Dew I., Miller J.R., Flanigan M.J., RA Edwards N.J., Bolanos R., Fasulo D., Halldorsson B.V., Hannenhalli S., RA Turner R., Yooseph S., Lu F., Nusskern D.R., Shue B.C., Zheng X.H., RA Zhong F., Delcher A.L., Huson D.H., Kravitz S.A., Mouchard L., Reinert K., RA Remington K.A., Clark A.G., Waterman M.S., Eichler E.E., Adams M.D., RA Hunkapiller M.W., Myers E.W., Venter J.C.; RL Submitted (SEP-2005) to the EMBL/GenBank/DDBJ databases. RN [5] RP NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA], AND VARIANT ASP-301. RC TISSUE=Skin; RX PubMed=15489334; DOI=10.1101/gr.2596504; RG The MGC Project Team; RT "The status, quality, and expansion of the NIH full-length cDNA project: RT the Mammalian Gene Collection (MGC)."; RL Genome Res. 14:2121-2127(2004). RN [6] RP INDUCTION. RX PubMed=20956525; DOI=10.1074/jbc.m110.151076; RA Katsoulidis E., Mavrommatis E., Woodard J., Shields M.A., Sassano A., RA Carayol N., Sawicki K.T., Munshi H.G., Platanias L.C.; RT "Role of interferon {alpha} (IFN{alpha})-inducible Schlafen-5 in regulation RT of anchorage-independent growth and invasion of malignant melanoma cells."; RL J. Biol. Chem. 285:40333-40341(2010). RN [7] RP IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS]. RX PubMed=21269460; DOI=10.1186/1752-0509-5-17; RA Burkard T.R., Planyavsky M., Kaupe I., Breitwieser F.P., Buerckstuemmer T., RA Bennett K.L., Superti-Furga G., Colinge J.; RT "Initial characterization of the human central proteome."; RL BMC Syst. Biol. 5:17-17(2011). RN [8] RP FUNCTION, TRNA-BINDING, AND INDUCTION. RX PubMed=23000900; DOI=10.1038/nature11433; RA Li M., Kao E., Gao X., Sandig H., Limmer K., Pavon-Eternod M., Jones T.E., RA Landry S., Pan T., Weitzman M.D., David M.; RT "Codon-usage-based inhibition of HIV protein synthesis by human schlafen RT 11."; RL Nature 491:125-128(2012). RN [9] RP FUNCTION, SUBCELLULAR LOCATION, AND TISSUE SPECIFICITY. RX PubMed=22927417; DOI=10.1073/pnas.1205943109; RA Zoppoli G., Regairaz M., Leo E., Reinhold W.C., Varma S., Ballestrero A., RA Doroshow J.H., Pommier Y.; RT "Putative DNA/RNA helicase Schlafen-11 (SLFN11) sensitizes cancer cells to RT DNA-damaging agents."; RL Proc. Natl. Acad. Sci. U.S.A. 109:15030-15035(2012). RN [10] RP FUNCTION, SUBCELLULAR LOCATION, INTERACTION WITH RPA1, AND MUTAGENESIS OF RP LYS-605 AND ASP-668. RX PubMed=26658330; DOI=10.15252/embr.201540964; RA Mu Y., Lou J., Srivastava M., Zhao B., Feng X.H., Liu T., Chen J., RA Huang J.; RT "SLFN11 inhibits checkpoint maintenance and homologous recombination RT repair."; RL EMBO Rep. 17:94-109(2016). RN [11] RP INDUCTION, AND INTERACTION WITH DHX9. RX PubMed=26625211; DOI=10.18632/oncotarget.6413; RA Nogales V., Reinhold W.C., Varma S., Martinez-Cardus A., Moutinho C., RA Moran S., Heyn H., Sebio A., Barnadas A., Pommier Y., Esteller M.; RT "Epigenetic inactivation of the putative DNA/RNA helicase SLFN11 in human RT cancer confers resistance to platinum drugs."; RL Oncotarget 7:3084-3097(2016). RN [12] RP INDUCTION. RX PubMed=28196596; DOI=10.1016/j.ccell.2017.01.006; RA Gardner E.E., Lok B.H., Schneeberger V.E., Desmeules P., Miles L.A., RA Arnold P.K., Ni A., Khodos I., de Stanchina E., Nguyen T., Sage J., RA Campbell J.E., Ribich S., Rekhtman N., Dowlati A., Massion P.P., RA Rudin C.M., Poirier J.T.; RT "Chemosensitive relapse in small cell lung cancer proceeds through an EZH2- RT SLFN11 axis."; RL Cancer Cell 31:286-299(2017). RN [13] RP INDUCTION. RX PubMed=27440269; DOI=10.1158/1078-0432.ccr-16-1040; RA Lok B.H., Gardner E.E., Schneeberger V.E., Ni A., Desmeules P., RA Rekhtman N., de Stanchina E., Teicher B.A., Riaz N., Powell S.N., RA Poirier J.T., Rudin C.M.; RT "PARP inhibitor activity correlates with SLFN11 expression and demonstrates RT synergy with temozolomide in small cell lung cancer."; RL Clin. Cancer Res. 23:523-535(2017). RN [14] RP INDUCTION. RX PubMed=28212573; DOI=10.18632/oncotarget.15338; RA Allison Stewart C., Tong P., Cardnell R.J., Sen T., Li L., Gay C.M., RA Masrorpour F., Fan Y., Bara R.O., Feng Y., Ru Y., Fujimoto J., Kundu S.T., RA Post L.E., Yu K., Shen Y., Glisson B.S., Wistuba I., Heymach J.V., RA Gibbons D.L., Wang J., Byers L.A.; RT "Dynamic variations in epithelial-to-mesenchymal transition (EMT), ATM, and RT SLFN11 govern response to PARP inhibitors and cisplatin in small cell lung RT cancer."; RL Oncotarget 8:28575-28587(2017). RN [15] RP FUNCTION, SUBCELLULAR LOCATION, INTERACTION WITH RPA1; MCM3 AND DHX9, AND RP MUTAGENESIS OF GLU-669. RX PubMed=29395061; DOI=10.1016/j.molcel.2018.01.012; RA Murai J., Tang S.W., Leo E., Baechler S.A., Redon C.E., Zhang H., RA Al Abo M., Rajapakse V.N., Nakamura E., Jenkins L.M.M., Aladjem M.I., RA Pommier Y.; RT "SLFN11 blocks stressed replication forks independently of ATR."; RL Mol. Cell 69:371-384(2018). RN [16] RP FUNCTION. RX PubMed=30374083; DOI=10.1038/s41594-018-0142-5; RA Li M., Kao E., Malone D., Gao X., Wang J.Y.J., David M.; RT "DNA damage-induced cell death relies on SLFN11-dependent cleavage of RT distinct type II tRNAs."; RL Nat. Struct. Mol. Biol. 25:1047-1058(2018). RN [17] {ECO:0007744|PDB:7ZEL, ECO:0007744|PDB:7ZEP, ECO:0007744|PDB:7ZES} RP STRUCTURE BY ELECTRON MICROSCOPY (2.80 ANGSTROMS) IN COMPLEX WITH DNA AND RP TRNA, FUNCTION, SUBUNIT, DOMAIN, ACTIVE SITE, CATALYTIC ACTIVITY, RP MUTAGENESIS OF E209A, E214A; K216A; Y234A; D252A AND SER-753, DNA-BINDING, RP AND COFACTOR. RX PubMed=36115853; DOI=10.1038/s41467-022-33123-0; RA Metzner F.J., Wenzl S.J., Kugler M., Krebs S., Hopfner K.P., Lammens K.; RT "Mechanistic understanding of human SLFN11."; RL Nat. Commun. 13:5464-5464(2022). RN [18] RP FUNCTION. RX PubMed=35105802; DOI=10.1073/pnas.2108173119; RA Nightingale K., Potts M., Hunter L.M., Fielding C.A., Zerbe C.M., RA Fletcher-Etherington A., Nobre L., Wang E.C.Y., Strang B.L., Houghton J.W., RA Antrobus R., Suarez N.M., Nichols J., Davison A.J., Stanton R.J., RA Weekes M.P.; RT "Human cytomegalovirus protein RL1 degrades the antiviral factor SLFN11 via RT recruitment of the CRL4 E3 ubiquitin ligase complex."; RL Proc. Natl. Acad. Sci. U.S.A. 119:0-0(2022). CC -!- FUNCTION: Inhibitor of DNA replication that promotes cell death in CC response to DNA damage (PubMed:22927417, PubMed:26658330, CC PubMed:29395061). Acts as a guardian of the genome by killing cells CC with defective replication (PubMed:29395061). Persistently blocks CC stressed replication forks by opening chromatin across replication CC initiation sites at stressed replication forks, possibly leading to CC unwind DNA ahead of the MCM helicase and block fork progression, CC ultimately leading to cell death (PubMed:29395061). Upon DNA damage, CC inhibits translation of ATR or ATM based on distinct codon usage CC without disrupting early DNA damage response signaling CC (PubMed:30374083). Antiviral restriction factor with manganese- CC dependent type II tRNA endoribonuclease (PubMed:36115853). A single CC tRNA molecule is bound and cleaved by the SLFN11 dimer CC (PubMed:36115853). Specifically abrogates the production of CC retroviruses such as human immunodeficiency virus 1 (HIV-1) by acting CC as a specific inhibitor of the synthesis of retroviruses encoded CC proteins in a codon-usage-dependent manner (PubMed:23000900). Impairs CC the replication of human cytomegalovirus (HCMV) and some Flaviviruses CC (PubMed:35105802, PubMed:36115853). Exploits the unique viral codon CC bias towards A/T nucleotides (PubMed:23000900). Also acts as an CC interferon (IFN)-induced antiviral protein which acts as an inhibitor CC of retrovirus protein synthesis (PubMed:23000900). CC {ECO:0000269|PubMed:22927417, ECO:0000269|PubMed:23000900, CC ECO:0000269|PubMed:26658330, ECO:0000269|PubMed:29395061, CC ECO:0000269|PubMed:30374083, ECO:0000269|PubMed:35105802, CC ECO:0000269|PubMed:36115853}. CC -!- COFACTOR: CC Name=Mg(2+); Xref=ChEBI:CHEBI:18420; CC Evidence={ECO:0000269|PubMed:36115853}; CC -!- SUBUNIT: Homodimer (PubMed:36115853). Interacts with MCM3 CC (PubMed:29395061). Interacts with DHX9 (PubMed:26625211, CC PubMed:29395061). Interacts with RPA1 (PubMed:26658330, CC PubMed:29395061). {ECO:0000269|PubMed:26625211, CC ECO:0000269|PubMed:26658330, ECO:0000269|PubMed:29395061, CC ECO:0000269|PubMed:36115853}. CC -!- SUBCELLULAR LOCATION: Nucleus {ECO:0000269|PubMed:22927417, CC ECO:0000269|PubMed:26658330, ECO:0000269|PubMed:29395061}. Chromosome CC {ECO:0000269|PubMed:26658330, ECO:0000269|PubMed:29395061}. CC Note=Recruited to stressed replication forks carrying extended RPA CC filaments (PubMed:29395061). Recruited to DNA damage sites via CC interaction with RPA1 (PubMed:26658330, PubMed:29395061). CC {ECO:0000269|PubMed:26658330, ECO:0000269|PubMed:29395061}. CC -!- TISSUE SPECIFICITY: Exhibits a wider expression range in ovarian and CC colon adenocarcinoma than in their corresponding healthy tissues. CC {ECO:0000269|PubMed:22927417}. CC -!- INDUCTION: Down-regulated in small cell lung cancer (SCLC) cells CC resistant to PARP inhibitor drugs (PubMed:26625211, PubMed:27440269, CC PubMed:28196596, PubMed:28212573). Up-regulated by type I interferons, CC poly-IC and poly-dAdT (PubMed:20956525, PubMed:23000900). CC {ECO:0000269|PubMed:20956525, ECO:0000269|PubMed:23000900, CC ECO:0000269|PubMed:26625211, ECO:0000269|PubMed:27440269, CC ECO:0000269|PubMed:28196596, ECO:0000269|PubMed:28212573}. CC -!- DOMAIN: The N-terminus contains an endonuclease domain. The C-terminus CC displays homology to superfamily I DNA/RNA helicases, although it is in CC an autoinhibited conformation. {ECO:0000269|PubMed:36115853}. CC -!- MISCELLANEOUS: Dominant determinant of sensitivity to DNA-damaging CC anticancer drugs: acts by mediating cell death in response to DNA CC damage induced by anticancer drugs (PubMed:29395061). Down-regulated in CC a number of chemoresistant tumors (PubMed:26625211, PubMed:27440269, CC PubMed:28196596, PubMed:28212573). {ECO:0000269|PubMed:26625211, CC ECO:0000269|PubMed:27440269, ECO:0000269|PubMed:28196596, CC ECO:0000269|PubMed:28212573, ECO:0000269|PubMed:29395061}. CC -!- SIMILARITY: Belongs to the Schlafen family. Subgroup III subfamily. CC {ECO:0000305}. CC -!- SEQUENCE CAUTION: CC Sequence=BAB85010.1; Type=Frameshift; Evidence={ECO:0000305}; CC --------------------------------------------------------------------------- CC Copyrighted by the UniProt Consortium, see https://www.uniprot.org/terms CC Distributed under the Creative Commons Attribution (CC BY 4.0) License CC --------------------------------------------------------------------------- DR EMBL; AK074184; BAB85010.1; ALT_FRAME; mRNA. DR EMBL; AK092241; BAC03835.1; -; mRNA. DR EMBL; AL831964; CAD38606.2; -; mRNA. DR EMBL; AC060766; -; NOT_ANNOTATED_CDS; Genomic_DNA. DR EMBL; CH471147; EAW80156.1; -; Genomic_DNA. DR EMBL; CH471147; EAW80157.1; -; Genomic_DNA. DR EMBL; CH471147; EAW80158.1; -; Genomic_DNA. DR EMBL; BC052586; AAH52586.1; -; mRNA. DR CCDS; CCDS11294.1; -. DR RefSeq; NP_001098057.1; NM_001104587.2. DR RefSeq; NP_001098058.1; NM_001104588.2. DR RefSeq; NP_001098059.1; NM_001104589.2. DR RefSeq; NP_001098060.1; NM_001104590.2. DR RefSeq; NP_001362936.1; NM_001376007.1. DR RefSeq; NP_001362937.1; NM_001376008.1. DR RefSeq; NP_001362938.1; NM_001376009.1. DR RefSeq; NP_001362939.1; NM_001376010.1. DR RefSeq; NP_001362940.1; NM_001376011.1. DR RefSeq; NP_001374087.1; NM_001387158.1. DR RefSeq; NP_001374088.1; NM_001387159.1. DR RefSeq; NP_001374089.1; NM_001387160.1. DR RefSeq; NP_001374090.1; NM_001387161.1. DR RefSeq; NP_001374091.1; NM_001387162.1. DR RefSeq; NP_001374092.1; NM_001387163.1. DR RefSeq; NP_689483.3; NM_152270.3. DR RefSeq; XP_047292998.1; XM_047437042.1. DR PDB; 7ZEL; EM; 2.80 A; A/B=1-901. DR PDB; 7ZEP; EM; 3.20 A; A/B=1-901. DR PDB; 7ZES; EM; 3.10 A; A/B=1-901. DR PDB; 9ERD; EM; 3.72 A; A=1-901. DR PDB; 9ERE; EM; 2.82 A; A/B=1-901. DR PDB; 9ERF; EM; 2.64 A; A/B=1-901. DR PDB; 9GMW; EM; 3.00 A; A/B=1-901. DR PDB; 9GMX; EM; 2.82 A; A/B=1-901. DR PDBsum; 7ZEL; -. DR PDBsum; 7ZEP; -. DR PDBsum; 7ZES; -. DR PDBsum; 9ERD; -. DR PDBsum; 9ERE; -. DR PDBsum; 9ERF; -. DR PDBsum; 9GMW; -. DR PDBsum; 9GMX; -. DR AlphaFoldDB; Q7Z7L1; -. DR EMDB; EMD-14690; -. DR EMDB; EMD-14691; -. DR EMDB; EMD-14692; -. DR EMDB; EMD-19912; -. DR EMDB; EMD-19913; -. DR EMDB; EMD-19914; -. DR EMDB; EMD-51456; -. DR EMDB; EMD-51457; -. DR SMR; Q7Z7L1; -. DR BioGRID; 124851; 380. DR FunCoup; Q7Z7L1; 1154. DR IntAct; Q7Z7L1; 18. DR MINT; Q7Z7L1; -. DR STRING; 9606.ENSP00000378067; -. DR iPTMnet; Q7Z7L1; -. DR PhosphoSitePlus; Q7Z7L1; -. DR SwissPalm; Q7Z7L1; -. DR BioMuta; SLFN11; -. DR DMDM; 313104011; -. DR jPOST; Q7Z7L1; -. DR MassIVE; Q7Z7L1; -. DR PaxDb; 9606-ENSP00000378067; -. DR PeptideAtlas; Q7Z7L1; -. DR ProteomicsDB; 69561; -. DR Pumba; Q7Z7L1; -. DR Antibodypedia; 15596; 58 antibodies from 17 providers. DR DNASU; 91607; -. DR Ensembl; ENST00000308377.8; ENSP00000312402.4; ENSG00000172716.18. DR Ensembl; ENST00000394566.5; ENSP00000378067.1; ENSG00000172716.18. DR Ensembl; ENST00000685675.1; ENSP00000510787.1; ENSG00000172716.18. DR GeneID; 91607; -. DR KEGG; hsa:91607; -. DR MANE-Select; ENST00000685675.1; ENSP00000510787.1; NM_001376007.1; NP_001362936.1. DR UCSC; uc002hjg.5; human. DR AGR; HGNC:26633; -. DR CIViC; 91607; 3 evidence items across 1 molecular profile. DR ClinPGx; PA144596358; -. DR CTD; 91607; -. DR DisGeNET; 91607; -. DR GeneCards; SLFN11; -. DR HGNC; HGNC:26633; SLFN11. DR HPA; ENSG00000172716; Low tissue specificity. DR MIM; 614953; gene. DR OpenTargets; ENSG00000172716; -. DR VEuPathDB; HostDB:ENSG00000172716; -. DR eggNOG; ENOG502QWKG; Eukaryota. DR GeneTree; ENSGT00410000025651; -. DR HOGENOM; CLU_007071_0_0_1; -. DR InParanoid; Q7Z7L1; -. DR OMA; HKLCVIP; -. DR OrthoDB; 6052143at2759; -. DR PAN-GO; Q7Z7L1; 2 GO annotations based on evolutionary models. DR PhylomeDB; Q7Z7L1; -. DR PathwayCommons; Q7Z7L1; -. DR SignaLink; Q7Z7L1; -. DR Agora; ENSG00000172716; -. DR BioGRID-ORCS; 91607; 17 hits in 1154 CRISPR screens. DR ChiTaRS; SLFN11; human. DR GeneWiki; SLFN11; -. DR GenomeRNAi; 91607; -. DR Pharos; Q7Z7L1; Tbio. DR PRO; PR:Q7Z7L1; -. DR Proteomes; UP000005640; Chromosome 17. DR RNAct; Q7Z7L1; protein. DR Bgee; ENSG00000172716; Expressed in monocyte and 140 other cell types or tissues. DR ExpressionAtlas; Q7Z7L1; baseline and differential. DR GO; GO:0005829; C:cytosol; IDA:HPA. DR GO; GO:0005654; C:nucleoplasm; IDA:HPA. DR GO; GO:0005634; C:nucleus; IDA:UniProtKB. DR GO; GO:0090734; C:site of DNA damage; IDA:UniProtKB. DR GO; GO:0005524; F:ATP binding; IEA:UniProtKB-KW. DR GO; GO:0016887; F:ATP hydrolysis activity; IDA:UniProtKB. DR GO; GO:0003677; F:DNA binding; IEA:UniProtKB-KW. DR GO; GO:0004519; F:endonuclease activity; IEA:UniProtKB-KW. DR GO; GO:0004386; F:helicase activity; IEA:UniProtKB-KW. DR GO; GO:0000049; F:tRNA binding; IDA:UniProtKB. DR GO; GO:0006338; P:chromatin remodeling; IDA:UniProtKB. DR GO; GO:0051607; P:defense response to virus; IMP:UniProtKB. DR GO; GO:0006974; P:DNA damage response; IDA:UniProtKB. DR GO; GO:0002376; P:immune system process; IEA:UniProtKB-KW. DR GO; GO:0008156; P:negative regulation of DNA replication; IDA:UniProtKB. DR GO; GO:2000134; P:negative regulation of G1/S transition of mitotic cell cycle; IMP:UniProtKB. DR GO; GO:0043111; P:replication fork arrest; IDA:UniProtKB. DR FunFam; 3.30.950.30:FF:000002; Schlafen family member 11; 1. DR FunFam; 3.40.50.300:FF:001322; Schlafen family member 11; 1. DR Gene3D; 3.40.50.300; P-loop containing nucleotide triphosphate hydrolases; 2. DR Gene3D; 3.30.950.30; Schlafen, AAA domain; 1. DR InterPro; IPR027417; P-loop_NTPase. DR InterPro; IPR031450; Poxin-SLFN/SLFN_N. DR InterPro; IPR029684; Schlafen. DR InterPro; IPR007421; Schlafen_AlbA_2_dom. DR InterPro; IPR038461; Schlafen_AlbA_2_dom_sf. DR InterPro; IPR018647; SLFN_3-like_DNA/RNA_helicase. DR InterPro; IPR048729; SLFN_GTPase-like. DR PANTHER; PTHR12155; SCHLAFEN; 1. DR PANTHER; PTHR12155:SF45; SCHLAFEN FAMILY MEMBER 11; 1. DR Pfam; PF17057; B3R; 1. DR Pfam; PF09848; SLFN-g3_helicase; 1. DR Pfam; PF04326; SLFN_AlbA_2; 1. DR Pfam; PF21026; SLFN_GTPase-like; 1. DR SUPFAM; SSF52540; P-loop containing nucleoside triphosphate hydrolases; 1. PE 1: Evidence at protein level; KW 3D-structure; Antiviral defense; ATP-binding; Chromosome; DNA damage; KW DNA-binding; Endonuclease; Helicase; Hydrolase; Immunity; Nuclease; KW Nucleotide-binding; Nucleus; Proteomics identification; Reference proteome; KW RNA-binding; tRNA-binding. FT CHAIN 1..901 FT /note="Schlafen family member 11" FT /id="PRO_0000283091" FT ACT_SITE 216 FT /evidence="ECO:0000269|PubMed:36115853" FT BINDING 209 FT /ligand="Mg(2+)" FT /ligand_id="ChEBI:CHEBI:18420" FT /ligand_note="catalytic" FT /evidence="ECO:0000269|PubMed:36115853" FT BINDING 214 FT /ligand="Mg(2+)" FT /ligand_id="ChEBI:CHEBI:18420" FT /ligand_note="catalytic" FT /evidence="ECO:0000269|PubMed:36115853" FT BINDING 285 FT /ligand="Zn(2+)" FT /ligand_id="ChEBI:CHEBI:29105" FT /evidence="ECO:0000269|PubMed:36115853" FT BINDING 287 FT /ligand="Zn(2+)" FT /ligand_id="ChEBI:CHEBI:29105" FT /evidence="ECO:0000269|PubMed:36115853" FT BINDING 321 FT /ligand="Zn(2+)" FT /ligand_id="ChEBI:CHEBI:29105" FT /evidence="ECO:0000269|PubMed:36115853" FT BINDING 322 FT /ligand="Zn(2+)" FT /ligand_id="ChEBI:CHEBI:29105" FT /evidence="ECO:0000269|PubMed:36115853" FT BINDING 599..606 FT /ligand="ATP" FT /ligand_id="ChEBI:CHEBI:30616" FT /evidence="ECO:0000255" FT VARIANT 121 FT /note="V -> F (in dbSNP:rs12453150)" FT /evidence="ECO:0000269|PubMed:14702039" FT /id="VAR_031492" FT VARIANT 301 FT /note="N -> D (in dbSNP:rs4796077)" FT /evidence="ECO:0000269|PubMed:14702039, FT ECO:0000269|PubMed:15489334, ECO:0000269|PubMed:17974005, FT ECO:0000269|Ref.4" FT /id="VAR_031493" FT VARIANT 489 FT /note="R -> L (in dbSNP:rs9898983)" FT /id="VAR_062186" FT VARIANT 822 FT /note="Y -> C (in dbSNP:rs3803860)" FT /id="VAR_031494" FT MUTAGEN 209 FT /note="E->A: Complete loss of endonuclease activity." FT /evidence="ECO:0000269|PubMed:36115853" FT MUTAGEN 214 FT /note="E->A: Complete loss of endonuclease activity." FT /evidence="ECO:0000269|PubMed:36115853" FT MUTAGEN 216 FT /note="K->A: Complete loss of endonuclease activity." FT /evidence="ECO:0000269|PubMed:36115853" FT MUTAGEN 234 FT /note="Y->A: No effect on endonuclease activity." FT /evidence="ECO:0000269|PubMed:36115853" FT MUTAGEN 252 FT /note="D->A: Slight increase in endonuclease activity." FT /evidence="ECO:0000269|PubMed:36115853" FT MUTAGEN 605 FT /note="K->M: Abolishes ATPase activity without affecting FT its role in DNA damage response; when associated with A- FT 668." FT /evidence="ECO:0000269|PubMed:26658330" FT MUTAGEN 668 FT /note="D->A: Abolishes ATPase activity without affecting FT its role in DNA damage response; when associated with M- FT 605." FT /evidence="ECO:0000269|PubMed:26658330" FT MUTAGEN 669 FT /note="E->Q: Abolishes ATPase activity, leading to abolish FT ability to inhibit DNA replication without affecting FT subcellular location." FT /evidence="ECO:0000269|PubMed:29395061" FT MUTAGEN 753 FT /note="S->D: Complete loss of tRNA cleavage and ssDNA FT binding." FT /evidence="ECO:0000269|PubMed:36115853" FT CONFLICT 20 FT /note="N -> S (in Ref. 1; BAC03835)" FT /evidence="ECO:0000305" FT CONFLICT 143 FT /note="M -> T (in Ref. 1; BAC03835)" FT /evidence="ECO:0000305" FT CONFLICT 324 FT /note="V -> M (in Ref. 2; CAD38606)" FT /evidence="ECO:0000305" FT CONFLICT 665 FT /note="I -> V (in Ref. 1; BAC03835 and 2; CAD38606)" FT /evidence="ECO:0000305" FT STRAND 9..11 FT /evidence="ECO:0007829|PDB:7ZEL" FT STRAND 14..16 FT /evidence="ECO:0007829|PDB:9ERF" FT STRAND 18..23 FT /evidence="ECO:0007829|PDB:9ERF" FT HELIX 28..32 FT /evidence="ECO:0007829|PDB:9ERF" FT HELIX 36..55 FT /evidence="ECO:0007829|PDB:9ERF" FT STRAND 59..64 FT /evidence="ECO:0007829|PDB:9ERF" FT STRAND 66..69 FT /evidence="ECO:0007829|PDB:9ERF" FT HELIX 75..85 FT /evidence="ECO:0007829|PDB:9ERF" FT HELIX 90..92 FT /evidence="ECO:0007829|PDB:9ERF" FT STRAND 94..99 FT /evidence="ECO:0007829|PDB:9ERF" FT STRAND 102..107 FT /evidence="ECO:0007829|PDB:9ERF" FT STRAND 113..115 FT /evidence="ECO:0007829|PDB:9ERF" FT HELIX 117..120 FT /evidence="ECO:0007829|PDB:9ERF" FT STRAND 133..136 FT /evidence="ECO:0007829|PDB:9ERF" FT STRAND 139..142 FT /evidence="ECO:0007829|PDB:9ERF" FT HELIX 145..156 FT /evidence="ECO:0007829|PDB:9ERF" FT HELIX 189..195 FT /evidence="ECO:0007829|PDB:9ERF" FT STRAND 197..200 FT /evidence="ECO:0007829|PDB:9ERF" FT STRAND 211..216 FT /evidence="ECO:0007829|PDB:9ERF" FT HELIX 223..240 FT /evidence="ECO:0007829|PDB:9ERF" FT STRAND 244..250 FT /evidence="ECO:0007829|PDB:9ERF" FT TURN 252..254 FT /evidence="ECO:0007829|PDB:9ERF" FT TURN 262..264 FT /evidence="ECO:0007829|PDB:9ERF" FT HELIX 267..280 FT /evidence="ECO:0007829|PDB:9ERF" FT STRAND 286..288 FT /evidence="ECO:0007829|PDB:9ERF" FT STRAND 295..304 FT /evidence="ECO:0007829|PDB:9ERF" FT STRAND 307..317 FT /evidence="ECO:0007829|PDB:9ERF" FT STRAND 321..324 FT /evidence="ECO:0007829|PDB:9ERF" FT STRAND 326..328 FT /evidence="ECO:0007829|PDB:9ERE" FT STRAND 332..335 FT /evidence="ECO:0007829|PDB:9ERF" FT STRAND 338..341 FT /evidence="ECO:0007829|PDB:9ERF" FT HELIX 344..352 FT /evidence="ECO:0007829|PDB:9ERF" FT HELIX 384..397 FT /evidence="ECO:0007829|PDB:9ERF" FT STRAND 402..409 FT /evidence="ECO:0007829|PDB:9ERF" FT HELIX 410..419 FT /evidence="ECO:0007829|PDB:9ERF" FT HELIX 423..430 FT /evidence="ECO:0007829|PDB:9ERF" FT TURN 431..433 FT /evidence="ECO:0007829|PDB:9ERF" FT STRAND 436..443 FT /evidence="ECO:0007829|PDB:9ERF" FT HELIX 445..448 FT /evidence="ECO:0007829|PDB:9ERF" FT STRAND 457..465 FT /evidence="ECO:0007829|PDB:9ERF" FT STRAND 471..478 FT /evidence="ECO:0007829|PDB:9ERF" FT HELIX 483..500 FT /evidence="ECO:0007829|PDB:9ERF" FT STRAND 511..517 FT /evidence="ECO:0007829|PDB:9ERF" FT HELIX 537..539 FT /evidence="ECO:0007829|PDB:9ERF" FT HELIX 544..559 FT /evidence="ECO:0007829|PDB:9ERF" FT HELIX 564..585 FT /evidence="ECO:0007829|PDB:9ERF" FT HELIX 586..588 FT /evidence="ECO:0007829|PDB:9ERF" FT TURN 589..591 FT /evidence="ECO:0007829|PDB:9ERF" FT STRAND 593..599 FT /evidence="ECO:0007829|PDB:9ERF" FT HELIX 605..620 FT /evidence="ECO:0007829|PDB:9ERF" FT HELIX 624..626 FT /evidence="ECO:0007829|PDB:9ERF" FT STRAND 627..632 FT /evidence="ECO:0007829|PDB:9ERF" FT HELIX 634..641 FT /evidence="ECO:0007829|PDB:9ERF" FT TURN 642..644 FT /evidence="ECO:0007829|PDB:9ERF" FT STRAND 645..650 FT /evidence="ECO:0007829|PDB:9ERF" FT HELIX 651..656 FT /evidence="ECO:0007829|PDB:9ERF" FT STRAND 664..667 FT /evidence="ECO:0007829|PDB:9ERF" FT HELIX 670..672 FT /evidence="ECO:0007829|PDB:9ERF" FT STRAND 675..677 FT /evidence="ECO:0007829|PDB:9GMW" FT HELIX 680..689 FT /evidence="ECO:0007829|PDB:9ERF" FT STRAND 692..695 FT /evidence="ECO:0007829|PDB:9ERF" FT STRAND 698..702 FT /evidence="ECO:0007829|PDB:9ERF" FT HELIX 704..706 FT /evidence="ECO:0007829|PDB:9ERF" FT TURN 718..720 FT /evidence="ECO:0007829|PDB:9ERF" FT STRAND 723..727 FT /evidence="ECO:0007829|PDB:9ERF" FT HELIX 735..750 FT /evidence="ECO:0007829|PDB:9ERF" FT STRAND 754..756 FT /evidence="ECO:0007829|PDB:7ZEL" FT HELIX 760..762 FT /evidence="ECO:0007829|PDB:9ERF" FT STRAND 776..779 FT /evidence="ECO:0007829|PDB:9ERF" FT HELIX 785..802 FT /evidence="ECO:0007829|PDB:9ERF" FT HELIX 806..808 FT /evidence="ECO:0007829|PDB:9ERF" FT STRAND 809..814 FT /evidence="ECO:0007829|PDB:9ERF" FT HELIX 816..818 FT /evidence="ECO:0007829|PDB:9ERF" FT HELIX 819..830 FT /evidence="ECO:0007829|PDB:9ERF" FT HELIX 831..833 FT /evidence="ECO:0007829|PDB:9ERF" FT HELIX 841..843 FT /evidence="ECO:0007829|PDB:9ERF" FT STRAND 846..853 FT /evidence="ECO:0007829|PDB:9ERF" FT HELIX 855..857 FT /evidence="ECO:0007829|PDB:9ERF" FT STRAND 862..868 FT /evidence="ECO:0007829|PDB:9ERF" FT HELIX 875..877 FT /evidence="ECO:0007829|PDB:9ERF" FT HELIX 878..886 FT /evidence="ECO:0007829|PDB:9ERF" FT STRAND 889..896 FT /evidence="ECO:0007829|PDB:9ERF" SQ SEQUENCE 901 AA; 102836 MW; 514FD89CB7C12E8D CRC64; MEANQCPLVV EPSYPDLVIN VGEVTLGEEN RKKLQKIQRD QEKERVMRAA CALLNSGGGV IRMAKKVEHP VEMGLDLEQS LRELIQSSDL QAFFETKQQG RCFYIFVKSW SSGPFPEDRS VKPRLCSLSS SLYRRSETSV RSMDSREAFC FLKTKRKPKI LEEGPFHKIH KGVYQELPNS DPADPNSDPA DLIFQKDYLE YGEILPFPES QLVEFKQFST KHFQEYVKRT IPEYVPAFAN TGGGYLFIGV DDKSREVLGC AKENVDPDSL RRKIEQAIYK LPCVHFCQPQ RPITFTLKIV NVLKRGELYG YACMIRVNPF CCAVFSEAPN SWIVEDKYVC SLTTEKWVGM MTDTDPDLLQ LSEDFECQLS LSSGPPLSRP VYSKKGLEHK KELQQLLFSV PPGYLRYTPE SLWRDLISEH RGLEELINKQ MQPFFRGILI FSRSWAVDLN LQEKPGVICD ALLIAQNSTP ILYTILREQD AEGQDYCTRT AFTLKQKLVN MGGYTGKVCV RAKVLCLSPE SSAEALEAAV SPMDYPASYS LAGTQHMEAL LQSLVIVLLG FRSLLSDQLG CEVLNLLTAQ QYEIFSRSLR KNRELFVHGL PGSGKTIMAM KIMEKIRNVF HCEAHRILYV CENQPLRNFI SDRNICRAET RKTFLRENFE HIQHIVIDEA QNFRTEDGDW YGKAKSITRR AKGGPGILWI FLDYFQTSHL DCSGLPPLSD QYPREELTRI VRNADPIAKY LQKEMQVIRS NPSFNIPTGC LEVFPEAEWS QGVQGTLRIK KYLTVEQIMT CVADTCRRFF DRGYSPKDVA VLVSTAKEVE HYKYELLKAM RKKRVVQLSD ACDMLGDHIV LDSVRRFSGL ERSIVFGIHP RTADPAILPN VLICLASRAK QHLYIFPWGG H // ID WRN_HUMAN Reviewed; 1432 AA. AC Q14191; A1KYY9; DT 15-DEC-1998, integrated into UniProtKB/Swiss-Prot. DT 08-FEB-2011, sequence version 2. DT 28-JAN-2026, entry version 251. DE RecName: Full=Bifunctional 3'-5' exonuclease/ATP-dependent helicase WRN {ECO:0000305}; DE AltName: Full=DNA helicase, RecQ-like type 3; DE AltName: Full=RecQ protein-like 2; DE AltName: Full=Werner syndrome protein {ECO:0000303|PubMed:9618508}; DE Includes: DE RecName: Full=3'-5' exonuclease; DE EC=3.1.-.- {ECO:0000269|PubMed:11863428}; DE Includes: DE RecName: Full=ATP-dependent helicase; DE EC=5.6.2.4 {ECO:0000269|PubMed:9611231, ECO:0000305|PubMed:9288107}; DE AltName: Full=DNA 3'-5' helicase WRN {ECO:0000305}; GN Name=WRN; Synonyms=RECQ3, RECQL2; OS Homo sapiens (Human). OC Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia; OC Eutheria; Euarchontoglires; Primates; Haplorrhini; Catarrhini; Hominidae; OC Homo. OX NCBI_TaxID=9606; RN [1] RP NUCLEOTIDE SEQUENCE [GENOMIC DNA], AND VARIANT PHE-1074. RX PubMed=8602509; DOI=10.1126/science.272.5259.258; RA Yu C.-E., Oshima J., Fu Y.-H., Wijsman E.M., Hisama F., Alisch R., RA Matthews S., Nakura J., Miki T., Ouais S., Martin G.M., Mulligan J., RA Schellenberg G.D.; RT "Positional cloning of the Werner's syndrome gene."; RL Science 272:258-262(1996). RN [2] RP NUCLEOTIDE SEQUENCE [MRNA], AND VARIANT PHE-1074. RX PubMed=16723399; DOI=10.1073/pnas.0600645103; RA Agrelo R., Cheng W.H., Setien F., Ropero S., Espada J., Fraga M.F., RA Herranz M., Paz M.F., Sanchez-Cespedes M., Artiga M.J., Guerrero D., RA Castells A., von Kobbe C., Bohr V.A., Esteller M.; RT "Epigenetic inactivation of the premature aging Werner syndrome gene in RT human cancer."; RL Proc. Natl. Acad. Sci. U.S.A. 103:8822-8827(2006). RN [3] RP NUCLEOTIDE SEQUENCE [MRNA], AND VARIANT PHE-1074. RA Paeper B.W., Gayle M., Brady W., Swartz A., Gillett L.A., Alisch R.S., RA Mulligan J., Galas D., Fu Y.-H.; RT "Genomic structure of the human Werner's gene and cloning of the mouse RT homolog."; RL Submitted (AUG-1999) to the EMBL/GenBank/DDBJ databases. RN [4] RP NUCLEOTIDE SEQUENCE [GENOMIC DNA], AND VARIANTS ILE-114; LYS-343; ILE-387; RP SER-533; CYS-612; PHE-708; CYS-834; SER-912; LEU-1079; ALA-1133; ILE-1339 RP AND ARG-1367. RG NIEHS SNPs program; RL Submitted (OCT-2003) to the EMBL/GenBank/DDBJ databases. RN [5] RP NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA]. RX PubMed=16421571; DOI=10.1038/nature04406; RA Nusbaum C., Mikkelsen T.S., Zody M.C., Asakawa S., Taudien S., Garber M., RA Kodira C.D., Schueler M.G., Shimizu A., Whittaker C.A., Chang J.L., RA Cuomo C.A., Dewar K., FitzGerald M.G., Yang X., Allen N.R., Anderson S., RA Asakawa T., Blechschmidt K., Bloom T., Borowsky M.L., Butler J., Cook A., RA Corum B., DeArellano K., DeCaprio D., Dooley K.T., Dorris L. III, RA Engels R., Gloeckner G., Hafez N., Hagopian D.S., Hall J.L., Ishikawa S.K., RA Jaffe D.B., Kamat A., Kudoh J., Lehmann R., Lokitsang T., Macdonald P., RA Major J.E., Matthews C.D., Mauceli E., Menzel U., Mihalev A.H., RA Minoshima S., Murayama Y., Naylor J.W., Nicol R., Nguyen C., O'Leary S.B., RA O'Neill K., Parker S.C.J., Polley A., Raymond C.K., Reichwald K., RA Rodriguez J., Sasaki T., Schilhabel M., Siddiqui R., Smith C.L., RA Sneddon T.P., Talamas J.A., Tenzin P., Topham K., Venkataraman V., Wen G., RA Yamazaki S., Young S.K., Zeng Q., Zimmer A.R., Rosenthal A., Birren B.W., RA Platzer M., Shimizu N., Lander E.S.; RT "DNA sequence and analysis of human chromosome 8."; RL Nature 439:331-335(2006). RN [6] RP FUNCTION AS A HELICASE, CATALYTIC ACTIVITY, AND MUTAGENESIS OF LYS-577. RX PubMed=9288107; DOI=10.1038/ng0997-100; RA Gray M.D., Shen J.C., Kamath-Loeb A.S., Blank A., Sopher B.L., Martin G.M., RA Oshima J., Loeb L.A.; RT "The Werner syndrome protein is a DNA helicase."; RL Nat. Genet. 17:100-103(1997). RN [7] RP FUNCTION AS A HELICASE. RX PubMed=9224595; DOI=10.1093/nar/25.15.2973; RA Suzuki N., Shimamoto A., Imamura O., Kuromitsu J., Kitao S., Goto M., RA Furuichi Y.; RT "DNA helicase activity in Werner's syndrome gene product synthesized in a RT baculovirus system."; RL Nucleic Acids Res. 25:2973-2978(1997). RN [8] RP FUNCTION AS A 3'-5' HELICASE, AND BIOPHYSICOCHEMICAL PROPERTIES. RX PubMed=9611231; DOI=10.1093/nar/26.12.2879; RA Shen J.C., Gray M.D., Oshima J., Loeb L.A.; RT "Characterization of Werner syndrome protein DNA helicase activity: RT directionality, substrate dependence and stimulation by replication protein RT A."; RL Nucleic Acids Res. 26:2879-2885(1998). RN [9] RP SUBCELLULAR LOCATION. RX PubMed=9618508; DOI=10.1073/pnas.95.12.6887; RA Marciniak R.A., Lombard D.B., Johnson F.B., Guarente L.; RT "Nucleolar localization of the Werner syndrome protein in human cells."; RL Proc. Natl. Acad. Sci. U.S.A. 95:6887-6892(1998). RN [10] RP REPEATS. RX PubMed=10049920; DOI=10.1093/genetics/151.3.1027; RA Kusano K., Berres M.E., Engels W.R.; RT "Evolution of the RECQ family of helicases: a Drosophila homolog, Dmblm, is RT similar to the human Bloom syndrome gene."; RL Genetics 151:1027-1039(1999). RN [11] RP FUNCTION, AND COFACTOR. RX PubMed=10212265; DOI=10.1074/jbc.274.18.12797; RA Fry M., Loeb L.A.; RT "Human werner syndrome DNA helicase unwinds tetrahelical structures of the RT fragile X syndrome repeat sequence d(CGG)n."; RL J. Biol. Chem. 274:12797-12802(1999). RN [12] RP POSSIBLE INVOLVEMENT IN CRC. RX PubMed=9989816; DOI=10.1038/sj.onc.1202340; RA Chughtai S.A., Crundwell M.C., Cruickshank N.R., Affie E., Armstrong S., RA Knowles M.A., Takle L.A., Kuo M., Khan N., Phillips S.M., Neoptolemos J.P., RA Morton D.G.; RT "Two novel regions of interstitial deletion on chromosome 8p in colorectal RT cancer."; RL Oncogene 18:657-665(1999). RN [13] RP FUNCTION AS AN EXONUCLEASE, MUTAGENESIS OF GLU-84, DNA-BINDING, INTERACTION RP WITH PCNA, AND SUBUNIT. RX PubMed=11863428; DOI=10.1021/bi0157161; RA Xue Y., Ratcliff G.C., Wang H., Davis-Searles P.R., Gray M.D., Erie D.A., RA Redinbo M.R.; RT "A minimal exonuclease domain of WRN forms a hexamer on DNA and possesses RT both 3'- 5' exonuclease and 5'-protruding strand endonuclease activities."; RL Biochemistry 41:2901-2912(2002). RN [14] RP PHOSPHORYLATION. RX PubMed=11889123; DOI=10.1074/jbc.m111523200; RA Karmakar P., Piotrowski J., Brosh R.M. Jr., Sommers J.A., Miller S.P., RA Cheng W.H., Snowden C.M., Ramsden D.A., Bohr V.A.; RT "Werner protein is a target of DNA-dependent protein kinase in vivo and in RT vitro, and its catalytic activities are regulated by phosphorylation."; RL J. Biol. Chem. 277:18291-18302(2002). RN [15] RP INTERACTION WITH EXO1. RX PubMed=12704184; DOI=10.1074/jbc.m212798200; RA Sharma S., Sommers J.A., Driscoll H.C., Uzdilla L.A., Wilson T.M., RA Brosh R.M. Jr.; RT "The exonucleolytic and endonucleolytic cleavage activities of human RT exonuclease 1 are stimulated by an interaction with the carboxyl-terminal RT region of the Werner syndrome protein."; RL J. Biol. Chem. 278:23487-23496(2003). RN [16] RP INTERACTION WITH SUPV3L1. RX PubMed=17961633; DOI=10.1016/j.mad.2007.09.001; RA Pereira M., Mason P., Szczesny R.J., Maddukuri L., Dziwura S., RA Jedrzejczak R., Paul E., Wojcik A., Dybczynska L., Tudek B., Bartnik E., RA Klysik J., Bohr V.A., Stepien P.P.; RT "Interaction of human SUV3 RNA/DNA helicase with BLM helicase; loss of the RT SUV3 gene results in mouse embryonic lethality."; RL Mech. Ageing Dev. 128:609-617(2007). RN [17] RP FUNCTION, AND SUBCELLULAR LOCATION. RX PubMed=17563354; DOI=10.1073/pnas.0702513104; RA Kamath-Loeb A.S., Lan L., Nakajima S., Yasui A., Loeb L.A.; RT "Werner syndrome protein interacts functionally with translesion DNA RT polymerases."; RL Proc. Natl. Acad. Sci. U.S.A. 104:10394-10399(2007). RN [18] RP IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS]. RC TISSUE=Embryonic kidney; RX PubMed=17525332; DOI=10.1126/science.1140321; RA Matsuoka S., Ballif B.A., Smogorzewska A., McDonald E.R. III, Hurov K.E., RA Luo J., Bakalarski C.E., Zhao Z., Solimini N., Lerenthal Y., Shiloh Y., RA Gygi S.P., Elledge S.J.; RT "ATM and ATR substrate analysis reveals extensive protein networks RT responsive to DNA damage."; RL Science 316:1160-1166(2007). RN [19] RP FUNCTION, SUBUNIT, AND DNA-BINDING. RX PubMed=18596042; DOI=10.1074/jbc.m803370200; RA Compton S.A., Tolun G., Kamath-Loeb A.S., Loeb L.A., Griffith J.D.; RT "The Werner syndrome protein binds replication fork and Holliday junction RT DNAs as an oligomer."; RL J. Biol. Chem. 283:24478-24483(2008). RN [20] RP PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-440 AND SER-467, AND RP IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS]. RC TISSUE=Cervix carcinoma; RX PubMed=18669648; DOI=10.1073/pnas.0805139105; RA Dephoure N., Zhou C., Villen J., Beausoleil S.A., Bakalarski C.E., RA Elledge S.J., Gygi S.P.; RT "A quantitative atlas of mitotic phosphorylation."; RL Proc. Natl. Acad. Sci. U.S.A. 105:10762-10767(2008). RN [21] RP IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS]. RX PubMed=19413330; DOI=10.1021/ac9004309; RA Gauci S., Helbig A.O., Slijper M., Krijgsveld J., Heck A.J., Mohammed S.; RT "Lys-N and trypsin cover complementary parts of the phosphoproteome in a RT refined SCX-based approach."; RL Anal. Chem. 81:4493-4501(2009). RN [22] RP FUNCTION, AND SUBCELLULAR LOCATION. RX PubMed=19652551; DOI=10.4161/cc.8.17.9410; RA Zecevic A., Menard H., Gurel V., Hagan E., DeCaro R., Zhitkovich A.; RT "WRN helicase promotes repair of DNA double-strand breaks caused by RT aberrant mismatch repair of chromium-DNA adducts."; RL Cell Cycle 8:2769-2778(2009). RN [23] RP FUNCTION. RX PubMed=19283071; DOI=10.1371/journal.pone.0004825; RA Opresko P.L., Sowd G., Wang H.; RT "The Werner syndrome helicase/exonuclease processes mobile D-loops through RT branch migration and degradation."; RL PLoS ONE 4:E4825-E4825(2009). RN [24] RP PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-426; SER-440; SER-453 AND RP SER-467, AND IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS]. RC TISSUE=Leukemic T-cell; RX PubMed=19690332; DOI=10.1126/scisignal.2000007; RA Mayya V., Lundgren D.H., Hwang S.-I., Rezaul K., Wu L., Eng J.K., RA Rodionov V., Han D.K.; RT "Quantitative phosphoproteomic analysis of T cell receptor signaling RT reveals system-wide modulation of protein-protein interactions."; RL Sci. Signal. 2:RA46-RA46(2009). RN [25] RP IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS]. RX PubMed=21269460; DOI=10.1186/1752-0509-5-17; RA Burkard T.R., Planyavsky M., Kaupe I., Breitwieser F.P., Buerckstuemmer T., RA Bennett K.L., Superti-Furga G., Colinge J.; RT "Initial characterization of the human central proteome."; RL BMC Syst. Biol. 5:17-17(2011). RN [26] RP FUNCTION, SUBCELLULAR LOCATION, AND INTERACTION WITH PML. RX PubMed=21639834; DOI=10.1134/s000629791105004x; RA Liu J., Song Y., Qian J., Liu B., Dong Y., Tian B., Sun Z.; RT "Promyelocytic leukemia protein interacts with werner syndrome helicase and RT regulates double-strand break repair in gamma-irradiation-induced DNA RT damage responses."; RL Biochemistry (Mosc.) 76:550-554(2011). RN [27] RP PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-1133, AND IDENTIFICATION BY RP MASS SPECTROMETRY [LARGE SCALE ANALYSIS]. RX PubMed=21406692; DOI=10.1126/scisignal.2001570; RA Rigbolt K.T., Prokhorova T.A., Akimov V., Henningsen J., Johansen P.T., RA Kratchmarova I., Kassem M., Mann M., Olsen J.V., Blagoev B.; RT "System-wide temporal characterization of the proteome and phosphoproteome RT of human embryonic stem cell differentiation."; RL Sci. Signal. 4:RS3-RS3(2011). RN [28] RP ACETYLATION [LARGE SCALE ANALYSIS] AT SER-2, CLEAVAGE OF INITIATOR RP METHIONINE [LARGE SCALE ANALYSIS], AND IDENTIFICATION BY MASS SPECTROMETRY RP [LARGE SCALE ANALYSIS]. RX PubMed=22814378; DOI=10.1073/pnas.1210303109; RA Van Damme P., Lasa M., Polevoda B., Gazquez C., Elosegui-Artola A., RA Kim D.S., De Juan-Pardo E., Demeyer K., Hole K., Larrea E., Timmerman E., RA Prieto J., Arnesen T., Sherman F., Gevaert K., Aldabe R.; RT "N-terminal acetylome analyses and functional insights of the N-terminal RT acetyltransferase NatB."; RL Proc. Natl. Acad. Sci. U.S.A. 109:12449-12454(2012). RN [29] RP POSSIBLE INVOLVEMENT IN CRC. RX PubMed=24308539; DOI=10.1186/1755-8794-6-54; RA Lee H., Flaherty P., Ji H.P.; RT "Systematic genomic identification of colorectal cancer genes delineating RT advanced from early clinical stage and metastasis."; RL BMC Med. Genomics 6:54-54(2013). RN [30] RP PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-478; SER-1133 AND SER-1400, RP AND IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS]. RC TISSUE=Cervix carcinoma, and Erythroleukemia; RX PubMed=23186163; DOI=10.1021/pr300630k; RA Zhou H., Di Palma S., Preisinger C., Peng M., Polat A.N., Heck A.J., RA Mohammed S.; RT "Toward a comprehensive characterization of a human cancer cell RT phosphoproteome."; RL J. Proteome Res. 12:260-271(2013). RN [31] RP FUNCTION, SUBCELLULAR LOCATION, INTERACTION WITH XRCC5 AND XRCC6, DOMAIN, RP XLM MOTIF, KBM MOTIFS, AND MUTAGENESIS OF TRP-18 AND GLU-84. RX PubMed=27063109; DOI=10.1038/ncomms11242; RA Grundy G.J., Rulten S.L., Arribas-Bosacoma R., Davidson K., Kozik Z., RA Oliver A.W., Pearl L.H., Caldecott K.W.; RT "The Ku-binding motif is a conserved module for recruitment and stimulation RT of non-homologous end-joining proteins."; RL Nat. Commun. 7:11242-11242(2016). RN [32] RP SUMOYLATION [LARGE SCALE ANALYSIS] AT LYS-154; LYS-241 AND LYS-252, AND RP IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS]. RX PubMed=28112733; DOI=10.1038/nsmb.3366; RA Hendriks I.A., Lyon D., Young C., Jensen L.J., Vertegaal A.C., RA Nielsen M.L.; RT "Site-specific mapping of the human SUMO proteome reveals co-modification RT with phosphorylation."; RL Nat. Struct. Mol. Biol. 24:325-336(2017). RN [33] {ECO:0007744|PDB:2AXL} RP STRUCTURE BY NMR OF 949-1092. RX PubMed=16339893; DOI=10.1073/pnas.0509380102; RA Hu J.S., Feng H., Zeng W., Lin G.X., Xi X.G.; RT "Solution structure of a multifunctional DNA- and protein-binding motif of RT human Werner syndrome protein."; RL Proc. Natl. Acad. Sci. U.S.A. 102:18379-18384(2005). RN [34] {ECO:0007744|PDB:2FBT, ECO:0007744|PDB:2FBV, ECO:0007744|PDB:2FBX, ECO:0007744|PDB:2FBY, ECO:0007744|PDB:2FC0} RP X-RAY CRYSTALLOGRAPHY (2.00 ANGSTROMS) OF 38-236 IN COMPLEXES WITH RP MAGNESIUM; MANGANESE; EUROPIUM AND GMP, PARTIAL PROTEIN SEQUENCE, RP IDENTIFICATION BY MASS SPECTROMETRY, CATALYTIC ACTIVITY, COFACTOR, RP MUTAGENESIS OF GLU-84; TRP-145 AND TYR-212, AND CHARACTERIZATION OF RP VARIANTS ILE-114 AND PRO-172. RX PubMed=16622405; DOI=10.1038/nsmb1088; RA Perry J.J., Yannone S.M., Holden L.G., Hitomi C., Asaithamby A., Han S., RA Cooper P.K., Chen D.J., Tainer J.A.; RT "WRN exonuclease structure and molecular mechanism imply an editing role in RT DNA end processing."; RL Nat. Struct. Mol. Biol. 13:414-422(2006). RN [35] RP REVIEW ON VARIANTS. RX PubMed=10220139; RX DOI=10.1002/(sici)1098-1004(1999)13:4<271::aid-humu2>3.0.co;2-q; RA Moser M.J., Oshima J., Monnat R.J. Jr.; RT "WRN mutations in Werner syndrome."; RL Hum. Mutat. 13:271-279(1999). RN [36] {ECO:0007744|PDB:2DGZ} RP STRUCTURE BY NMR OF 1140-1239. RG RIKEN structural genomics initiative (RSGI); RA Abe C., Muto Y., Inoue M., Kigawa T., Terada T., Shirouzu M., Yokoyama S.; RT "Solution structure of the helicase and RNase D C-terminal domain in Werner RT syndrome ATP-dependent helicase."; RL Submitted (SEP-2006) to the PDB data bank. RN [37] {ECO:0007744|PDB:2E1E, ECO:0007744|PDB:2E1F} RP X-RAY CRYSTALLOGRAPHY (2.00 ANGSTROMS) OF 1142-1242, PARTIAL PROTEIN RP SEQUENCE, IDENTIFICATION BY MASS SPECTROMETRY, AND CIRCULAR DICHROISM. RX PubMed=17148451; DOI=10.1074/jbc.m610142200; RA Kitano K., Yoshihara N., Hakoshima T.; RT "Crystal structure of the HRDC domain of human Werner syndrome protein, RT WRN."; RL J. Biol. Chem. 282:2717-2728(2007). RN [38] {ECO:0007744|PDB:3AAF} RP X-RAY CRYSTALLOGRAPHY (1.90 ANGSTROMS) OF 949-1079 IN COMPLEX WITH RP DOUBLE-STRANDED DNA, INTERACTION WITH DNA, AND MUTAGENESIS OF ARG-987; RP SER-989; ARG-993; PHE-1037 AND MET-1038. RX PubMed=20159463; DOI=10.1016/j.str.2009.12.011; RA Kitano K., Kim S.Y., Hakoshima T.; RT "Structural basis for DNA strand separation by the unconventional winged- RT helix domain of RecQ helicase WRN."; RL Structure 18:177-187(2010). RN [39] {ECO:0007744|PDB:6TYV} RP X-RAY CRYSTALLOGRAPHY (1.93 ANGSTROMS) OF 8-23 IN COMPLEX WITH X.LAEVIS RP XRCC5. RX PubMed=31733588; DOI=10.1016/j.dnarep.2019.102739; RA Kim K., Min J., Kirby T.W., Gabel S.A., Pedersen L.C., London R.E.; RT "Ligand binding characteristics of the Ku80 von Willebrand domain."; RL DNA Repair 85:102739-102739(2020). RN [40] {ECO:0007744|PDB:6YHR} RP X-RAY CRYSTALLOGRAPHY (2.20 ANGSTROMS) OF 517-1093 IN COMPLEX WITH ADP AND RP ZINC, FUNCTION, DOMAIN, AND MUTAGENESIS OF GLU-84; LYS-577 AND GLU-669. RX PubMed=33199508; DOI=10.26508/lsa.202000795; RA Newman J.A., Gavard A.E., Lieb S., Ravichandran M.C., Hauer K., Werni P., RA Geist L., Boettcher J., Engen J.R., Rumpel K., Samwer M., Petronczki M., RA Gileadi O.; RT "Structure of the helicase core of Werner helicase, a key target in RT microsatellite instability cancers."; RL Life. Sci Alliance 4:0-0(2021). RN [41] RP VARIANT ARG-1367. RX PubMed=9021029; RX DOI=10.1002/(sici)1096-8628(19970211)68:4<494::aid-ajmg30>3.0.co;2-l; RA Ye L., Miki T., Nakura J., Oshima J., Kamino K., Rakugi H., Ikegami H., RA Higaki J., Edland S.D., Martin G.M., Ogihara T.; RT "Association of a polymorphic variant of the Werner helicase gene with RT myocardial infarction in a Japanese population."; RL Am. J. Med. Genet. 68:494-498(1997). RN [42] RP ERRATUM OF PUBMED:9021029. RA Ye L., Miki T., Nakura J., Oshima J., Kamino K., Rakugi H., Ikegami H., RA Higaki J., Edland S.D., Martin G.M., Ogihara T.; RL Am. J. Med. Genet. 70:103-103(1997). RN [43] RP VARIANTS ILE-387 AND PHE-1074. RX PubMed=9450180; RA Meisslitzer C., Ruppitsch W., Weirich-Schwaiger H., Weirich H.G., RA Jabkowsky J., Klein G., Schweiger M., Hirsch-Kauffmann M.; RT "Werner syndrome: characterization of mutations in the WRN gene in an RT affected family."; RL Eur. J. Hum. Genet. 5:364-370(1997). RN [44] RP SUBCELLULAR LOCATION, AND INTERACTION WITH RECQL5. RX PubMed=23180761; DOI=10.1093/nar/gks1134; RA Popuri V., Huang J., Ramamoorthy M., Tadokoro T., Croteau D.L., Bohr V.A.; RT "RECQL5 plays co-operative and complementary roles with WRN syndrome RT helicase."; RL Nucleic Acids Res. 41:881-899(2013). RN [45] RP VARIANT ILE-387. RX PubMed=10206685; RX DOI=10.1002/(sici)1098-1004(1998)11:5<413::aid-humu16>3.0.co;2-i; RA Vidal V., Bay J.-O., Champomier F., Grancho M., Beauville L., RA Glowaczower C., Lemery D., Ferrara M., Bignon Y.-J.; RT "The 1396del A mutation and a missense mutation or a rare polymorphism of RT the WRN gene detected in a French Werner family with a severe phenotype and RT a case of an unusual vulvar cancer."; RL Hum. Mutat. 11:413-414(1998). RN [46] RP VARIANTS ALA-324 AND ARG-1367. RX PubMed=10069711; RX DOI=10.1002/(sici)1096-8628(19990219)82:5<399::aid-ajmg8>3.3.co;2-i; RA Castro E., Ogburn C.E., Hunt K.E., Tilvis R., Louhija J., Penttinen R., RA Erkkola R., Panduro A., Riestra R., Piussan C., Deeb S.S., Wang L., RA Edland S.D., Martin G.M., Oshima J.; RT "Polymorphisms at the Werner locus: I. Newly identified polymorphisms, RT ethnic variability of 1367Cys/Arg, and its stability in a population of RT Finnish centenarians."; RL Am. J. Med. Genet. 82:399-403(1999). RN [47] RP VARIANTS ARG-32; ILE-114; PRO-172; LYS-240; TRP-383; ILE-387; LEU-724; RP PHE-1074; GLU-1269 AND ARG-1367. RX PubMed=11161804; DOI=10.1006/geno.2000.6405; RA Passarino G., Shen P., Van Kirk J.B., Lin A.A., De Benedictis G., RA Cavalli-Sforza L.L., Oefner P.J., Underhill P.A.; RT "The Werner syndrome gene and global sequence variation."; RL Genomics 71:118-122(2001). RN [48] RP VARIANTS WRN ASN-125 AND GLU-135. RX PubMed=16673358; DOI=10.1002/humu.20337; RA Huang S., Lee L., Hanson N.B., Lenaerts C., Hoehn H., Poot M., Rubin C.D., RA Chen D.-F., Yang C.-C., Juch H., Dorn T., Spiegel R., Oral E.A., Abid M., RA Battisti C., Lucci-Cordisco E., Neri G., Steed E.H., Kidd A., Isley W., RA Showalter D., Vittone J.L., Konstantinow A., Ring J., Meyer P., RA Wenger S.L., Herbay A.V., Wollina U., Schuelke M., Huizenga C.R., RA Leistritz D.F., Martin G.M., Mian I.S., Oshima J.; RT "The spectrum of WRN mutations in Werner syndrome patients."; RL Hum. Mutat. 27:558-567(2006). RN [49] RP VARIANT [LARGE SCALE ANALYSIS] VAL-92. RX PubMed=16959974; DOI=10.1126/science.1133427; RA Sjoeblom T., Jones S., Wood L.D., Parsons D.W., Lin J., Barber T.D., RA Mandelker D., Leary R.J., Ptak J., Silliman N., Szabo S., Buckhaults P., RA Farrell C., Meeh P., Markowitz S.D., Willis J., Dawson D., Willson J.K.V., RA Gazdar A.F., Hartigan J., Wu L., Liu C., Parmigiani G., Park B.H., RA Bachman K.E., Papadopoulos N., Vogelstein B., Kinzler K.W., RA Velculescu V.E.; RT "The consensus coding sequences of human breast and colorectal cancers."; RL Science 314:268-274(2006). RN [50] RP VARIANT [LARGE SCALE ANALYSIS] LEU-1141. RX PubMed=18987736; DOI=10.1038/nature07485; RA Ley T.J., Mardis E.R., Ding L., Fulton B., McLellan M.D., Chen K., RA Dooling D., Dunford-Shore B.H., McGrath S., Hickenbotham M., Cook L., RA Abbott R., Larson D.E., Koboldt D.C., Pohl C., Smith S., Hawkins A., RA Abbott S., Locke D., Hillier L.W., Miner T., Fulton L., Magrini V., RA Wylie T., Glasscock J., Conyers J., Sander N., Shi X., Osborne J.R., RA Minx P., Gordon D., Chinwalla A., Zhao Y., Ries R.E., Payton J.E., RA Westervelt P., Tomasson M.H., Watson M., Baty J., Ivanovich J., Heath S., RA Shannon W.D., Nagarajan R., Walter M.J., Link D.C., Graubert T.A., RA DiPersio J.F., Wilson R.K.; RT "DNA sequencing of a cytogenetically normal acute myeloid leukaemia RT genome."; RL Nature 456:66-72(2008). CC -!- FUNCTION: Multifunctional enzyme that has magnesium and ATP-dependent CC 3'-5' DNA-helicase activity on partially duplex substrates CC (PubMed:9224595, PubMed:9288107, PubMed:9611231). Also has 3'->5' CC exonuclease activity towards double-stranded (ds)DNA with a 5'-overhang CC (PubMed:11863428). Has no nuclease activity towards single-stranded CC (ss)DNA or blunt-ended dsDNA (PubMed:11863428). Helicase activity is CC most efficient with (d)ATP, but (d)CTP will substitute with reduced CC efficiency; strand displacement is enhanced by single-strand binding- CC protein (heterotrimeric replication protein A complex, RPA1, RPA2, CC RPA3) (PubMed:9611231). Binds preferentially to DNA substrates CC containing alternate secondary structures, such as replication forks CC and Holliday junctions. May play an important role in the dissociation CC of joint DNA molecules that can arise as products of homologous CC recombination, at stalled replication forks or during DNA repair. CC Alleviates stalling of DNA polymerases at the site of DNA lesions. CC Plays a role in the formation of DNA replication focal centers; stably CC associates with foci elements generating binding sites for RP-A (By CC similarity). Plays a role in double-strand break repair after gamma- CC irradiation (PubMed:9224595, PubMed:9288107, PubMed:9611231). Unwinds CC some G-quadruplex DNA (d(CGG)n tracts); unwinding seems to occur in CC both 5'-3' and 3'-5' direction and requires a short single-stranded CC tail (PubMed:10212265). d(CGG)n tracts have a propensity to assemble CC into tetraplex structures; other G-rich substrates from a telomeric or CC IgG switch sequence are not unwound (PubMed:10212265). Depletion leads CC to chromosomal breaks and genome instability (PubMed:33199508). CC {ECO:0000250|UniProtKB:O09053, ECO:0000269|PubMed:10212265, CC ECO:0000269|PubMed:11863428, ECO:0000269|PubMed:17563354, CC ECO:0000269|PubMed:18596042, ECO:0000269|PubMed:19283071, CC ECO:0000269|PubMed:19652551, ECO:0000269|PubMed:21639834, CC ECO:0000269|PubMed:27063109, ECO:0000269|PubMed:33199508, CC ECO:0000269|PubMed:9224595, ECO:0000269|PubMed:9288107, CC ECO:0000269|PubMed:9611231}. CC -!- CATALYTIC ACTIVITY: CC Reaction=Couples ATP hydrolysis with the unwinding of duplex DNA by CC translocating in the 3'-5' direction.; EC=5.6.2.4; CC Evidence={ECO:0000269|PubMed:9611231, ECO:0000305|PubMed:10212265, CC ECO:0000305|PubMed:9224595, ECO:0000305|PubMed:9288107}; CC -!- CATALYTIC ACTIVITY: CC Reaction=ATP + H2O = ADP + phosphate + H(+); Xref=Rhea:RHEA:13065, CC ChEBI:CHEBI:15377, ChEBI:CHEBI:15378, ChEBI:CHEBI:30616, CC ChEBI:CHEBI:43474, ChEBI:CHEBI:456216; EC=5.6.2.4; CC Evidence={ECO:0000269|PubMed:16622405, ECO:0000269|PubMed:9224595, CC ECO:0000269|PubMed:9288107, ECO:0000269|PubMed:9611231}; CC -!- COFACTOR: CC Name=a divalent metal cation; Xref=ChEBI:CHEBI:60240; CC Evidence={ECO:0000269|PubMed:16622405}; CC Note=Binds 2 magnesium or manganese ions in the exonuclease domain; has CC high exonuclease activity with both ions in vitro (PubMed:16622405). CC Unwinding of G-quadruplex DNA requires Mg(2+) (PubMed:10212265). CC {ECO:0000269|PubMed:10212265, ECO:0000269|PubMed:16622405}; CC -!- COFACTOR: CC Name=Zn(2+); Xref=ChEBI:CHEBI:29105; CC Evidence={ECO:0000269|PubMed:33199508, ECO:0000312|PDB:6YHR}; CC Note=Binds a Zn(2+) ion in the helicase domain (PubMed:33199508). CC {ECO:0000269|PubMed:33199508, ECO:0000312|PDB:6YHR}; CC -!- BIOPHYSICOCHEMICAL PROPERTIES: CC Kinetic parameters: CC KM=51 uM for ATP in helicase activity {ECO:0000269|PubMed:9611231}; CC KM=119 uM for dATP in helicase activity {ECO:0000269|PubMed:9611231}; CC KM=2.1 uM for CTP in helicase activity {ECO:0000269|PubMed:9611231}; CC KM=3.9 uM for dCTP in helicase activity {ECO:0000269|PubMed:9611231}; CC -!- SUBUNIT: Monomer, and homooligomer (PubMed:11863428, PubMed:18596042, CC PubMed:20159463). May exist as homodimer, homotrimer, homotetramer CC and/or homohexamer (PubMed:11863428, PubMed:18596042, PubMed:20159463). CC Homotetramer, or homohexamer, when bound to DNA (PubMed:11863428, CC PubMed:18596042, PubMed:20159463). Interacts via its N-terminal domain CC with WRNIP1 (By similarity). Interacts with EXO1, PCNA and SUPV3L1 CC (PubMed:12704184, PubMed:17961633). Interacts with PML (isoform PML-4) CC (PubMed:21639834). Interacts (via KBM motif) with XRCC5 and XRCC6; CC promoting recruitment to DNA damage sites (PubMed:27063109). Interacts CC with RECQL5; this interaction stimulates WRN helicase activity on DNA CC fork duplexes (PubMed:23180761). {ECO:0000250|UniProtKB:O09053, CC ECO:0000269|PubMed:11863428, ECO:0000269|PubMed:12704184, CC ECO:0000269|PubMed:17961633, ECO:0000269|PubMed:18596042, CC ECO:0000269|PubMed:20159463, ECO:0000269|PubMed:21639834, CC ECO:0000269|PubMed:23180761, ECO:0000269|PubMed:27063109}. CC -!- INTERACTION: CC Q14191; P54132: BLM; NbExp=9; IntAct=EBI-368417, EBI-621372; CC Q14191; P45973: CBX5; NbExp=3; IntAct=EBI-368417, EBI-78219; CC Q14191; P39748: FEN1; NbExp=9; IntAct=EBI-368417, EBI-707816; CC Q14191; P16104: H2AX; NbExp=6; IntAct=EBI-368417, EBI-494830; CC Q14191; P09874: PARP1; NbExp=8; IntAct=EBI-368417, EBI-355676; CC Q14191; P43351: RAD52; NbExp=9; IntAct=EBI-368417, EBI-706448; CC Q14191; P27694: RPA1; NbExp=9; IntAct=EBI-368417, EBI-621389; CC Q14191; Q96EB6: SIRT1; NbExp=9; IntAct=EBI-368417, EBI-1802965; CC Q14191; Q15554: TERF2; NbExp=8; IntAct=EBI-368417, EBI-706637; CC Q14191; P04637: TP53; NbExp=5; IntAct=EBI-368417, EBI-366083; CC Q14191; P12956: XRCC6; NbExp=11; IntAct=EBI-368417, EBI-353208; CC -!- SUBCELLULAR LOCATION: Nucleus, nucleolus {ECO:0000269|PubMed:23180761, CC ECO:0000269|PubMed:9618508}. Nucleus {ECO:0000269|PubMed:17563354, CC ECO:0000269|PubMed:19652551, ECO:0000269|PubMed:23180761}. Nucleus, CC nucleoplasm {ECO:0000269|PubMed:21639834}. Chromosome CC {ECO:0000269|PubMed:27063109}. Note=Gamma-irradiation leads to its CC translocation from nucleoli to nucleoplasm and PML regulates the CC irradiation-induced WRN relocation (PubMed:21639834). Localizes to DNA CC damage sites (PubMed:27063109). {ECO:0000269|PubMed:21639834, CC ECO:0000269|PubMed:27063109}. CC -!- DOMAIN: The KBM 2 (Ku-binding motif 2) and XLM (XLF-like motif) mediate CC cooperative interaction with XRCC5/Ku80 and XRCC6/Ku70 and recruitment CC to DNA damage sites (PubMed:27063109). The isolated helicase core CC (residues 517-1093) interacts weakly with the HDRC domain in vitro CC (PubMed:33199508). {ECO:0000269|PubMed:27063109, CC ECO:0000269|PubMed:33199508}. CC -!- PTM: Phosphorylated by PRKDC. {ECO:0000269|PubMed:11889123}. CC -!- DISEASE: Werner syndrome (WRN) [MIM:277700]: A rare autosomal recessive CC progeroid syndrome characterized by the premature onset of multiple CC age-related disorders, including atherosclerosis, cancer, non-insulin- CC dependent diabetes mellitus, ocular cataracts and osteoporosis. The CC major cause of death, at a median age of 47, is myocardial infarction. CC {ECO:0000269|PubMed:16673358}. Note=The disease is caused by variants CC affecting the gene represented in this entry. CC -!- DISEASE: Colorectal cancer (CRC) [MIM:114500]: A complex disease CC characterized by malignant lesions arising from the inner wall of the CC large intestine (the colon) and the rectum. Genetic alterations are CC often associated with progression from premalignant lesion (adenoma) to CC invasive adenocarcinoma. Risk factors for cancer of the colon and CC rectum include colon polyps, long-standing ulcerative colitis, and CC genetic family history. {ECO:0000305|PubMed:24308539, CC ECO:0000305|PubMed:9989816}. Note=The disease may be caused by variants CC affecting the gene represented in this entry. CC -!- SIMILARITY: Belongs to the helicase family. RecQ subfamily. CC {ECO:0000305}. CC -!- WEB RESOURCE: Name=WRN; Note=WRN mutation db (Warner disease); CC URL="http://www.pathology.washington.edu/werner/ws_wrn.html"; CC -!- WEB RESOURCE: Name=Atlas of Genetics and Cytogenetics in Oncology and CC Haematology; CC URL="https://atlasgeneticsoncology.org/gene/284/WRN"; CC --------------------------------------------------------------------------- CC Copyrighted by the UniProt Consortium, see https://www.uniprot.org/terms CC Distributed under the Creative Commons Attribution (CC BY 4.0) License CC --------------------------------------------------------------------------- DR EMBL; L76937; AAC41981.1; -; Genomic_DNA. DR EMBL; AY818673; AAX21098.1; -; mRNA. DR EMBL; AF091214; AAC63361.1; -; mRNA. DR EMBL; AF181897; AAF06162.1; -; Genomic_DNA. DR EMBL; AF181896; AAF06162.1; JOINED; Genomic_DNA. DR EMBL; AY442327; AAR05448.1; -; Genomic_DNA. DR EMBL; AC084736; -; NOT_ANNOTATED_CDS; Genomic_DNA. DR CCDS; CCDS6082.1; -. DR RefSeq; NP_000544.2; NM_000553.6. DR PDB; 2AXL; NMR; -; A=949-1092. DR PDB; 2DGZ; NMR; -; A=1140-1239. DR PDB; 2E1E; X-ray; 2.30 A; A=1142-1242. DR PDB; 2E1F; X-ray; 2.00 A; A=1142-1242. DR PDB; 2FBT; X-ray; 2.05 A; A=38-236. DR PDB; 2FBV; X-ray; 2.40 A; A=38-236. DR PDB; 2FBX; X-ray; 2.20 A; A=38-236. DR PDB; 2FBY; X-ray; 2.00 A; A=38-236. DR PDB; 2FC0; X-ray; 2.00 A; A=38-236. DR PDB; 3AAF; X-ray; 1.90 A; A/B=949-1079. DR PDB; 6TYV; X-ray; 1.93 A; B=8-23. DR PDB; 6YHR; X-ray; 2.20 A; A=517-1093. DR PDB; 7GQS; X-ray; 1.57 A; A=517-945. DR PDB; 7GQT; X-ray; 2.21 A; A=517-945. DR PDB; 7GQU; X-ray; 1.54 A; A=517-945. DR PDB; 7XUT; X-ray; 1.60 A; A/B=435-451. DR PDB; 8PFL; X-ray; 1.80 A; A=517-945. DR PDB; 8PFO; X-ray; 1.90 A; A=517-945. DR PDB; 8PFP; X-ray; 1.60 A; A=517-945. DR PDB; 8YLE; X-ray; 1.86 A; A=517-945. DR PDB; 9OG3; X-ray; 2.06 A; A=526-946. DR PDB; 9OG8; X-ray; 1.66 A; A=526-946. DR PDB; 9OW9; X-ray; 2.34 A; A=500-942. DR PDB; 9OWA; X-ray; 1.98 A; A=500-942. DR PDB; 9OWB; X-ray; 1.56 A; A/B/C/D=500-942. DR PDB; 9OWC; X-ray; 1.67 A; A=500-942. DR PDB; 9OWD; X-ray; 1.96 A; A=500-942. DR PDBsum; 2AXL; -. DR PDBsum; 2DGZ; -. DR PDBsum; 2E1E; -. DR PDBsum; 2E1F; -. DR PDBsum; 2FBT; -. DR PDBsum; 2FBV; -. DR PDBsum; 2FBX; -. DR PDBsum; 2FBY; -. DR PDBsum; 2FC0; -. DR PDBsum; 3AAF; -. DR PDBsum; 6TYV; -. DR PDBsum; 6YHR; -. DR PDBsum; 7GQS; -. DR PDBsum; 7GQT; -. DR PDBsum; 7GQU; -. DR PDBsum; 7XUT; -. DR PDBsum; 8PFL; -. DR PDBsum; 8PFO; -. DR PDBsum; 8PFP; -. DR PDBsum; 8YLE; -. DR PDBsum; 9OG3; -. DR PDBsum; 9OG8; -. DR PDBsum; 9OW9; -. DR PDBsum; 9OWA; -. DR PDBsum; 9OWB; -. DR PDBsum; 9OWC; -. DR PDBsum; 9OWD; -. DR AlphaFoldDB; Q14191; -. DR BMRB; Q14191; -. DR SMR; Q14191; -. DR BioGRID; 113323; 124. DR CORUM; Q14191; -. DR DIP; DIP-31380N; -. DR ELM; Q14191; -. DR FunCoup; Q14191; 2264. DR IntAct; Q14191; 67. DR MINT; Q14191; -. DR STRING; 9606.ENSP00000298139; -. DR BindingDB; Q14191; -. DR ChEMBL; CHEMBL2146312; -. DR GuidetoPHARMACOLOGY; 3259; -. DR GlyGen; Q14191; 1 site, 1 O-linked glycan (1 site). DR iPTMnet; Q14191; -. DR PhosphoSitePlus; Q14191; -. DR SwissPalm; Q14191; -. DR BioMuta; WRN; -. DR DMDM; 322510082; -. DR jPOST; Q14191; -. DR MassIVE; Q14191; -. DR PaxDb; 9606-ENSP00000298139; -. DR PeptideAtlas; Q14191; -. DR ProteomicsDB; 59913; -. DR Pumba; Q14191; -. DR ABCD; Q14191; 1 sequenced antibody. DR Antibodypedia; 10619; 313 antibodies from 41 providers. DR DNASU; 7486; -. DR Ensembl; ENST00000298139.7; ENSP00000298139.5; ENSG00000165392.12. DR GeneID; 7486; -. DR KEGG; hsa:7486; -. DR MANE-Select; ENST00000298139.7; ENSP00000298139.5; NM_000553.6; NP_000544.2. DR UCSC; uc003xio.5; human. DR AGR; HGNC:12791; -. DR ClinPGx; PA367; -. DR CTD; 7486; -. DR DisGeNET; 7486; -. DR GeneCards; WRN; -. DR GeneReviews; WRN; -. DR HGNC; HGNC:12791; WRN. DR HPA; ENSG00000165392; Low tissue specificity. DR MalaCards; WRN; -. DR MIM; 114500; phenotype. DR MIM; 277700; phenotype. DR MIM; 604611; gene. DR OpenTargets; ENSG00000165392; -. DR Orphanet; 902; Werner syndrome. DR VEuPathDB; HostDB:ENSG00000165392; -. DR eggNOG; KOG0351; Eukaryota. DR eggNOG; KOG4373; Eukaryota. DR GeneTree; ENSGT00940000159168; -. DR HOGENOM; CLU_001103_11_1_1; -. DR InParanoid; Q14191; -. DR OMA; TYLIHMV; -. DR OrthoDB; 10261556at2759; -. DR PAN-GO; Q14191; 11 GO annotations based on evolutionary models. DR PhylomeDB; Q14191; -. DR BRENDA; 3.6.4.12; 2681. DR PathwayCommons; Q14191; -. DR Reactome; R-HSA-174414; Processive synthesis on the C-strand of the telomere. DR Reactome; R-HSA-174437; Removal of the Flap Intermediate from the C-strand. DR Reactome; R-HSA-3108214; SUMOylation of DNA damage response and repair proteins. DR Reactome; R-HSA-5685938; HDR through Single Strand Annealing (SSA). DR Reactome; R-HSA-5685942; HDR through Homologous Recombination (HRR). DR Reactome; R-HSA-5693554; Resolution of D-loop Structures through Synthesis-Dependent Strand Annealing (SDSA). DR Reactome; R-HSA-5693568; Resolution of D-loop Structures through Holliday Junction Intermediates. DR Reactome; R-HSA-5693579; Homologous DNA Pairing and Strand Exchange. DR Reactome; R-HSA-5693607; Processing of DNA double-strand break ends. DR Reactome; R-HSA-5693616; Presynaptic phase of homologous DNA pairing and strand exchange. DR Reactome; R-HSA-6804756; Regulation of TP53 Activity through Phosphorylation. DR Reactome; R-HSA-69473; G2/M DNA damage checkpoint. DR Reactome; R-HSA-9701192; Defective homologous recombination repair (HRR) due to BRCA1 loss of function. DR Reactome; R-HSA-9704331; Defective HDR through Homologous Recombination Repair (HRR) due to PALB2 loss of BRCA1 binding function. DR Reactome; R-HSA-9704646; Defective HDR through Homologous Recombination Repair (HRR) due to PALB2 loss of BRCA2/RAD51/RAD51C binding function. DR Reactome; R-HSA-9709570; Impaired BRCA2 binding to RAD51. DR Reactome; R-HSA-9709603; Impaired BRCA2 binding to PALB2. DR SignaLink; Q14191; -. DR SIGNOR; Q14191; -. DR Agora; ENSG00000165392; -. DR BioGRID-ORCS; 7486; 55 hits in 1158 CRISPR screens. DR CD-CODE; 8C2F96ED; Centrosome. DR CD-CODE; 91857CE7; Nucleolus. DR CD-CODE; B5B9A610; PML body. DR ChiTaRS; WRN; human. DR EvolutionaryTrace; Q14191; -. DR GeneWiki; Werner_syndrome_ATP-dependent_helicase; -. DR GenomeRNAi; 7486; -. DR Pharos; Q14191; Tbio. DR PRO; PR:Q14191; -. DR Proteomes; UP000005640; Chromosome 8. DR RNAct; Q14191; protein. DR Bgee; ENSG00000165392; Expressed in calcaneal tendon and 165 other cell types or tissues. DR ExpressionAtlas; Q14191; baseline and differential. DR GO; GO:0005813; C:centrosome; IDA:UniProtKB. DR GO; GO:0005694; C:chromosome; IBA:GO_Central. DR GO; GO:0000781; C:chromosome, telomeric region; IDA:BHF-UCL. DR GO; GO:0005737; C:cytoplasm; IBA:GO_Central. DR GO; GO:0016607; C:nuclear speck; IDA:HPA. DR GO; GO:0005730; C:nucleolus; IDA:UniProtKB. DR GO; GO:0005654; C:nucleoplasm; IDA:UniProtKB. DR GO; GO:0005634; C:nucleus; IBA:GO_Central. DR GO; GO:0005657; C:replication fork; ISS:BHF-UCL. DR GO; GO:0043138; F:3'-5' DNA helicase activity; IDA:UniProtKB. DR GO; GO:0008408; F:3'-5' exonuclease activity; IDA:UniProtKB. DR GO; GO:0070337; F:3'-flap-structured DNA binding; IDA:BHF-UCL. DR GO; GO:1905773; F:8-hydroxy-2'-deoxyguanosine DNA binding; IDA:BHF-UCL. DR GO; GO:0005524; F:ATP binding; IEA:UniProtKB-KW. DR GO; GO:0016887; F:ATP hydrolysis activity; IDA:UniProtKB. DR GO; GO:0000405; F:bubble DNA binding; IDA:UniProtKB. DR GO; GO:0003677; F:DNA binding; IDA:UniProtKB. DR GO; GO:0003678; F:DNA helicase activity; IDA:UniProtKB. DR GO; GO:0004527; F:exonuclease activity; IDA:MGI. DR GO; GO:0061749; F:forked DNA-dependent helicase activity; IDA:BHF-UCL. DR GO; GO:0000400; F:four-way junction DNA binding; IDA:BHF-UCL. DR GO; GO:0009378; F:four-way junction helicase activity; IDA:UniProtKB. DR GO; GO:0051880; F:G-quadruplex DNA binding; IDA:UniProtKB. DR GO; GO:0000287; F:magnesium ion binding; IDA:UniProtKB. DR GO; GO:0030145; F:manganese ion binding; IDA:UniProtKB. DR GO; GO:0032405; F:MutLalpha complex binding; IDA:UniProtKB. DR GO; GO:0042803; F:protein homodimerization activity; IDA:UniProtKB. DR GO; GO:0044877; F:protein-containing complex binding; IDA:UniProtKB. DR GO; GO:0061821; F:telomeric D-loop binding; IDA:BHF-UCL. DR GO; GO:0061849; F:telomeric G-quadruplex DNA binding; IDA:BHF-UCL. DR GO; GO:0000403; F:Y-form DNA binding; IDA:UniProtKB. DR GO; GO:0006284; P:base-excision repair; IDA:UniProtKB. DR GO; GO:0071480; P:cellular response to gamma radiation; IDA:UniProtKB. DR GO; GO:0009267; P:cellular response to starvation; IDA:MGI. DR GO; GO:0090398; P:cellular senescence; IMP:GO_Central. DR GO; GO:0008340; P:determination of adult lifespan; IEA:Ensembl. DR GO; GO:0006974; P:DNA damage response; IDA:UniProtKB. DR GO; GO:0032392; P:DNA geometric change; IDA:BHF-UCL. DR GO; GO:0006259; P:DNA metabolic process; IDA:UniProtKB. DR GO; GO:0006260; P:DNA replication; IMP:UniProtKB. DR GO; GO:0000731; P:DNA synthesis involved in DNA repair; IDA:UniProtKB. DR GO; GO:0006302; P:double-strand break repair; IMP:UniProtKB. DR GO; GO:0000724; P:double-strand break repair via homologous recombination; IBA:GO_Central. DR GO; GO:0006298; P:mismatch repair; IDA:BHF-UCL. DR GO; GO:0051345; P:positive regulation of hydrolase activity; IDA:UniProtKB. DR GO; GO:0098530; P:positive regulation of strand invasion; IDA:BHF-UCL. DR GO; GO:1902570; P:protein localization to nucleolus; IDA:MGI. DR GO; GO:0040009; P:regulation of growth rate; IEA:Ensembl. DR GO; GO:0031297; P:replication fork processing; IDA:UniProtKB. DR GO; GO:0090399; P:replicative senescence; IEA:Ensembl. DR GO; GO:0006979; P:response to oxidative stress; IDA:UniProtKB. DR GO; GO:0010225; P:response to UV-C; IDA:UniProtKB. DR GO; GO:0090656; P:t-circle formation; TAS:BHF-UCL. DR GO; GO:0000723; P:telomere maintenance; IDA:BHF-UCL. DR GO; GO:0032201; P:telomere maintenance via semi-conservative replication; TAS:Reactome. DR GO; GO:0061820; P:telomeric D-loop disassembly; IDA:BHF-UCL. DR CDD; cd18017; DEXHc_RecQ3; 1. DR CDD; cd06129; RNaseD_like; 1. DR CDD; cd18794; SF2_C_RecQ; 1. DR DisProt; DP00443; -. DR FunFam; 1.10.10.10:FF:000369; Werner syndrome ATP-dependent helicase; 1. DR FunFam; 1.10.150.80:FF:000005; Werner syndrome ATP-dependent helicase homolog; 1. DR FunFam; 3.30.420.10:FF:000053; Werner syndrome ATP-dependent helicase homolog; 1. DR FunFam; 3.40.50.300:FF:000941; Werner syndrome RecQ like helicase; 1. DR FunFam; 3.40.50.300:FF:001023; Werner syndrome RecQ like helicase; 1. DR Gene3D; 1.10.150.80; HRDC domain; 1. DR Gene3D; 3.40.50.300; P-loop containing nucleotide triphosphate hydrolases; 2. DR Gene3D; 3.30.420.10; Ribonuclease H-like superfamily/Ribonuclease H; 1. DR Gene3D; 1.10.10.10; Winged helix-like DNA-binding domain superfamily/Winged helix DNA-binding domain; 1. DR IDEAL; IID00246; -. DR InterPro; IPR002562; 3'-5'_exonuclease_dom. DR InterPro; IPR011545; DEAD/DEAH_box_helicase_dom. DR InterPro; IPR004589; DNA_helicase_ATP-dep_RecQ. DR InterPro; IPR014001; Helicase_ATP-bd. DR InterPro; IPR001650; Helicase_C-like. DR InterPro; IPR029491; Helicase_HTH. DR InterPro; IPR010997; HRDC-like_sf. DR InterPro; IPR002121; HRDC_dom. DR InterPro; IPR044876; HRDC_dom_sf. DR InterPro; IPR027417; P-loop_NTPase. DR InterPro; IPR032284; RecQ_Zn-bd. DR InterPro; IPR012337; RNaseH-like_sf. DR InterPro; IPR036397; RNaseH_sf. DR InterPro; IPR018982; RQC_domain. DR InterPro; IPR036388; WH-like_DNA-bd_sf. DR InterPro; IPR036390; WH_DNA-bd_sf. DR NCBIfam; TIGR00614; recQ_fam; 1. DR PANTHER; PTHR13710:SF120; BIFUNCTIONAL 3'-5' EXONUCLEASE_ATP-DEPENDENT HELICASE WRN; 1. DR PANTHER; PTHR13710; DNA HELICASE RECQ FAMILY MEMBER; 1. DR Pfam; PF00270; DEAD; 1. DR Pfam; PF01612; DNA_pol_A_exo1; 1. DR Pfam; PF00271; Helicase_C; 1. DR Pfam; PF00570; HRDC; 1. DR Pfam; PF14493; HTH_40; 1. DR Pfam; PF16124; RecQ_Zn_bind; 1. DR Pfam; PF09382; RQC; 1. DR SMART; SM00474; 35EXOc; 1. DR SMART; SM00487; DEXDc; 1. DR SMART; SM00490; HELICc; 1. DR SMART; SM00341; HRDC; 1. DR SMART; SM00956; RQC; 1. DR SUPFAM; SSF47819; HRDC-like; 1. DR SUPFAM; SSF52540; P-loop containing nucleoside triphosphate hydrolases; 1. DR SUPFAM; SSF53098; Ribonuclease H-like; 1. DR SUPFAM; SSF46785; Winged helix' DNA-binding domain; 1. DR PROSITE; PS51192; HELICASE_ATP_BIND_1; 1. DR PROSITE; PS51194; HELICASE_CTER; 1. DR PROSITE; PS50967; HRDC; 1. PE 1: Evidence at protein level; KW 3D-structure; Acetylation; ATP-binding; Chromosome; KW Direct protein sequencing; Disease variant; DNA damage; DNA repair; KW DNA-binding; Exonuclease; Helicase; Hydrolase; Isomerase; Isopeptide bond; KW Magnesium; Metal-binding; Multifunctional enzyme; Nuclease; KW Nucleotide-binding; Nucleus; Phosphoprotein; Proteomics identification; KW Reference proteome; Repeat; Ubl conjugation; Zinc. FT INIT_MET 1 FT /note="Removed" FT /evidence="ECO:0007744|PubMed:22814378" FT CHAIN 2..1432 FT /note="Bifunctional 3'-5' exonuclease/ATP-dependent FT helicase WRN" FT /id="PRO_0000205045" FT DOMAIN 60..228 FT /note="3'-5' exonuclease" FT /evidence="ECO:0000255, ECO:0000269|PubMed:11863428" FT REPEAT 424..450 FT /note="1" FT /evidence="ECO:0000269|PubMed:10049920" FT REPEAT 451..477 FT /note="2" FT /evidence="ECO:0000269|PubMed:10049920" FT DOMAIN 558..724 FT /note="Helicase ATP-binding" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00541" FT DOMAIN 749..899 FT /note="Helicase C-terminal" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00542" FT DOMAIN 1150..1229 FT /note="HRDC" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00328" FT REGION 2..277 FT /note="Interaction with WRNIP1" FT /evidence="ECO:0000250|UniProtKB:O09053" FT REGION 424..477 FT /note="2 X 27 AA tandem repeats of H-L-S-P-N-D-N-E-N-D-T-S- FT Y-V-I-E-S-D-E-D-L-E-M-E-M-L-K" FT REGION 498..529 FT /note="Disordered" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT REGION 987..993 FT /note="Interaction with DNA" FT /evidence="ECO:0000269|PubMed:20159463" FT MOTIF 11..23 FT /note="KBM 1" FT /evidence="ECO:0000305|PubMed:27063109" FT MOTIF 668..671 FT /note="DEAH box" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00541" FT MOTIF 1403..1412 FT /note="KBM 2" FT /evidence="ECO:0000305|PubMed:27063109" FT MOTIF 1419..1432 FT /note="XLM" FT /evidence="ECO:0000305|PubMed:27063109" FT COMPBIAS 507..525 FT /note="Acidic residues" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT BINDING 82 FT /ligand="Mn(2+)" FT /ligand_id="ChEBI:CHEBI:29035" FT /ligand_label="1" FT /ligand_note="catalytic" FT /evidence="ECO:0000269|PubMed:16622405, FT ECO:0007744|PDB:2FBV, ECO:0007744|PDB:2FBX, FT ECO:0007744|PDB:2FC0" FT BINDING 82 FT /ligand="Mn(2+)" FT /ligand_id="ChEBI:CHEBI:29035" FT /ligand_label="2" FT /ligand_note="catalytic" FT /evidence="ECO:0000269|PubMed:16622405, FT ECO:0007744|PDB:2FBV, ECO:0007744|PDB:2FBX, FT ECO:0007744|PDB:2FC0" FT BINDING 84 FT /ligand="Mn(2+)" FT /ligand_id="ChEBI:CHEBI:29035" FT /ligand_label="1" FT /ligand_note="catalytic" FT /evidence="ECO:0000269|PubMed:16622405, FT ECO:0007744|PDB:2FBV, ECO:0007744|PDB:2FBX, FT ECO:0007744|PDB:2FC0" FT BINDING 216 FT /ligand="Mn(2+)" FT /ligand_id="ChEBI:CHEBI:29035" FT /ligand_label="1" FT /ligand_note="catalytic" FT /evidence="ECO:0000269|PubMed:16622405, FT ECO:0007744|PDB:2FBV, ECO:0007744|PDB:2FBX, FT ECO:0007744|PDB:2FC0" FT BINDING 546 FT /ligand="ATP" FT /ligand_id="ChEBI:CHEBI:30616" FT /evidence="ECO:0000305|PubMed:33199508, FT ECO:0000312|PDB:6YHR" FT BINDING 548 FT /ligand="ATP" FT /ligand_id="ChEBI:CHEBI:30616" FT /evidence="ECO:0000312|PDB:6YHR" FT BINDING 550 FT /ligand="ATP" FT /ligand_id="ChEBI:CHEBI:30616" FT /evidence="ECO:0000305|PubMed:33199508" FT BINDING 553 FT /ligand="ATP" FT /ligand_id="ChEBI:CHEBI:30616" FT /evidence="ECO:0000305|PubMed:33199508, FT ECO:0000312|PDB:6YHR" FT BINDING 574 FT /ligand="ATP" FT /ligand_id="ChEBI:CHEBI:30616" FT /evidence="ECO:0000312|PDB:6YHR" FT BINDING 908 FT /ligand="Zn(2+)" FT /ligand_id="ChEBI:CHEBI:29105" FT /evidence="ECO:0000269|PubMed:33199508, FT ECO:0000312|PDB:6YHR" FT BINDING 935 FT /ligand="Zn(2+)" FT /ligand_id="ChEBI:CHEBI:29105" FT /evidence="ECO:0000269|PubMed:33199508, FT ECO:0000312|PDB:6YHR" FT BINDING 936 FT /ligand="Zn(2+)" FT /ligand_id="ChEBI:CHEBI:29105" FT /evidence="ECO:0000269|PubMed:33199508, FT ECO:0000312|PDB:6YHR" FT BINDING 939 FT /ligand="Zn(2+)" FT /ligand_id="ChEBI:CHEBI:29105" FT /evidence="ECO:0000269|PubMed:33199508, FT ECO:0000312|PDB:6YHR" FT SITE 145 FT /note="Interaction with DNA" FT /evidence="ECO:0000305|PubMed:20159463" FT SITE 1037 FT /note="Interaction with DNA" FT /evidence="ECO:0000305|PubMed:20159463" FT MOD_RES 2 FT /note="N-acetylserine" FT /evidence="ECO:0007744|PubMed:22814378" FT MOD_RES 426 FT /note="Phosphoserine" FT /evidence="ECO:0007744|PubMed:19690332" FT MOD_RES 440 FT /note="Phosphoserine" FT /evidence="ECO:0007744|PubMed:18669648, FT ECO:0007744|PubMed:19690332" FT MOD_RES 453 FT /note="Phosphoserine" FT /evidence="ECO:0007744|PubMed:19690332" FT MOD_RES 467 FT /note="Phosphoserine" FT /evidence="ECO:0007744|PubMed:18669648, FT ECO:0007744|PubMed:19690332" FT MOD_RES 478 FT /note="Phosphoserine" FT /evidence="ECO:0007744|PubMed:23186163" FT MOD_RES 1133 FT /note="Phosphoserine" FT /evidence="ECO:0007744|PubMed:21406692, FT ECO:0007744|PubMed:23186163" FT MOD_RES 1400 FT /note="Phosphoserine" FT /evidence="ECO:0007744|PubMed:23186163" FT CROSSLNK 154 FT /note="Glycyl lysine isopeptide (Lys-Gly) (interchain with FT G-Cter in SUMO2)" FT /evidence="ECO:0007744|PubMed:28112733" FT CROSSLNK 241 FT /note="Glycyl lysine isopeptide (Lys-Gly) (interchain with FT G-Cter in SUMO2)" FT /evidence="ECO:0007744|PubMed:28112733" FT CROSSLNK 252 FT /note="Glycyl lysine isopeptide (Lys-Gly) (interchain with FT G-Cter in SUMO2)" FT /evidence="ECO:0007744|PubMed:28112733" FT VARIANT 32 FT /note="K -> R (in dbSNP:rs34477820)" FT /evidence="ECO:0000269|PubMed:11161804" FT /id="VAR_017453" FT VARIANT 92 FT /note="G -> V (in a colorectal cancer sample; somatic FT mutation)" FT /evidence="ECO:0000269|PubMed:16959974" FT /id="VAR_036318" FT VARIANT 114 FT /note="V -> I (no effect on exonuclease activity; FT dbSNP:rs2230009)" FT /evidence="ECO:0000269|PubMed:11161804, FT ECO:0000269|PubMed:16622405, ECO:0000269|Ref.4" FT /id="VAR_017454" FT VARIANT 125 FT /note="K -> N (in WRN; dbSNP:rs387906337)" FT /evidence="ECO:0000269|PubMed:16673358" FT /id="VAR_026588" FT VARIANT 135 FT /note="K -> E (in WRN; dbSNP:rs267607008)" FT /evidence="ECO:0000269|PubMed:16673358" FT /id="VAR_026589" FT VARIANT 172 FT /note="T -> P (no effect on exonuclease activity; FT dbSNP:rs367991517)" FT /evidence="ECO:0000269|PubMed:11161804, FT ECO:0000269|PubMed:16622405" FT /id="VAR_017455" FT VARIANT 240 FT /note="N -> K (in dbSNP:rs148229804)" FT /evidence="ECO:0000269|PubMed:11161804" FT /id="VAR_017456" FT VARIANT 324 FT /note="T -> A (in dbSNP:rs1800390)" FT /evidence="ECO:0000269|PubMed:10069711" FT /id="VAR_006904" FT VARIANT 329 FT /note="Q -> R (in dbSNP:rs4987237)" FT /id="VAR_020450" FT VARIANT 343 FT /note="E -> K (in dbSNP:rs11574222)" FT /evidence="ECO:0000269|Ref.4" FT /id="VAR_018941" FT VARIANT 383 FT /note="L -> F (in dbSNP:rs4987238)" FT /id="VAR_020451" FT VARIANT 383 FT /note="L -> W" FT /evidence="ECO:0000269|PubMed:11161804" FT /id="VAR_017457" FT VARIANT 387 FT /note="M -> I (in dbSNP:rs1800391)" FT /evidence="ECO:0000269|PubMed:10206685, FT ECO:0000269|PubMed:11161804, ECO:0000269|PubMed:9450180, FT ECO:0000269|Ref.4" FT /id="VAR_006905" FT VARIANT 533 FT /note="N -> S (in dbSNP:rs11574240)" FT /evidence="ECO:0000269|Ref.4" FT /id="VAR_018942" FT VARIANT 612 FT /note="S -> C (in dbSNP:rs11574250)" FT /evidence="ECO:0000269|Ref.4" FT /id="VAR_018943" FT VARIANT 708 FT /note="S -> F (in dbSNP:rs11574289)" FT /evidence="ECO:0000269|Ref.4" FT /id="VAR_018944" FT VARIANT 711 FT /note="R -> W (in dbSNP:rs34560788)" FT /id="VAR_057124" FT VARIANT 724 FT /note="Q -> L" FT /evidence="ECO:0000269|PubMed:11161804" FT /id="VAR_017458" FT VARIANT 834 FT /note="R -> C (in dbSNP:rs3087425)" FT /evidence="ECO:0000269|Ref.4" FT /id="VAR_014913" FT VARIANT 912 FT /note="I -> S (in dbSNP:rs11574323)" FT /evidence="ECO:0000269|Ref.4" FT /id="VAR_018945" FT VARIANT 1074 FT /note="L -> F (in dbSNP:rs1801195)" FT /evidence="ECO:0000269|PubMed:11161804, FT ECO:0000269|PubMed:16723399, ECO:0000269|PubMed:8602509, FT ECO:0000269|PubMed:9450180, ECO:0000269|Ref.3" FT /id="VAR_007903" FT VARIANT 1079 FT /note="S -> L (in dbSNP:rs3087414)" FT /evidence="ECO:0000269|Ref.4" FT /id="VAR_014914" FT VARIANT 1133 FT /note="S -> A (in dbSNP:rs11574358)" FT /evidence="ECO:0000269|Ref.4" FT /id="VAR_018946" FT VARIANT 1141 FT /note="S -> L (in dbSNP:rs139323683)" FT /evidence="ECO:0000269|PubMed:18987736" FT /id="VAR_054162" FT VARIANT 1269 FT /note="K -> E (in dbSNP:rs746648510)" FT /evidence="ECO:0000269|PubMed:11161804" FT /id="VAR_017459" FT VARIANT 1339 FT /note="V -> I (in dbSNP:rs11574395)" FT /evidence="ECO:0000269|Ref.4" FT /id="VAR_018947" FT VARIANT 1367 FT /note="C -> R (associated with a higher risk of myocardial FT infarction; dbSNP:rs1346044)" FT /evidence="ECO:0000269|PubMed:10069711, FT ECO:0000269|PubMed:11161804, ECO:0000269|PubMed:9021029, FT ECO:0000269|Ref.4" FT /id="VAR_006906" FT MUTAGEN 18 FT /note="W->G: Abolished interaction with XRCC5 and XRCC6." FT /evidence="ECO:0000269|PubMed:27063109" FT MUTAGEN 84 FT /note="E->A: Abolishes exonuclease activity. Restores FT chromosome stability in depletion experiments." FT /evidence="ECO:0000269|PubMed:11863428, FT ECO:0000269|PubMed:16622405, ECO:0000269|PubMed:27063109, FT ECO:0000269|PubMed:33199508" FT MUTAGEN 88 FT /note="L->A: No effect on exonuclease activity." FT MUTAGEN 145 FT /note="W->A: Reduces exonuclease activity." FT /evidence="ECO:0000269|PubMed:16622405" FT MUTAGEN 212 FT /note="Y->F: Strongly reduces exonuclease activity." FT /evidence="ECO:0000269|PubMed:16622405" FT MUTAGEN 577 FT /note="K->M: Loss of helicase activity, loss of DNA- FT dependent ATPase activity. Does not restore chromosome FT stability in depletion experiments." FT /evidence="ECO:0000269|PubMed:33199508, FT ECO:0000269|PubMed:9288107" FT MUTAGEN 669 FT /note="E->A: Does not restore chromosome stability in FT depletion experiments." FT /evidence="ECO:0000269|PubMed:33199508" FT MUTAGEN 987 FT /note="R->A: Reduces affinity for DNA about 8-fold. Loss of FT DNA binding; when associated with A-993." FT /evidence="ECO:0000269|PubMed:20159463" FT MUTAGEN 989 FT /note="S->A: Reduces affinity for DNA about 4-fold." FT /evidence="ECO:0000269|PubMed:20159463" FT MUTAGEN 993 FT /note="R->A: Reduces affinity for DNA about 20-fold. Loss FT of DNA binding; when associated with A-987." FT /evidence="ECO:0000269|PubMed:20159463" FT MUTAGEN 993 FT /note="R->E: Loss of DNA binding." FT /evidence="ECO:0000269|PubMed:20159463" FT MUTAGEN 1037 FT /note="F->A: Reduces affinity for DNA about 8-fold." FT /evidence="ECO:0000269|PubMed:20159463" FT MUTAGEN 1038 FT /note="M->A: Reduces affinity for DNA about 4-fold." FT /evidence="ECO:0000269|PubMed:20159463" FT HELIX 17..19 FT /evidence="ECO:0007829|PDB:6TYV" FT HELIX 39..41 FT /evidence="ECO:0007829|PDB:2FBY" FT STRAND 51..56 FT /evidence="ECO:0007829|PDB:2FBY" FT HELIX 59..72 FT /evidence="ECO:0007829|PDB:2FBY" FT STRAND 78..84 FT /evidence="ECO:0007829|PDB:2FBY" FT STRAND 99..105 FT /evidence="ECO:0007829|PDB:2FBY" FT STRAND 108..112 FT /evidence="ECO:0007829|PDB:2FBY" FT HELIX 114..116 FT /evidence="ECO:0007829|PDB:2FBY" FT STRAND 117..119 FT /evidence="ECO:0007829|PDB:2FBY" FT HELIX 122..128 FT /evidence="ECO:0007829|PDB:2FBY" FT STRAND 133..139 FT /evidence="ECO:0007829|PDB:2FBY" FT HELIX 140..151 FT /evidence="ECO:0007829|PDB:2FBY" FT STRAND 157..160 FT /evidence="ECO:0007829|PDB:2FBY" FT HELIX 161..169 FT /evidence="ECO:0007829|PDB:2FBY" FT HELIX 177..185 FT /evidence="ECO:0007829|PDB:2FBY" FT HELIX 193..196 FT /evidence="ECO:0007829|PDB:2FBY" FT STRAND 202..204 FT /evidence="ECO:0007829|PDB:2FBY" FT HELIX 207..228 FT /evidence="ECO:0007829|PDB:2FBY" FT HELIX 435..447 FT /evidence="ECO:0007829|PDB:7XUT" FT HELIX 524..527 FT /evidence="ECO:0007829|PDB:8PFL" FT HELIX 534..544 FT /evidence="ECO:0007829|PDB:7GQU" FT HELIX 551..563 FT /evidence="ECO:0007829|PDB:7GQU" FT STRAND 567..570 FT /evidence="ECO:0007829|PDB:7GQU" FT TURN 575..577 FT /evidence="ECO:0007829|PDB:8PFL" FT HELIX 579..588 FT /evidence="ECO:0007829|PDB:7GQU" FT STRAND 590..595 FT /evidence="ECO:0007829|PDB:7GQU" FT HELIX 599..611 FT /evidence="ECO:0007829|PDB:7GQU" FT STRAND 616..618 FT /evidence="ECO:0007829|PDB:7GQU" FT HELIX 625..632 FT /evidence="ECO:0007829|PDB:7GQU" FT STRAND 637..641 FT /evidence="ECO:0007829|PDB:7GQU" FT HELIX 643..648 FT /evidence="ECO:0007829|PDB:7GQU" FT HELIX 650..659 FT /evidence="ECO:0007829|PDB:7GQU" FT STRAND 662..667 FT /evidence="ECO:0007829|PDB:7GQU" FT HELIX 670..673 FT /evidence="ECO:0007829|PDB:7GQU" FT STRAND 677..679 FT /evidence="ECO:0007829|PDB:8PFL" FT HELIX 682..688 FT /evidence="ECO:0007829|PDB:7GQU" FT HELIX 689..693 FT /evidence="ECO:0007829|PDB:7GQU" FT STRAND 699..704 FT /evidence="ECO:0007829|PDB:7GQU" FT HELIX 708..718 FT /evidence="ECO:0007829|PDB:7GQU" FT STRAND 724..727 FT /evidence="ECO:0007829|PDB:7GQU" FT STRAND 735..741 FT /evidence="ECO:0007829|PDB:7GQU" FT HELIX 746..750 FT /evidence="ECO:0007829|PDB:7GQU" FT HELIX 751..753 FT /evidence="ECO:0007829|PDB:7GQU" FT STRAND 754..756 FT /evidence="ECO:0007829|PDB:7GQU" FT STRAND 761..765 FT /evidence="ECO:0007829|PDB:7GQU" FT STRAND 767..770 FT /evidence="ECO:0007829|PDB:7GQU" FT HELIX 774..786 FT /evidence="ECO:0007829|PDB:7GQU" FT STRAND 791..795 FT /evidence="ECO:0007829|PDB:7GQU" FT HELIX 800..811 FT /evidence="ECO:0007829|PDB:7GQU" FT STRAND 816..821 FT /evidence="ECO:0007829|PDB:7GQU" FT HELIX 826..828 FT /evidence="ECO:0007829|PDB:7GQS" FT STRAND 835..840 FT /evidence="ECO:0007829|PDB:7GQU" FT HELIX 845..853 FT /evidence="ECO:0007829|PDB:7GQU" FT STRAND 862..868 FT /evidence="ECO:0007829|PDB:7GQU" FT HELIX 873..875 FT /evidence="ECO:0007829|PDB:7GQU" FT HELIX 877..879 FT /evidence="ECO:0007829|PDB:7GQS" FT HELIX 886..904 FT /evidence="ECO:0007829|PDB:7GQU" FT HELIX 909..915 FT /evidence="ECO:0007829|PDB:7GQU" FT STRAND 917..919 FT /evidence="ECO:0007829|PDB:7GQU" FT HELIX 924..929 FT /evidence="ECO:0007829|PDB:7GQU" FT TURN 933..935 FT /evidence="ECO:0007829|PDB:7GQU" FT HELIX 937..944 FT /evidence="ECO:0007829|PDB:7GQU" FT STRAND 956..958 FT /evidence="ECO:0007829|PDB:6YHR" FT HELIX 960..972 FT /evidence="ECO:0007829|PDB:3AAF" FT TURN 973..975 FT /evidence="ECO:0007829|PDB:3AAF" FT HELIX 980..986 FT /evidence="ECO:0007829|PDB:3AAF" FT HELIX 996..1000 FT /evidence="ECO:0007829|PDB:3AAF" FT TURN 1002..1009 FT /evidence="ECO:0007829|PDB:3AAF" FT HELIX 1012..1024 FT /evidence="ECO:0007829|PDB:3AAF" FT STRAND 1027..1032 FT /evidence="ECO:0007829|PDB:3AAF" FT TURN 1036..1038 FT /evidence="ECO:0007829|PDB:2AXL" FT STRAND 1039..1043 FT /evidence="ECO:0007829|PDB:3AAF" FT HELIX 1045..1054 FT /evidence="ECO:0007829|PDB:3AAF" FT STRAND 1062..1064 FT /evidence="ECO:0007829|PDB:6YHR" FT TURN 1067..1069 FT /evidence="ECO:0007829|PDB:6YHR" FT HELIX 1147..1171 FT /evidence="ECO:0007829|PDB:2E1F" FT HELIX 1175..1178 FT /evidence="ECO:0007829|PDB:2E1F" FT HELIX 1181..1190 FT /evidence="ECO:0007829|PDB:2E1F" FT HELIX 1195..1198 FT /evidence="ECO:0007829|PDB:2E1F" FT STRAND 1201..1203 FT /evidence="ECO:0007829|PDB:2DGZ" FT HELIX 1206..1211 FT /evidence="ECO:0007829|PDB:2E1F" FT HELIX 1213..1225 FT /evidence="ECO:0007829|PDB:2E1F" SQ SEQUENCE 1432 AA; 162461 MW; 63F10D19E90AA461 CRC64; MSEKKLETTA QQRKCPEWMN VQNKRCAVEE RKACVRKSVF EDDLPFLEFT GSIVYSYDAS DCSFLSEDIS MSLSDGDVVG FDMEWPPLYN RGKLGKVALI QLCVSESKCY LFHVSSMSVF PQGLKMLLEN KAVKKAGVGI EGDQWKLLRD FDIKLKNFVE LTDVANKKLK CTETWSLNSL VKHLLGKQLL KDKSIRCSNW SKFPLTEDQK LYAATDAYAG FIIYRNLEIL DDTVQRFAIN KEEEILLSDM NKQLTSISEE VMDLAKHLPH AFSKLENPRR VSILLKDISE NLYSLRRMII GSTNIETELR PSNNLNLLSF EDSTTGGVQQ KQIREHEVLI HVEDETWDPT LDHLAKHDGE DVLGNKVERK EDGFEDGVED NKLKENMERA CLMSLDITEH ELQILEQQSQ EEYLSDIAYK STEHLSPNDN ENDTSYVIES DEDLEMEMLK HLSPNDNEND TSYVIESDED LEMEMLKSLE NLNSGTVEPT HSKCLKMERN LGLPTKEEEE DDENEANEGE EDDDKDFLWP APNEEQVTCL KMYFGHSSFK PVQWKVIHSV LEERRDNVAV MATGYGKSLC FQYPPVYVGK IGLVISPLIS LMEDQVLQLK MSNIPACFLG SAQSENVLTD IKLGKYRIVY VTPEYCSGNM GLLQQLEADI GITLIAVDEA HCISEWGHDF RDSFRKLGSL KTALPMVPIV ALTATASSSI REDIVRCLNL RNPQITCTGF DRPNLYLEVR RKTGNILQDL QPFLVKTSSH WEFEGPTIIY CPSRKMTQQV TGELRKLNLS CGTYHAGMSF STRKDIHHRF VRDEIQCVIA TIAFGMGINK ADIRQVIHYG APKDMESYYQ EIGRAGRDGL QSSCHVLWAP ADINLNRHLL TEIRNEKFRL YKLKMMAKME KYLHSSRCRR QIILSHFEDK QVQKASLGIM GTEKCCDNCR SRLDHCYSMD DSEDTSWDFG PQAFKLLSAV DILGEKFGIG LPILFLRGSN SQRLADQYRR HSLFGTGKDQ TESWWKAFSR QLITEGFLVE VSRYNKFMKI CALTKKGRNW LHKANTESQS LILQANEELC PKKLLLPSSK TVSSGTKEHC YNQVPVELST EKKSNLEKLY SYKPCDKISS GSNISKKSIM VQSPEKAYSS SQPVISAQEQ ETQIVLYGKL VEARQKHANK MDVPPAILAT NKILVDMAKM RPTTVENVKR IDGVSEGKAA MLAPLLEVIK HFCQTNSVQT DLFSSTKPQE EQKTSLVAKN KICTLSQSMA ITYSLFQEKK MPLKSIAESR ILPLMTIGMH LSQAVKAGCP LDLERAGLTP EVQKIIADVI RNPPVNSDMS KISLIRMLVP ENIDTYLIHM AIEILKHGPD SGLQPSCDVN KRRCFPGSEE ICSSSKRSKE EVGINTETSS AERKRRLPVW FAKGSDTSKK LMDKTKRGGL FS //